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Background: It has been proposed that altered microbial colonization patterns during infancy 
may be partly responsible for the increase of allergic diseases in developed countries. The gut 
microbiota differs in composition and diversity during the first months of life in children who 
later do or do not develop allergic disease. However, little is known about the significance of 
early mucosal immune responses to the gut microbiota in childhood allergy development, and the 
findings regarding the protective effect of breastmilk microbiota in the risk of allergy 
development have been inconclusive. Furthermore, even though the oral cavity is the first site of 
encounter between a majority of foreign antigens and the immune system, the influence of oral 
bacteria on allergy development during childhood has not yet been reported. 
Objectives: The general aim of this thesis was to assess the microbial composition and diversity 
of oral, fecal and breastmilk samples, together with its interaction with IgA, in order to study the 
role of microbial development during early childhood in health and allergic disease. 
Subjects: The infants and mothers included in this study were part of a larger randomized 
double-blind trial in Sweden, between 2001 and 2003, where potential allergy preventive effects 
of Lactobacillus reuteri ATCC 55730 were evaluated until 2 and 7 years of age. In this thesis, we 
used longitudinally collected stool and oral samples from infants, obtained at 1 and 12 months 
and 3, 6, 12, 24 months and 7 years of age, respectively. Furthermore, we analyzed breastmilk 
samples, collected at one month post partum, from the corresponding mothers. 
Methods: Next-generation sequencing technologies targeting the 16S rRNA gene, in 
combination with cell activated cell sorting, were used in order to address mucosal IgA responses 
towards gut and breastmilk bacteria. Furthermore, sequencing of the 16S rRNA gene was used in 
order to describe oral microbiota colonization, in longitudinally obtained saliva samples, from 
children developing allergy or staying healthy. Bacterial load levels in different microbial habitats 
were obtained by qPCR methodology and total IgA levels of stool samples were determined by 
ELISA immunoassays.  
Results and conclusion: Colonization of the oral cavity during early childhood is transitional, 
increasing in complexity with time, and several external factors appear to greatly influence oral 
microbiota maturation, having either a short or a long-term impact. Early changes in oral 
microbial composition seem to influence immune maturation and allergy development in 
childhood, and the presence of specific bacterial species may be important for this progress. 
Furthermore, altered IgA responses towards the gut microbiota during infancy preceded asthma 
and allergy manifestations during the first 7 years of life, and consumption of breastmilk with a 
reduced microbial richness in the first month of life may increase the risk for allergy development 
during childhood. Findings observed here need to be confirmed in larger cohorts and the 
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importance of postnatal environmental factors for early microbiota development should be 
addressed further. Future research should go beyond characterization of bacterial community 
composition and investigate the functional mechanisms between early colonizing 
microorganisms, immune maturation and allergy and asthma development during childhood. 




RESUMEN - Castellano 
 
Antecedentes: Los patrones de colonización microbiana alterados durante la infancia pueden ser 
en parte responsables del aumento de enfermedades alérgicas en los países desarrollados. La 
microbiota intestinal difiere en composición y diversidad durante los primeros meses de vida en 
niños que luego desarrollan o no una enfermedad alérgica. Sin embargo, poco se sabe sobre la 
importancia de las respuestas inmunitarias tempranas de la mucosa a la microbiota intestinal en el 
desarrollo de alergias infantiles. Además, los estudios con respecto al efecto protector de la 
microbiota de la leche materna en el riesgo de desarrollar alergias no han sido concluyentes. 
Aunque la cavidad bucal es el primer lugar de encuentro entre la mayoría de los antígenos 
exógenos y el sistema inmunológico, no existen datos sobre la influencia de las bacterias orales en 
el desarrollo de alergias durante la infancia. 
Objetivos: El objetivo general de esta tesis fue evaluar la composición y diversidad microbiana 
en muestras orales, intestinales y de leche materna, junto con su interacción con IgA, para 
estudiar el papel de la colonización microbiana durante edades tempranas de la vida en 
condiciones de salud y de enfermedad alérgica. 
Sujetos: Los bebés y las madres incluidas en este estudio forman parte del ensayo aleatorio doble 
ciego más grande de Suecia, entre 2001 y 2003, donde se evaluaron los posibles efectos 
preventivos sobre la alergia de Lactobacillus reuteri ATCC 55730 hasta los 2 y 7 años. En esta tesis, 
utilizamos muestras de heces recogidas a los 1 y 12 meses, y muestras orales de bebés, obtenidas 
longitudinalmente a los 3, 6, 12, 24 meses y 7 años. Además, analizamos muestras de leche 
materna, recogidas a un mes después del parto de las madres correspondientes. 
Métodos: Se utilizaron tecnologías de secuenciación de segunda generación dirigidas al gen 16S 
rARN, en combinación con citometría de células marcadas por fluorescencia, para abordar las 
respuestas de IgA de la mucosa hacia las bacterias intestinales y de la leche materna. Además, se 
utilizó la secuenciación del gen 16S para describir la colonización oral de la microbiota, en 
muestras de saliva, de niños que desarrollaron alergias o de aquellos que se mantuvieron sanos. 
Los niveles de carga bacteriana en diferentes hábitats microbianos se obtuvieron mediante la 
metodología de qPCR y los niveles totales de IgA de las muestras de heces se determinaron 
mediante inmuno-ensayo ELISA. 
Resultados y conclusión: La colonización de la cavidad bucal durante la infancia temprana es 
progresiva, aumenta en complejidad con el tiempo, y varios factores externos parecen influir en 
gran medida en la maduración de la microbiota oral, ya sea con un impacto a corto o largo plazo. 
Los cambios tempranos en la composición microbiana oral parecen influir en la maduración 
inmune y el desarrollo de alergias en la infancia, y la presencia de especies bacterianas específicas 
puede ser importante para este proceso. Además, las respuestas de IgA alteradas hacia la 
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microbiota intestinal durante la infancia precedieron a las manifestaciones de asma y alergia 
durante los primeros 7 años de vida, y el consumo de leche materna con una riqueza microbiana 
reducida en el primer mes de vida puede aumentar el riesgo de desarrollar alergia durante la 
infancia. Los hallazgos observados en la presente tesis deben confirmarse en cohortes más 
grandes y la importancia de los factores ambientales postnatales para el desarrollo temprano de la 
microbiota debe abordarse más a fondo. Las investigaciones futuras deben ir más allá de la 
caracterización de la composición de la comunidad bacteriana e investigar los mecanismos 
funcionales entre los microorganismos colonizadores tempranos, la maduración inmunitaria y la 
alergia, así como el desarrollo del asma durante la infancia. 
RESUMEN – Valenciano 
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RESUMEN - Valenciano 
 
Antecedents: S’ha proposat que els patrons de colonització microbiana alterats durant la infància 
podrien ser en part els responsables de l'augment de malalties al·lèrgiques als països 
desenvolupats. La microbiota intestinal difereix en composició i diversitat durant els primers 
mesos de vida en els nens que després van desenvolupar una malaltia al·lèrgica. No obstant això, 
poc es sap sobre la importància de les respostes immunes de la mucosa a la microbiota intestinal 
en el desenvolupament d’al·lèrgies infantils. A més, les investigacions amb relació a l'efecte 
protector de la microbiota de la llet materna en el risc de desenvolupar al·lèrgies no han sigut 
concloents. Encara que la cavitat bucal és el primer lloc de trobada entre la majoria dels gèneres 
externs i el sistema immunològic, encara no s’ha descobert la influència dels bacteris en el 
desenvolupament d’una al·lèrgia durant la infància. 
Objectius: L'objectiu general d'aquesta tesi va ser avaluar la composició microbiana i la diversitat 
de mostres orals, fecals i llet materns, juntament amb la seva interacció amb IgA, per estudiar el 
paper del desenvolupament microbià durant el període de la infància primerenca a la salut i la 
malaltia al·lèrgica. 
Subjectes: Les mares i xiquets inclosos en aquest estudi formen part d'un estudi aleatori doble-
cec a Suècia, entre el 2001 i el 2003, on es van avaluar els possibles efectes preventius de la 
suplementació amb Lactobacillus ATCC 55730 fins als 2 i 7 anys. En aquesta tesi, s’utilitzaren 
mostres de bebès arreplegades longitudinalment, obtinguts a 1 i 12 mesos, 3, 6, 12, 24 mesos i 7 
anys, respectivament. A més, s’analitzaren les mostres de llet materna, arreplegades a un mes 
postpart de les corresponents mares. 
Mètodes: S'han utilitzat tecnologies de seqüenciació de nova generació dirigides al ARNr 16S, en 
combinació amb la classificació de les cèl·lules activades, per abordar les respostes de la mucosa 
cap als bacteris intestinals i de la llet materna. A més, s’utilitzà la seqüenciació d’Illumina MiSeq 
del gen 16S per descriure la colonització microbiana oral, i es van obtenir mostres longitudinals 
de saliva de menuts que varen desenvolupar al·lèrgies i d’alguns que es van mantenir saludables. 
Els nivells de càrrega bacteriana en diferents nínxols microbians s’han obtingut mitjançant la 
metodologia de qPCR i els nivells totals d’IgA de les mostres fecals es determinaren mitjançant 
l’immunoassaig ELISA. 
Resultats i conclusions: La colonització de la cavitat bucal durant la primera infància és 
transitòria, augmenta la seva complexitat amb el temps, i diversos factors externs influeixen en 
gran mesura el procés de maduració de la microbiota oral, amb un impacte a curt i llarg termini. 
Els canvis primerencs en la composició microbiana oral pareixen influir en la maduració del 
sistema immunològic i el desenvolupament d’al·lèrgies a la infància, així com la presència 
d'espècies bacterianes específiques pot ser important per a aquest progrés. A més, les respostes 
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d’IgA alterades cap a la microbiota intestinal durant la infància precedeixen a les manifestacions 
relatives a la malaltia asmàtica i al·lèrgiques durant els primers 7 anys de vida. Per altra banda, el 
consum de llet materna amb una microbiota de riquesa reduïda al primer mes de vida podria 
augmentar el risc de desenvolupar al·lèrgia durant la infància. Els resultats observats en aquest 
estudi haurien de confirmar-se en cohorts humanes més grans i la importància dels factors 
ambientals post natals que influeixen en el desenvolupament de la microbiota primerenca han de 
ser més estudiats. Les investigacions futures deuen anar més enllà de la caracterització de la 
composició de la comunitat bacteriana i investigar els mecanismes funcionals entre els 
microorganismes colonitzadors primerencs, la maduració del sistema immunològic i el 










AB Antibiotics taken 
APRIL A proliferation-inducing ligand 
ARC Allergic rhinoconjunctivitis  
As Asthmatic 
BAFF B cell-activating factor 
BF Breastfed 
C-section Caesarean section 
CA Caries active 
CCA Constrained correspondence analysis 
CF Caries free 
CFU Colony forming unit 
DC Dendritic cells 
FEno Fractional exhaled nitric oxid 
FITC Fluorescein isothiocyanate  
GALT Gut-associated lymphoid tissue 
H Healthy 
HMO Human milk oligosaccharides 
HOMD Human oral microbiome database 
Ig Immunoglobulin 
IL Interleukin 
LDA Logarithmic discriminant analysis 
LEfSe Linear discriminant analysis effect size  
MAMPs Microbe-associated molecular patterns 
OUT Operational taxonomic unit 
PCA Principal Component Analyses 
PCR Polymerase chain reaction 
qPCR Quantitative PCR  
RDP Ribosomal Database Project  
rRNA Ribosomal RNA 
SCFA Short chain fatty acid 
SFB Segmented filamentous bacteria 
SIgA Secretory IgA  
SPT Skin prick test 
Th T helper cell 
TLR Toll Like Receptor 
Treg Regulatory T Cells 
VD Vaginal delivery 












The microbial cells that colonize the human body are at least as abundant as our somatic cells, 
although they certainly possess far more genes, with higher genetic diversity, than the human 
genome.[1–4] Specifying the definition of the human microbiome has been challenging due to 
confusion about terminology where, for instance, “microbiota” (the microbial taxa, including 
bacteria, yeasts, filamentous fungi, archaea and viruses, associated with humans) and “microbiome” 
(the collection of these microbes and their genes) are often used interchangeably.[5] However, 
the term “microbiota” in the current thesis refers to the bacterial taxa described at different body 
habitats. Interestingly, although host-associated microbiota is likely acquired from the 
surrounding environment, the composition of mammalian microbial communities, particularly 
the gut, varies greatly from common free-living microorganisms. This indicates that long co-
evolution between mammalian hosts and colonizing microbes has formed specialized microbial 
communities that thrive in habitats like the gut.[6] The resulting relationship between the human 
host and microbial symbionts benefits both parties; the microbial colonizers are provided with 
continuous source of nutrients while the host obtains metabolites from bacterial digestion, 
pathogen protection and immune system education, among other beneficial functions.[7–9] 
 
One of the most ground-breaking progresses in the biological sciences in the past decades has 
been the understanding of the fact that microbial communities inhabit nearly every environment 
and have crucial roles in human health and disease. Numerous studies have focused on 
describing the complexity of microbial communities on particular body habitats, including gut 
[10–14], oral cavity [11, 12, 14, 15], skin [12, 14, 16, 17], milk [18–21], reproductive tract [22], and 
respiratory tract.[23] A common characteristic for each habitat is that the establishment of 
microbes is highly interpersonal and abundances, among different taxa, vary radically. Moreover, 
community composition is more similar within than between different environments while 
interpersonal dissimilarity within habitats is larger than intra-individual variability over time.[11] 
The complexity of the microbial community depends on the particular habitat and only selected 
microorganisms will be able to survive and colonize under the conditions characteristic for that 
body site. One of the principal objectives in human microbiota studies is to reveal how the 
composition, diversity and functions of the constituent microorganisms influence and regulate 
health and disease. By understanding this, we will be able to learn how to manipulate the 
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composition and metabolic activities of the microbiome, thus maximizing the health benefits to 
the host. Advances in this research area of biological science have been possible to achieve due to 
development of different culture-independent omics technologies based on massive sequencing 
in combination with innovative bioinformatics and system biology approaches. 
 
 
Colonization with pioneer microbiota 
Although some authors consider that the fetus resides in a sterile environment [24, 25], this idea 
has been challenged in other studies.[26–29] This is primarily due to discovery of the presence of 
complex bacterial community in the meconium [13, 30–32], and placenta [33, 34], reflecting a 
potential in utero microbial colonization, but also by the manifestation of bacteria and bacterial 
DNA at the maternal-fetal interphase. Several studies have examined the potential bacterial 
transmission through placental barrier, in healthy term pregnancies, and through the umbilical 
cord blood [35], fetal membranes [36, 37], and amniotic fluid [36, 38] from healthy neonates. 
However, the bacterial load levels in the fetal environment has been estimated to be extremely 
low, suggesting the possibility for (environmental) contamination upon sampling.[24] 
 
Through the birth and following hours, the neonate encounters a wide range and large amount of 
microorganisms found in the mother´s vagina, gastrointestinal tract and skin, but also from 
microbes of other individuals present at the delivery and from the immediate environment.[7] 
This postnatal microbiota acquisition is of crucial role for the infants’ future health, where by 
creating resilience against pathogens, it stimulates the immune system and initiates appropriate 
immune priming and education of immune cells. The timing of bacterial colonization influences 
the immune system development and, in turn, a life-long symbiotic relationship between the host 
and the microbiota.[7, 39, 40] Studies have concluded that during the early postnatal period there 
is a “window of opportunity” [39, 41], where the immune system interaction with specific microbe-
associated molecular patterns (MAMPs) initiates a cascade of events that are crucial for a proper 
immune development of the infant.[39, 42] Therefore, particular microbial exposure here will 
determine if the specific immune events will be durably imprinted, or not. MAMPs are necessary 
for maintaining the dialogue between the host and the microbiota, thus promoting an adequate 
microbial colonization.[43] Likely, during this time-limited early period of colonization, the 
immune system of the infant appears to be more susceptible for microbial instructions.[39, 41] 
The microbial communities are highly dynamic during the first year of life [44], assembling an 
adult-like community structure possibly by preadolescence.[13, 44–46] Inadequate microbial 
acquisition during this critical time frame may shift the microbiome out of the healthy state, 
resulting in a less resilient microbial community, that in turn could favors the blooming of 
opportunistic pathogens and disturb microbial immune priming.[39, 40, 47] Succession and 
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assembly of the microbial community, of the respective human habitat may be affected by early 
exposure of the infant, e.g. the availability of each microbe in the local environment of the host 







Oral microbiota development 
The human oral microbiota is an ecological community consisting of symbionts and pathogenic 
microorganisms found in the oral cavity. The oral cavity consists of a wide range of niches, 
including the tongue, teeth and gingival crevice and the buccal mucosa, all with different 
characteristics and specific selective environment thus supporting diverse bacterial communities. 
A unique feature of the oral environment, compared to other body parts, is the presence of both 
non-shedding surfaces (teeth) and shedding (mucosal) surfaces, facilitating the microbial 
colonization with diverse characteristics.[7] Due to the high flow rate and generally low levels of 
nutrients that impede bacterial multiplication, the large numbers of bacteria (108 per ml) 
encountered in saliva are mainly representing the types of organisms found on the dorsal surface 
of the tongue.[7] 
 
Unraveling how the oral microbiome is shaped and defined is important for the understanding of 
both oral and general systemic health. Research on development and maturation of the human 
microbiome during infancy has mainly been focused on the gut while knowledge of the 
establishment and structure of the neonatal oral microbiome colonization following delivery is 
still limited. Streptococcus and Actinomyces, belonging to Firmicutes and Acinetobacteria phyla 
respectively, are considered to be pioneer oral colonizers that are acquired at birth and following 
hours (Fig. 1).[48, 49] Gradually, by production and excretion of metabolic products from these 
colonizers, the growth of more strict anaerobes like Veillonella and Fusobacteria, is favored.[48, 49] 
As the infant grows, microbial communities become more complex and diverse, reaching the 
adult-like stability later in childhood.[48, 50, 51] The early microbial environment of the oral 
cavity is heavily shaped by microorganisms of maternal origin, by contact with the outside world 
through breathing and through contact with parents and medical staff.[48, 52, 53] This is how the 
process of permanent colonization of the oral cavity begins. Moreover, early oral microbiota 
development has been shown to be influenced by breastfeeding habits and delivery mode.[54, 55] 
To study the pattern of oral microbiota development is important because it has been shown that 
early colonization of certain pathogens may increase the rates of oral diseases such as dental 
caries.[56] In addition, the potential modulation of the immune system by microbes of the oral 
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mucosa and other tissues is relatively unknown in comparison with the large interest and 
resources devoted to understanding the role played by gut microorganisms. 
 
 
Gut microbiota development 
Gut bacteria is the key player of microbial host stimulation, providing specific signals for 
adequate immune stimulation and development.[57] Facultative bacteria such as Lactobacillus and 
Staphylococcus dominate the gut microbiota during the first days of life since the absence of oxygen 
prevents the colonization of obligate anaerobes. A few days later, Enterococcus and Enterobacteriaceae 
appear and, together with further expansion of facultative bacteria, create an anaerobic 
environment by consuming the oxygen. The following state will favour the colonization with the 
obligate anaerobes Bifidobacterium, Bacteroides and Clostridium, where Bifidobacterium is a dominant 
bacterial genus in the gut microbiota of breastfed infants.[58, 59] It is believed that the pioneer 
microbiota, consisting of Firmicutes, Bacteroidetes, Proteobacteria (Enterobacteriaceae), Veillonella and 
especially Bifidobacterium (Actinobacteria phylum) [39, 60], is responsible for initial education of 
the evolving immune system as it provides the favorable environment for further microbial 
settlement, specific compounds and protection from the systemic immune system.[61] The early 
intestinal microbiota is characterized by low diversity and a relative dominance of the phyla 
Proteobacteria, Actinobacteria and Firmicutes (Fig. 1).[13] With introduction of solid foods, the 
early microbes with a genetic profile that facilitate lactate utilization are replaced by bacteria 
enriched in genes coding the digestion of different carbohydrates and genes involved in vitamin 
synthesis and degradation of xenobiotics.[61] 
 
The settlement of bacteria on the gut surface can protect against pathogen penetration, a process 
known as ‘colonization resistance’, which is of great importance for the prevention of pathogen-
induced gastrointestinal inflammation.[43] Commensal bacteria have been shown to control the 
potential pathogen-infection by competition for nutrients, adhesion sites, pH, receptors and 
production of specific metabolites and antimicrobial peptides, and by creating an environment 
hostile for pathogen survival end establishment (for instance, lactobacilli in vaginal environment 
that reduce local pH, and produce specific compounds that prevent expansion of other bacterial 
taxa).[43, 62, 63] 
 
 
Human breastmilk microbiota 
Breastmilk hosts a wide range of microbiota and potential probiotic bacteria (at concentrations of 
approximately 106 bacteria/ml sample [19]) that are believed to orchestrate the infant's 
developing mucosal immune system.[64, 65] Although information about the function of 
breastmilk bacteria is scarce, it has been proposed that they play a crucial role as seeding 
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colonizers of the infant microbiota, to facilitate infant digestion, to compete for nutrients and 
space with pathogens and to improve intestinal barrier functions by augmenting mucin 
production.[18, 66] Moreover, the breastmilk microbiota may promote an adequate initial 
intestinal immune homeostasis that encourages a shift from an intrauterine T helper cell 2 (Th2) 
predominant to a Th1/Th2 balanced response and to trigger regulatory T cell differentiation in 
infant.[40, 66] Culture-independent techniques, including 16S rDNA sequencing and 
metagenomics analysis, have demonstrated a complex and diverse group of bacteria in human 
milk, including the presence of Staphylococcus, Lactobacillus, Pseudomonas, Streptococcus, 
and Acinetobacter, with large degree of individual-specific profiles.[18, 19, 67, 68] Lactobacillus from 
breastmilk have been shown to prevent colonization and growth of gastrointestinal pathogens, 
including Escherichia coli and Shigella spp, and reduce the incidence of gastrointestinal, respiratory, 
and total infections.[69–71] Streptococcus and Staphylococcus species are the most commonly 
abundant bacterial families in human milk.[18, 21, 72, 73] The progressive establishment of the 
infant microbiota [18, 65, 72, 74], favored by breastfeeding, is crucial for instructing their 
immune system to tolerance [68] and many epidemiologic studies have documented differences 
in the microbial composition of gut in breastfed and formula-fed infants.[75–77]  
 
Multiple studies have observed the sharing of several microbial strains, including Bifidobacterium, 
Lactobacillus, Enterococcus, and Staphylococcus, between breastmilk and infant stool.[78–80] Neonates 
who mainly breastfeed, during the first period of life, share 28% of their stool microbes with 
their mother’s milk microbes – a percentage that increases in dose dependent manner.[72] The 
fact that the bacteria encountered in the infant gut mostly resemble the bacteria from their own 
mother [72], suggests the importance of breastfeeding for an initial colonization of the infant.  
 
The origin of the bacteria in breastmilk is not yet clearly established and breast tissue itself 
contains a diverse community of bacteria, identified even in non-lactating woman.[81, 82] It is 
believed that maternal commensal skin flora, ingested by the infant during breastfeeding, may 
contribute to the bacterial communities both in baby’s mouth and mother’s milk duct 
colonization.[83, 84] However, this theory does not fully explain the presence of strict anaerobes, 
including Bifidobacterium, Clostridium, or Bacteroides species, in breastmilk. [68] Another theory is 
that bacteria from the mother’s intestinal tract may translocate to mammary gland and reach the 
infant by breastfeeding.[18, 65, 85] The theory underlying the so named entero-mammary 
pathway, speculates that the bacteria from intestinal lumen invade the maternal gut, by 
internalization in dendritic cells (DC), and reach the mammary grand by the lymphatic system 
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Maternal factors, including the mode of delivery, geographical locations (mothers from Europe, 
Africa and Asia express different milk microbiota profiles [20, 72, 87]), maternal health and 
antibiotics use (associated with decrease in milk microbiota diversity)[88], have all been shown to 
influence milk microbiota composition and diversity. While some studies have reported that 
lower bacterial diversity has been demonstrated in milk from mothers that deliver by caesarean 
section [89–91], other studies have not found any link between the mode of delivery and milk 
microbiota diversity.[20, 72] However, more studies are needed in order to understand the 






Fig. 1. A global overview of microbial composition across the different infant body niches. Key phyla of 
the infant microbiota composition are presented at different stage of early life. Concentric circular 




Microbiota and Immune System 
 
 
Mucosal immunity in the gut 
Despite the mostly symbiotic relationship of the host-microbial interactions, the close contact 
with microbial communities present at mucosal sites results in continuous immune challenge. It 
is still not fully understood how the neonatal gut tissue adapts to this constant microbial 
exposure, but features of the maternal breastmilk (discussed in detail below) are considered to 
direct some of these early responses to commensal microbes.[93] Moreover, properties of the 
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tolerate microbiota colonization. The early and developing immune system is characterized by 
dampened pro-inflammatory cytokine responses, resulting in a more regulatory profile [63], that 
favors the establishment of the microbiota.  
The gut mucosal barrier provides a dynamic interface between the sterile milieu of surrounding 
tissues and the external environment with its enormous microbial load. This barrier consists of 
various layers, including the mucus layers, intestinal epithelium layer, layer with immune effector 
cells that are either associated with the epithelium or embedded in the lamina propria mucosae and 
gut-associated lymphoid tissue (GALT) layer, where adaptive immune responses can be initiated 
(Fig. 2).[94, 95] The epithelium, as a main component of mucosal barrier, blocks the invasion of 
pathogenic and commensal bacterial to the surrounding gut tissue.[96] This defense is achieved 
by two barrier subtypes, chemical and physical.[97] The chemical protection consists of 
antimicrobial peptides and lysozyme, among other bioactive factors, with the main function to 
separate the gut bacteria from the intestinal epithelial cells of the small intestine.[98, 99] Physical 
barriers inhibit microbial invasion by the mucus layer, the glycocalyx (a network of carbohydrate 
moites of glycoproteins/glycolipids) on the microvilli of absorptive inter-epithelial cells, and the 
cell tight junctions firmly uniting intestinal epithelial cells thus maintaining the integrity and the 
structure of the mucosal barrier.[97] Mucus, a viscous fluid consisting of mucin glycoproteins, is 
secreted by goblet cells that are enriched in the large intestine. The large intestinal epithelium, in 
contrast to the small intestine, are lined by a two-layered mucus layer: the outer loose and the 
inner firm mucus layer.[100] The outer mucus layer is inhabited by numerous bacteria, due to it 
loose physiology, while the inner mucus layer is denser and contains various antimicrobial 
molecules including immunoglobulin A (IgA), thus preventing the penetration of bacteria.[100] 
For bacteria overcoming both the mucus barrier, tight junctions connecting the epithelial cells is 
a final wall that hamper the invasion.[101] 
The epithelial defense is exceptionally well-established and complex in the gut, where it contains 
large amounts of commensal microbes that are involved in digestion of polysaccharides, 
production of vitamins, maturation of the immune system and prevention of pathogenic bacterial 
colonization.[102] In return, the intestine provides symbionts with a proper milieu with abundant 
energy derived from ingested food.[97] The relationship between the host and prokaryotic cells 
requires a continuous interaction, where the signaling program sent by commensals present at the 
site is interpreted by diverse cell compartments, in order to educate the mucosal immune system 
and ensure hypo-responsiveness against commensals while being prepared for protection against 
pathogens.[95, 103, 104] The importance of host recognition of commensals has been confirmed 
in germ-free mice that demonstrate an altered immune system organization and reduced 
cellularity, when compared to mice harboring a complex microbiota.[94]  
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Fig. 2. Schematic view of the gut mucosa. The intestinal mucus barrier is composed of different 
compartments that are important for maintaining immune homeostasis and integrity. The thick layer of 
mucus facing the gut lumen contains secretory immunoglobulin IgA, antimicrobial peptides and 
commensals. The underlying intestinal epithelium is composed of enterocytes, mucus producing goblet 
cells, Paneth cells (that secrete antimicrobial peptides), intraepithelial lymphocytes and hormone-producing 
enteroendocrine cells. The majority of intraepithelial lymphocytes are memory CD8+ cells and they are 
responsible for maintaining the integrity of epithelium. Gut-associated lymphoid (GALT) consists of 
Peyer’s Patches, clusters of lymphoid follicles several smaller lymphoid aggregates. Peyer’s Patches consist 
of B cell follicles with naïve B cells and interfollicular T cell zones. In the core of each B cell follicle, there 
is a germinal centre where activated B cells expand, undergo class switching, somatic hypermutation and 
maturate into IgA producing plasma cells. The Peyer’s Patches also contain microfold (M) cells with ability 
to take up the antigen from the gut and present it to the immature dendritic cells (DC) or macrophages, 
present in subepithelial dome region of the Peyer’s Patches. Dendritic cells in lamina propria, supporting 
the epithelium, are also responsible for sampling gut bacteria. Upon invasive infections, Th17 cells are 
needed for the elimination of microbes trying to penetrate the surface epithelial cell layer. Foxp3+ 
regulatory T cells, also found here, are important for maintaining the intestinal immune homeostasis in the 
presence of a nonpathogenic commensal bacteria. Modified from TT. MacDonald and G. Monteleone. 




Mucosal immune system control of microbiota 
Although intestinal bacteria are mainly restricted to the luminal side of the gut, some microbes 
succeed to overcome the barrier protections and penetrate the intestinal epithelial cells. 
Commonly, these commensals get here phagocytosed and eliminated by macrophages present in 
lamina propria of the tissue.[105] Also, the mucosal immune system may use some of the 
invading bacteria in order to direct specific immune responses (Fig. 2), including the initiation of 
protective secretory IgA production by B cells through regulatory T cells (Tregs) activation.[106] 
The IgA antibodies are then distributed throughout all mucosal surfaces where it may exert 
directed immune responses, against commensals.[94]  
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The importance of the immune system for microbiota shaping is confirmed in immune deficient 
mice that, for instance, lack IgA antibodies. These mice then show priming of serum IgG 
responses against commensal bacteria, which is likely due to the fact that the commensals can 
overcome the mucosal barrier protection thus causing systemic immune responses.[94, 107] 
Moreover, since IgA antibodies have been shown to promote the adhesion of microbiota in 
the gut to the epithelial surface, thus selecting for the growth and colonization of specific 
bacterial species, the lack of this antibody may affect the microbial composition and 
establishment of non-beneficial species.[108] Similarly, disruptions of regulatory T cells 
networks (for instance due to Foxp3 deficiency) have been shown to induce chronic intestinal 
inflammation in the presence of a triggering intestinal microbiota and lack of tolerance within the 
intestine.[109, 110] 
Findings here suggest that the host appears to have some control over the microbial consortia 
composition of the gut and that defects in the host immune system can cause a dysbiosis. 
However, it is still to be determined in detail to which extent, and how, the immune system 
influences the composition and location of commensals in other niches, including the oral cavity 
where this information is still very meagre. 
 
 
The importance of microbiota in shaping the immune system 
Microbial colonization of the neonatal gut might direct initial immune maturation, playing an 
essential role for a balanced postnatal innate and adaptive immune system. The microbial 
pleiotropic effect on the host includes its involvement in shaping the architecture of the immune 
system, in regulating the balance between immune cell types present and in influencing the 
development of immune cell populations.[93] The early studies comparing germ-free and 
colonized mice demonstrated the importance of microbial colonization for a proper formation of 
lymphoid tissue and further immune development.[111] Besides having reduced numbers of 
intestinal CD4+ cells, IgA producing cells and aberrant Peyer´s patches, germ-free mice are 
typically Th2 skewed [112], but a balance of Treg/Th2 responses can be achieved by introduction 
of symbiotic bacteria.[94, 113] However, this needs to occur during the critical developmental 
window, in the first 1,000 days of life of the neonate (and first postnatal week in mouse studies) 
when many biological systems are established.[42] Bacterial cell wall components, including LPS 
and flagellin [114, 115], and commensal microbiome metabolites display immune-regulatory 
properties within the gut mucosa that contribute to host-microbiota homeostasis.[94, 111]  
 
Effects on T helper cell subsets. T cells are crucial for protection of the host from various 
pathogenic microorganisms. Based on their unique cytokine profile, effector T helper cells can be 
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classified into Th1, Th2, Th17 and Treg subpopulations (Fig.3).[116] Homeostasis in the gut 
mucosa is maintained by an interplay between potentially pro-inflammatory and anti-
inflammatory cells, and the balance of effector lymphoid cells and Treg cells can have a great 
influence on the mucosal responses upon stress/tissue damage. It has been demonstrated that 
the microbiota composition is important for Th cell differentiation and also that the metabolites 
produced by different symbionts may be instrumental for the bacterium’s success as a 





Fig. 3. Schematic view of T helper cell subsets. The graphic presents the differentiation of naïve CD4+ T 
cell, key regulators of the immune system, into different T helper cells (Th) and regulatory T cells (Treg) 
that possess distinctive biological functions. The CD4+ T cells´ ability to differentiate into distinct cell 
types is determined by the presence of key-signaling cytokines. Once programmed, activated cells secret 




By producing their key cytokine IFNγ, Th1 cells stimulate immune responses against intracellular 
microbial infections, complement activating and opsonizing antibody production, while Th2 
secrete IL-4, IL-5 and IL-13 to induce humoral immune responses against parasites and 
allergens.[116, 120] Th17 cells, involved in defenses against fungi and extracellular bacteria, 
produce the pro-inflammatory cytokine IL-17 that may also be involved in tissue damage and in 
different autoimmune diseases.[121] Even though the CD4+ Th17 subset are considered to be 
pathogenic because of their abundant presence in a variety of inflammatory conditions, other 
studies have revealed that Th17 may also have a homeostatic role in the gut.[122]  
 
Clostridial strains belonging mainly to cluster IV and XIVa, have been demonstrated to favor the 
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free mice with a damaged gut epithelium, the colonization with the cluster IV and XIVa resulted 
in reduced disease symptoms.[123] In a mouse model, the recognition of flagellin of 
the Lachnospiraceae family of Clostridiales by Tregs provide tolerance to commensal bacteria by 
promoting the survival of antigen-specific IgA+ B cells.[124] While the mechanisms in which the 
commensal-induced regulatory T cells perform systemic anti-inflammatory functions is not yet 
known, it has been observed that some Tregs in the gut possess T cell receptors with specificity 
for distinct commensal bacteria.[125] Other bacterial surface antigens, including Polysaccharide-
A of Bacteroides fragilis provokes an IL-10 response by regulating CD4+ T cell transformation 
toward Foxp3+ Treg, which in turn prevents epithelial barrier damage by inhibiting the 
differentiation of Th17 cells.[126] Moreover, in homeostatic conditions, B. fragilis elicits the 
induction of Th1 or Treg cells in the circulation, defending the host from pathogenic infections 
or by preventing immune activation by self-antigens.[117, 126] Together, these findings show 
that commensal bacteria have a general impact on immunity that reaches well beyond mucosal 
tissues. 
 
Interactions between B-cells and microbiota. Through their production of antibodies that 
protect the host against pathogenic invasions, B cells are an important part of the adaptive 
immune system. These cells can limit aggressive immune reactivity, mainly by production of 
cytokine IL-10, and they can be activated in both T cell-dependent and independent 
manners.[127] In T cell-independent pathways, intestinal lamina propria DCs directly present 
antigen to B cells and activate them through B cell-activating factor (BAFF) and a proliferation-
inducing ligand (APRIL).[128, 129] IgA is a dominant antibody at mucosal surfaces where it plays 
a crucial role in maintaining gut homeostasis.[130] IgA secreting-B cells home to the intestinal 
lamina propria where IgA is produced in dimeric form (containing the joining (J) chain) and 
transported by the polymeric immunoglobulin receptor across the epithelium barrier and 
positioned on the apical surface.[118] Upon release into intestinal lumen, secretory IgA (SIgA) 
binds and prevents the uptake of microbial antigens [131], neutralizes pathogenic bacterial toxins 
[132] and disarm and clear potentially invasive microbes without starting any inflammatory 
responses or bacterial killing.[133] It is believed that the gut microbiota has an impact on B cells 
isotype switching due to the fact that microbiota alterations in mice, as a consequence of broad 
spectrum antibiotics or germ-free conditions, can lead to a switch to IgE, through enhanced Th2 
responses [134], rather than IgA and subsequent activation of basophils, mast cells and 
inflammation.[135, 136] Moreover, IgA+ plasma cells in gut lymphoid tissues and lamina propria 
are greatly reduced in germ-free or antibiotics-treated mice.[137, 138]  
 
It has been observed that IgA antibodies at mucosal surfaces may have polyreactive features and 
coat a broad, but defined, subset of microbiota.[136, 139] This suggests that the IgA, though 
originating from adaptive immunity, have innate-like recognition characteristics that may assist 
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the adaptation to a broad range of microbiota and their antigens encountered at mucosal surface 
of the gut.[136] It has also been reported in murine models that the majority of IgA responses 
here are T cell-dependent, highly antigen-specific and featured with high-affinity binding.[136, 
140] SIgA has been shown to induce members of the gut microbiota, including some species of 
Bacteroides, to down-regulate their expression of pro-inflammatory surface antigens.[141] By 
coating the commensals, SIgA monitors bacterial entry into Peyer´s patches and germinal center 
in the lamina propria, thus establishing a positive antigen-specific IgA loop.[142] Selected 
commensals can induce systemic IgA-mediated immunity, thus constitutively protecting against 
bacterial sepsis in mouse model.[143] Overall, IgA might be important for diversity and balance 
of commensals through controlling their expansion in the gut, which is evident in their role in 
gene-expression regulation of commensals, thus selecting species that possess less inflammatory 
activity on the host’s tissue.[141] IgA has also been shown to promote bacterial adhesion to the 
mucus layer of the intestinal epithelium, enriching for the growth and colonization of particular 
microbial strains, as observed in vitro and in vivo.[108, 144, 145] Furthermore, commensals, 
particularly Bacteroides fragilis, appear to be capable of modifying their surface architecture in order 
to attract IgA binding and allow robust mucosal colonization and single-strain stability in 
epithelial cell models.[145] Studies have shown that lack of intestinal stimulation by commensals 
results in lower levels of IgA+ plasma cells, and thus reduced abundance of IgA [146, 147], 
which could be due to aberrant development of lymphoid tissue that is important for IgA 
production.[148] 
 
Besides SIgA, IgM and IgG antibody subclasses are also able to bind to microbiota and their 
responses are mainly induced through T-cell independent pathways.[149, 150] In contrast to mice 
where IgM responses are characterized by low affinity binding [149], human hosts have more 
abundant and specified IgM responses that help to maintain diversity of bacterial communities 
together with IgA. [151] Even considerable IgG amounts, with low affinity binding feature, have 
been detected in the secretory compartment of the gut as well, in homeostatic conditions.[139] 
However, lack of active translocation of secretory IgA and IgM to mucosal surfaces of the gut 
have been observed to lead to increased serum IgG antibodies against gut commensals and 
pathogens in mice, reflecting the importance of secretory anti-inflammatory antibodies in 
restricting systemic exposure to microbiota antigens.[152] 
 
Short chain fatty acids and microbiota. The colonic microorganisms play a crucial role in 
metabolic activities associated with homeostasis in large intestine. Short chain fatty acids 
(SCFAs), including acetate, butyrate, and propionate [153], are principle metabolic outputs of the 
microbiota. Their quantity and relative amounts in adults have been closely linked to diet, where 
a high-fiber diet increases blood concentrations of SCFAs [154], as well as microbiota 
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composition, diversity, and activity.[155] The main producers of SCFAs are classified 
as Ruminococcaceae (cluster IV) and Eubacterium (cluster XIVa) in the order Clostridia, 
class Clostridia, and phylum Firmicutes.[153] SCFAs mainly bind to G-protein coupled 
receptors encountered on the cells of the intestinal tract, immune cells (including Tregs) and 
adipose tissue. Among other physiological functions, SCFAs, in concentration depended 
manners, regulate T cell polarization and accumulation [156], the chemotaxis and the viability of 
neutrophils [157] and immune regulation in monocytes and macrophages.[158] For instance, 
propionate may suppress the Th1-type immune response in stimulated human peripheral blood 
mononuclear cells [159], butyrate can inhibit the proliferation and apoptosis in activated T 
lymphocytes [153], and butyrate and propionate play a complex role in Treg differentiation and 
intestinal tract immune regulation.[153, 160]  
 
Exclusive breastfeeding during infancy has been was associated with lower absolute 
concentrations of total SCFAs, including acetate, butyrate, propionate and valerate, and higher 
concentrations of lactate in stool samples.[161] Moreover, a higher relative proportion of acetate 
has also been related to exclusive breastfeeding.[161] This may in part be due to the breakdown 
of breastmilk-acquired human milk oligosaccharides by Bifidobacterium [162], in the gut of 
breastfed infants [163, 164], resulting in an increased production of acetate and lactate.[165] A 
positive correlation between bifidobacterial counts and fecal acetate has also been confirmed in a 
study Martin et al.[166] Although evidence is still limited, higher acetate in breastfed infants might 
provide protection against intestinal pathogens and allergic disease.[167, 168] Therefore, 





Factors Influencing Early Microbial Colonization 
 
Early establishment of microbial communities and species interactions appear to be influenced by 
the order and timing of species immigration to the host tissue.[40] Factors including mode of 
delivery (vaginal or caesarean delivery), breastfeeding habits (duration of breastfeeding and 
formula feeding), gestational age, the number of older siblings, pet ownership and antibiotics use 
may all shape the patterns of early microbial colonization, thus favoring the expansion of specific 
microbial niches.[169, 170] These events may alter a priority effect of bacterial colonization and 
contribute to long-lasting consequences during early stages of gut microbiota development, 
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Delivery mode 
The initial neonatal colonization differs depending on delivery mode (Fig. 4). Infants born by 
caesarean section (C-section) are not exposed to their mother´s vaginal and fecal bacteria and 
their microbiota resembles the colonizers found on the skin, oral cavity and the surrounding 
environment [163], including Staphylococcus, Corynebacterium, and Propionibacterium.[171] Moreover, 
these infants are less likely to be colonized by Bifidobacterium and Bacteroides at both three days and 
one month of age, while having increased presence of C. difficile.[172, 173] Furthermore, 
decreased levels of intestinal Bacteroides genus has also been detected in the microbiota of C-
section infants at three-four months of age, together with higher abundance of the genera 
Escherichia, when compared to vaginally delivered babies.[77] This was further confirmed in 
another study where caesarean section delivered infants either lacked or showed a delayed 
colonization (by up one year for some infants) of the phylum Bacteroidetes.[174] This was 
accompanied with lower total microbiota diversity as well, which may be a consequence of the 
absence of this phylum.[174] Moreover, C-section delivered neonates have been observed to 
have lower leucocyte counts, lower haemoglobin and cytokine GM-CSF levels in cord blood 
[175], and reduced Th1 responses during the first two years of life.[174] Delivery by C-section 
has also been associated with an increased risk for immune disorders, including allergic rhinitis, 




Breastfeeding plays an important role in shaping the microbiota and the immune system. The 
presence of myriad bioactive components in breastmilk with multifunctional and anti-
inflammatory characteristics that protect against infections, together with a diverse array of 
microbiota, support the recommendation from World Health Organization (WHO) of exclusive 
maternal breastfeeding during the first 6 months of life for all healthy women and children. [64, 
178–180] This first span of life with recommended exclusive breastfeeding coincides with a 
critical window for microbial imprinting, which in turn may be important for infant´s immune 
development. Moreover, protection provided by breastmilk may extend beyond the weaning 
period, thus having long-term benefits for the infant.[181–183]  
 
However, there is increasing concern that the current recommendation of delaying solid foods 
complementation may be problematic for the risk of developing eczema and allergic disease. 
Conflicting guidelines, recommending the optimal time point for the introduction of 
complementary foods, have been presented [180, 181, 184–186], and some researchers support 
the hypothesis that later introduction of foods increases allergic responses.[187] The 
recommendations from WHO were not taking into account the association between early 
complementary foods introduction and allergy prevention, which must be further evaluated. 
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However, gut colonization through continued breastfeeding may promote tolerance and 
protection when complementary feeding is initiated. 
 
Breastfed newborns have been demonstrated to have a more stable and uniform bacterial 
population, when compared to the formula fed babies.[188] While some studies have not 
observed differences in Bifidobacterium levels between breastfed and formula fed [189–191], 
Bezirtzoglou et al. detected that breastfed infants harbor more than double counts of 
Bifidobacterium cells when compared to formula fed.[188, 192] Within the genus Bifidobacterium, B. 
breve, B. adolescentis, B. longum, and B. bifidum have been isolated in both formula fed and breastfed 
infants, whereas B. infantis is a common commensal in breastfed neonates and Bacteroides fragilis in 
formula fed neonates.[172, 190] Another cohort-study demonstrated that exclusively breastfed, 
four-month-old infants had increased levels of bacterial taxa that are commonly used as 
probiotics, such as Lactobacillus johnsonii/L.gasseri, L. paracasei/L. casei.[163] However, differences 
between breastfed and formula fed are diminished between the first and second year of life.[59, 
190] 
 
Other human breastmilk components 
HMOs. Among the bioactive factors, breastmilk contains various immunological substances, 
including immunoglobulins, cytokines, chemokines, human milk oligosaccharides (HMO) and 
growth factors that can be transferred to the offspring through breastfeeding.[193] Colostrum, 
the first form of milk produced by the mammary glands, contains especially high concentrations 
of HMOs, which are indigestible by human enzymes alone. HMO are responsible for selectively 
promoting the growth and colonization of beneficial commensal bacteria, including Bifidobacterium 
and Lactobacillus, where they serve as a substrate for fermentation thus selecting for growth of 
specific bacterial species.[194] Furthermore, the breakdown products of HMOs 
from commensals, lactate and SCFAs, suppress growth of pathogens like Escherichia 
coli and Clostridium perfringens, thus giving commensals an advantage over pathogens in the 
developing infant gut.[195]  
 
Immunoglobulins. Breastmilk antibodies are believed to reflect the numerous pathogens which 
the mother has had contact with in the gut and airways, thus providing an important defense 
against the same pathogens likely encountered by her infant.[196, 197] Although all 
immunoglobulin isotypes can be encountered in breastmilk, SIgA is considered most important 
for their anti-inflammatory properties and defenses of the mucous membranes.[198] SIgA acts 
locally on the newborn’s mucosal surfaces, thus regulating the binding and penetration of 
commensals and pathogenic microorganisms to epithelial cells.[196] While the concentrations of 
IgA in breastmilk are high during the first weeks post partum, the levels decrease as the infant’s 
endogenous levels of this antibody augments.[199, 200] Interestingly, the quantities of SIgA in 
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milk from mothers delivering preterm are higher, which may reflect the importance of breastmilk 
protection of premature infants, whose immune system is more vulnerable to early life 
infections.[201]  
 
Breastmilk components including SIgA and TGF-β are believed to protect the infant from 
developing allergies, whereas others might act in the opposite fashion (e g arachidonic acid and 
the cytokines IL-4, IL-5, IL-13 that are most intimately involved with IgE production and 
induction of eosinophils).[202] For instance, low levels of SIgA in breastmilk have been 
associated with increased risk of cow's milk allergy in infants in some studies.[203] Additionally, 
mothers having allergies were observed to have decreased SIgA responses to the antigen 
ovalbumin, compared to healthy mothers, but the presence of these antibodies was not predictive 
for allergy development in their infants.[204] However, it is still unclear how the presented 
immunomodulatory factors in breastmilk might affect and predict the development of allergic 




The use of antibiotics in early life may have an effect on microbial succession, diversity, and 
resistance to treatment that can last long past infancy. It has been observed that antibiotics may 
cause a shift in the composition of the gut microbiota towards a profile dominated by 
Proteobacteria and low abundance of Actinobacteria populations.[205, 206] Antibiotics have also 
been shown to decrease the overall bacterial diversity of the infant’s microbiota, making the baby 
more susceptible to infections, and select for the growth of drug-resistant bacteria.[207, 208] In a 
study by Tanaka et al., the fecal microbiota of newborn that were treated with broad-spectrum 
antibiotics during the first four days of life, showed less bacterial diversity and decreased 
colonization with Bifidobacterium and Enteroccoccus, during the first weeks of life.[205] At one 
month of age, overgrowth of Enterobacteriaceae and Enterococcus was observed in infants in the 
antibiotic-treated group. Interestingly, a similar trend was observed microbiota development of 
C-section delivered neonates whose mothers were administered with a closely related 
antibiotic.[205] Correspondingly, antibiotics treatment during early infancy appeared to influence 
the maturation of Th1 immune responses, the balance in activity and development of 
Th1/Th2/Th17 as well as regulatory T cell function in mice.[209] Some studies have also shown 
that prenatal exposure to antibiotics increases the risk of subsequent asthma and wheeze 
development [210–213], as well as eczema.[214] However, the biological mechanisms behind 
deserves to be evaluated further. Additionally, the use of antibiotics during infancy has been 
linked to increased risk in developing allergic diseases like asthma, food allergy, eczema and 
autoimmune diabetes (Fig. 4).[215, 216] Taken together, early exposure to antibiotics may shape 
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Fig. 4. Schematic overview describing the possible consequences of antibiotics use in early childhood. 
Adapted from: The effects of antibiotics on the microbiome throughout development and alternative 





Allergy and Hypersensitivity 
 
Allergy is characterized by inappropriate hypersensitive immune reactions to innocuous antigens, 
developing due to interactions between environmental and genetic factors. The term allergy is 
today most commonly used to define the Type 1 (of four different types) hypersensitivity 
reaction, which is mediated by immunoglobulin E (IgE) antibodies (atopic allergy).[217, 218] 
However, allergy or allergic hypersensitivity also includes non-IgE mediated allergies and 
hypersensitivities, characterized by nonspecific immune interactions instead (Fig. 5).[217, 218] An 
allergic reaction occurs when the immune system is triggered by allergens to which the affected 
individual is sensitized, activating an antibody response that in turn cause a cascade of immune 
events.[134, 218] Type 1 is an immediate reaction that can either cause anaphylaxis (to food 
allergens, drugs and insect venoms), asthmatic and rhinoconjunctivitis reactions (due to inhalant 
allergens such as pollen, cat and dog dander and house dust mites) and skin and gastrointestinal 
reactions caused by food allergens such as peanuts, eggs and milk.[217–219] Allergic asthma, a 
heterogeneous disease influenced both by genetics and environmental factors, has become the 
most prevalent chronic childhood disease in recent decades.[220]  
 
Atopy is a personal and/or familiar genetic predisposition to become sensitized and produce IgE 
antibodies upon ordinary exposure to allergens.[217] Atopic allergic diseases are characterized by 
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excessive Th2-like immunity to allergens, with elevated production of IgE inducing IL-4 and IL-
13 and eosinophilia promoting IL-5.[218, 221] In the early phase, allergen cross-linking of IgE 
antibodies bound to mast cells and basophils triggers the release of inflammatory mediators, 
including histamine, prostaglandins, cytokines and chemokines. Later, in the late-phase reaction 
(after 6-8 hours), cytotoxic mediators from eosinophils are released, leading to chronic 
inflammation, which includes epithelial damage and increased mucus production. Moreover, the 
inflammatory mediators IL-4, IL-13, CXCL8 and GM-CSF that are released from infiltrating 
leucocytes, sustain the activation, proliferation and further recruitment of inflammatory 
cells.[218, 221] However, in non-allergic individuals, regulatory T cells and Th1 cells normally 
suppress these responses.[222] Children suffering from atopic dermatitis and/or food allergy 
early in life are more likely to develop inhalant allergen sensitization together with asthmatic and 










Immune Development in Healthy and Atopic Children 
It is now becoming clear that the early life period represents a window of both vulnerability and 
opportunity that subsequently impacts the immune development and tissue homeostasis. 
Maturation of the human fetal innate immunity is already initiated during the first trimester of 
pregnancy where relevant precursors population are detectable, in the thymus and bone marrow, 
between weeks 8 to 12.[224] It is evident that the possibly “harmful” responses, such as the 
production of Th1 key cytokine IFN-γ, are selectively restricted during intrauterine development 
but also during the early infancy.[27, 225, 226] A combination of epigenetic mechanism and 
Hypersensitivity
“Conditions clinically resembling allergy that cause objectively reproducible 
symptoms or signs, initiated by exposure to a defined stimulus at a dose 
tolerated by normal subjects”
Allergy or allergic hypersensitivity
“Hypersensitivity reaction initiated by a proven or strongly 
suspected immunologic mechanisms”
Non-allergic hypersensitivity





Allergy - Hypersensitivity reaction initiated by proven or strongly suspected
immunologic mechanisms. The triggers are substances that the subject has been
previously exposed and sensitized.
Sensitization – Clinical presence of specific IgE or T lymphocytes to an allergen.
The diagnosis of allergy is obtained by sensitization test together with a specific
compatible clinical history.
Atopy - Personal and/or familial predisposition to become sensitized and produce
IgE antibodies in response to exposures to allergens.
Atopic disease - Development of typical symptoms of asthma, rhinoconjunctivitis
or eczema in atopic patients. These clinical manifestations can occur separately or
in combination , having generally a differentcourse throughout life (atopic march).
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additional cellular processes contribute to overall weaken capacity of T cell activation, thus 
shifting the responses towards a more Th2 immuno-profile.[227–229] This pre-determined Th2 
propensity from fetal stages may be responsible for the limited inflammatory functions of 
infantile leukocytes, leading to immunotolerance and low control over infections.[230] The Th2 
bias of the newborn is also involved in maturation of Th1-like responses [231, 232] and 
appropriate development of regulatory T cell responses [233, 234], which are both important 
features for the mature immune phenotype development during childhood. A failure of silencing 
Th2 responses during maturation of the immune system may underlie development of Th2- 
mediated allergic disease [235] and various studies have reported that these early life neonatal 
Th2-biased responses are even more manifested, and difficult to attenuate during the immune 
maturation, in infants who later develop allergies.[231, 233, 236, 237]  
 
Slow postnatal maturation of immunocompetence, including the ability to produce IL-12, IL-10 
and IFN-γ, together with reduced circulating numbers and function of DCs and regulatory T cell, 
has been reported as a risk factor for allergic/asthmatic disease development in infants/children 
at high genetic risk susceptibility for these diseases.[238–242] This means that the children with 
family history of atopy have a more delayed development of immune function maturation, thus 
taking longer time to reach adult-like levels of immune competence.[224] The mechanisms 
underlying these immune deficiencies, that are evident already at birth [240, 243], are not well-
understood but interestingly, susceptibility to severe lower tract respiratory infections (recognized 
as a strong risk in atopic asthma development) have been associated with poor production of the 
above mentioned cytokines and dendritic cells.[239, 241, 244] Moreover, establishment of an 
adequate mucosal barrier function, for instance by increasing the production of SIgA during 
infancy, seems important to counteract allergic responses.[41, 245, 246] 
 
A longitudinal study of healthy infant peripheral blood observed that neonatal T cells have an 
increased propensity to differentiate into Treg cells in the first 12 months of life but that they 
also have the capacity to become Th17 cells already at age of 3 months.[247] This suggests that 
while the proportions of both resting and activated Tregs increase from birth to 6 months of age 
[248], in order to establish a regulatory immune profile and support the development of acquired 
immunity, the production of adaptive immunity Th17 -supporting cytokines, including IL-6 and 
IL-23, is greatly active in combating the pathogens and keeping colonizing microbes in 
check.[249, 250] Interestingly, high proportions of regulatory T cells in neonates, at birth and 
early infancy, have been positively associated with allergic sensitization at 18 or 36 months of 
life.[251] This implies that high proportions of regulatory T cells this early in life may counteract 
the important activation and maturation of the immune system, thus triggering the immune 
mechanisms that may be involved in sensitization later in life. Alternatively, the increased 
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numbers of regulatory T cells may also be masking their impaired function, as observed in a 
study by Hrdý et al. They detected that an impaired function of regulatory T cells present in the 
cord blood of children of allergic mothers, characterized by decreased expression of regulatory 
cytokine IL-10 and TFG-beta, which was compensated by an increased number of Treg in these 
neonates, in comparison with the healthy group.[252] Speculatively, this insufficient function of 
Treg early in life may be involved in compromised tolerance development in infancy and 
subsequent allergen sensitization in high-risk individuals during the childhood.  
 
Innate immunity, including the surface expression of toll-like receptors and the production of 
their effector molecules, decreased level of phagocytosis and poorly developed complement 
system, are also compromised during the early neonatal period.[230, 253] For instance, the 
expression of TLRs involved in recognition of surface molecules of pathogens is either absent or 
expressed at very low levels in newborn mice.[254] Human studies are obviously harder to 
perform but nasal mucosal explants from young children, exposed to TLR stimulation, showed 
increased allergen-induced T cell reactivity and expansion, augmented production of Th1 
cytokines, IL-10 secretion, and TLR4 expression, as compared with explants from adults.[255] 
Perinatal TLR responses are increased in cord blood cells of newborns, particularly in subjects 
who subsequently develop allergic disease. Babies from allergic mothers, or those infants that 
subsequently developed allergies, had increased production of TNF and IL-6, following 
stimulation of TLR 3/4/5 and TLR 4/5. In contrast, T cell-derived IFNγ responses were 
decreased when compared to non-allergic children.[256] In another longitudinal study of TLR 
responses in children developing allergies and children staying healthy, non-allergic children 
displayed increased production of IL-10, TNF and IL-6 in response to TLR stimulation over the 
first 5 years of life. On the contrary, allergic children show greater cytokine production at birth 
but the levels decreased over time, thus being lower by age of 5 in comparison to similar aged 
non-allergic children.[257] In another study, exposure to common environmental allergens, such 
as cockroach, or dust mite, was associated with increased cytokines responses at age 3 years, 
including production of IFN-α and IL-10. Moreover, reduced LPS-induced IL-10 responses as 
birth were related with recurrent wheeze by age of 3.[258]  
 
Taken together, the innate immunity recognition receptor responses, the cytokine balance, 
transient Th2 activation and the function of regulatory T cells during the early period of life 
appears to be important for subsequent allergy development in childhood. The mechanisms that 
direct the immune maturation process are still not completely understood, but it is becoming 
clear that a wide range of environmental factors during pregnancy and early neonatal life can 
have profound effects and long-lasting consequences on the immune status of the infant and 
their further susceptibility to inflammatory diseases.[224] Additionally, it has now been 
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recognized that a major driver of a normal postnatal maturation is the microbiota inhabiting the 
gastrointestinal tract within a crucial developmental time window, as described elsewhere in this 
literature overview. It has also to be kept in mind that the potential role of the oral microbiota in 
that immune maturation has not been addressed. 
 
 
Allergy and Microbial Dysbiosis 
The prevalence of allergic diseases has increased drastically during the last decades and it is 
believed that factors associated with Western lifestyle, including the improved living standard, 
cleaner environments, the eradication of certain pathogens, antibiotics, increased time spent 
indoors, and smaller family size may be of great importance. These factors are assumed to reduce 
exposure to infectious and commensal microbes, a phenomenon known as “hygiene hypothesis”, 
in early life which may contribute to a lack of shifting of allergen-specific Th2 responses to the 
Th1 phenotype.[61, 259] Moreover, development of allergic disease in the first year of life has 
been associated with reduced responses of Tregs to microbial stimuli, likely reflecting failure of 
immune tolerance development in infancy.[260] A reduced regulatory T cell function may also be 
reflected in Th1-mediated autoimmune-mediated diseases such as multiple sclerosis, type I 
diabetes and Crohn’s disease also have increased in prevalence in affluent countries.[234, 261–
264]  
 
The gut microbiota differs in children who later do or do not develop allergic disease, particularly 
during the first months of life.[61] Moreover, the diversity of the microbiota plays also an 
important role in regulating allergy and mucosal immunity development during infancy.[59, 265–
269] Several prospective studies have observed decreased microbial diversity to precede the 
development of eczema [265, 268–270], atopic sensitization and allergic rhinitis [267], and 
asthma.[266] Intestinal bacterial colonization during infancy is closely related to the development 
of the immune system compartments and the gut microbial stimulation may provide a primary 
signal for the maturation of a balanced postnatal innate and adaptive immune system.[61, 169, 
220, 271, 272] Germ-free mice have poorly developed gut and mesenteric lymphoid tissue 
together with limited production of IgA, stronger Th2 responses and augmented allergic 
phenotype.[224] This suggests that perturbations to the colonization and intestinal bacterial 
acquirement (dysbiosis), may disrupt the natural immune cell-microbe interactions, resulting in 
biased infant immune system towards a more hypersensitive (allergic) state.[273] This is in line 
with the results from various cohort studies where they observed that alterations in gut 
microbiota in early infancy and childhood, are associated with allergic disease development later 
in life.[168, 265, 268, 274–278] For instance, lower relative abundance of intestinal bacterial 
genera Lachnospira, Veillonella, Faecalibacterium, and Rothia were significantly decreased in children 
at risk of developing asthma. This was further confirmed in a mouse model of allergic asthma 
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where the colonization with mentioned genera reduced airway inflammation.[168] Therefore, 
microbial exposure is crucial for mounting balanced and tolerant immune responses, thus 
preventing subsequent allergy development. However, the exposure needs to occur during the 
important “window of opportunity” in early life, in parallel with the maturation of the neonatal 
immune system. Postnatal factors like pet ownership, family size, day care attendance, animal 
exposure and the history of certain infectious diseases, during this early period of life, were found 
to influence the risk of developing allergic diseases.[279, 280] 
 
A lack of diverse microbial exposure might result in the development of atopic diseases in early 
life.[281] For instance, development of IgE-associated eczema during the first two years of life 
was associated with a reduced diversity of the gut microbiota at 1 month of age.[265] Toddlers 
with eczema harboured significantly lower abundance of Bifidobacterium and Bacteroides and higher 
prevalence of Enterobacteriaceae.[275, 282] Allergic symptoms among Swedish children have been 
associated with low levels of house dust endotoxin when compared to Estonian households 
where endotoxin levels are higher (and allergy prevalence lower).[283] Moreover, children 
growing up on farms in Central Europe are exposed to a wider range or microbial diversity, 
which is related to protection from development of asthma.[284] Following the presented 
hypothesis, the prevalence of allergic diseases was found to be significantly higher in urban 
children when compared with rural children, likely due to higher level of bacterial endotoxin, and 
other microbial products, in the environment where the rural children were living.[285, 286] For 
instance the lipopolysaccharide from Acinetobacter lwoffi, isolated from a farming environment, was 
observed to have potential allergy-protection abilities by inducing Th1 polarization of dendritic 
cell in vitro.[287] One central mode of action through which microbes trigger immune responses 
is through recognition of microbial motifs by pattern recognition receptors, including TLRs.[224] 
Local mucosal administration of natural/synthetic TLR agonists has been shown to result in 
protection against experimental asthma in several murine models.[224] In line with this, 
transmaternal asthma-protective effects of Acinetobacter lwoffii was observed to depend on intact 
toll-like receptor signaling the mothers as well as TLR expression patterns in the placenta.[288]  
 
Noteworthy, ethnicity, genetics, diets, living environments, or other factors, together with study 
methodologies, sampling and analytical tools can influence the investigated microbial 
composition.  
 
Allergy and Probiotic Interventions 
The endorsed definition of probiotics is “live microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host”.[289] They have wide range of effect where the main aim is 
to restore or improve a dysbiotic microbiota.[290–292] Species within the genus Lactobacillus has 
been commonly used as probiotics,[293] with L. reuteri being effective against antibiotic-
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associated diarrhea [294] and L. salivarius preventive against Listeria infections.[295] Moreover, 
Bifidobacterium species have also been widely acknowledged to have immunomodulatory 
properties and health-promoting probiotics potential.[296] Most studies used single strains of 
Lactobacillus and Bifidobacteium, or their combination [263] in both humans and mouse models in 
order to determine the potential probiotic effects of these bacteria to treat various infections, 
inflammatory conditions and allergies.[297–300] Generally, probiotics are mainly used to treat 
gastrointestinal disorders, including infectious diarrhea caused by rotavirus.[301] Even though the 
results have not been always conclusive, the studies are suggesting that the beneficial effect of 
mentioned potential probiotics depends on the pathogens present, particular patient groups, 
disease condition and host immunity.[296]  
 
The timing of probiotic intervention is critical, as early life events occurring during the “window of 
opportunity”, where both the immune system and initial bacterial colonization are vulnerable, can 
have long-term impact on children’s health. Therefore, it is of great interest to understand if 
microbiome-host response interactions can be modified at early life or even during pregnancy. 
Speculatively, starting probiotic supplementation already from the second trimester of pregnancy, 
when circulating fetal T cells have developed [302], may have a significant effect on fetal immune 
physiology and perhaps even affect microbial colonization of the infant postnatally. Hence, 
supplementation with probiotics have been performed in pregnant and breastfeeding mothers in 
order to potentially reduce the immune-related disease risk in children. For instance, probiotics 
administration to pregnant woman (2-4 weeks before delivery) and to their infants, six months 
postnatally, have been shown to significantly decrease the risk of development of atopic eczema 
during the first 7 years of life.[303, 304] Also, an effect on gut microbiota composition in the 
neonate has been reported in some studies of pre- and postnatal probiotic supplementation [305, 
306], while solely maternal probiotic administration was not able to influence the infant 
microbiota diversity postnatally.[307] The probiotic effect on microbial composition and immune 
system modulation depends possibly on treatment duration as well as probiotic strain selection, 
as discussed by Forsberg et al.[308], where certain strains are more efficient colonizers than 
others. Also, since bacterial isolates are unique organisms with strain-specific properties and 
different mechanisms of action, a combination of different probiotic strains may increase the 
beneficial health effect.[309]  
 
Possible mechanisms of probiotic interventions through mothers may be linked to an increase of 
immunomodulatory factors, including cytokines and growth factors, in breastmilk.[303] Beside 
probiotics, prebiotics, substrates that are selectively utilized by host microorganisms conferring a 
health benefit [289, 310], and synbiotics, the combination of probiotics and prebiotics, have also 
been used to favorably modulate gut microbiota.[263] An example of prebiotics are complex, 
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non-digestible carbohydrates that benefit the host by selectively favoring the growth or activity of 
specific bacteria in the colon, thus positively affecting gut function. Human milk 
oligosaccharides, for instance, are assumed to be naturally functional prebiotics with potential 
health benefits in breastfeeding infants.[311] Previously, human milk has been the only source 
for significant levels of HMOs, while these components have been mostly absent from infant 
formula. However, many infant formula on today’s market contain mixtures of industrial-made 
SCFAs (including galactooligosaccharides - GOS, fructooligosaccharides - FOS and inulin) that 
mimic the prebiotic effects of human milk and promote a microbial colonization that resembles 
that of breastfed infants.[311] A potential allergy protective effect of these probiotics, during 
infancy, has also been evaluated.[263] A systemic review for allergy prevention reported a 
preventive effect on eczema in studies with combined pre- and postnatal supplementation, while 
results in asthma and recurrent wheeze have been inconclusive.[312, 313] The protective effects 
of synbiotics for eczema development have also been reported in two randomized, double-blind, 
placebo-controlled trial.[314, 315] However, these prebiotic components are structurally very 
different from the oligosaccharides occurring naturally in human milk, which might also imply 
that they have distinctive effects than natural HMOs.  
 
In conclusion, and as previously addressed [308, 316–318], probiotics administered prenatally and 
postnatally may provide microbial stimuli that support the early maturation of both innate and 
adaptive immune responses, while limiting inappropriate inflammatory responses to different 
allergens. Moreover, the potential role of prebiotics and synbiotics in improving health and 
reducing risk of allergic diseases mediated by microbial aberrations should not be excluded. This 
field would benefit from research focusing on specific mechanisms of action, addressing host 
response processes and understanding how different probiotics strains and prebiotic structures 
associates to the function and health outputs. Therefore, more research is required in the 
selection of probiotics strains, prebiotic substances, treatment combinations, timing and duration 
of administration.  
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Methodologies for Characterizing the Microbiota 
 
The classic microbiology methods for culturing bacteria from human subjects exclude a 
numerous uncultured or non-identified bacterial taxa while, at the same time, they are not 
providing a correct abundance of the taxa present. During the last decade, microbial analyses 
have shifted from culture-dependent techniques to culture-independent genetic sequencing, 
providing a fundamental breakthrough in research areas concerning microbial communities. 
 
Quantitative PCR in real time (qPCR) and fingerprinting methodologies, including temperature 
gradient gel electrophoresis and Denaturing Gradient Gel Electrophoresis, have been widely used 
for quantification and assessment of the structure of microbial communities within a 
sample.[319] However, these traditional molecular techniques are rapidly being replaced by high-
throughput next generation sequencing techniques, that together with advanced bioinformatics 
tools, have facilitated the profiling and functionality of human microbiome and improved the 




In 454 pyrosequencing (Roche Applied Science, Basel, Switzerland) of 16S rRNA genes, 
barcoded primers for amplifying 16S rRNA genes are used to examine and compare both 
dominant and low-abundance microbial communities from multiple samples. 16S ribosomal 
RNA (rRNA) sequencing is a common amplicon sequencing method used to identify, study and 
compare complex bacterial consortia within a given sample.[319] Here, sequences from different 
samples can be identified in the same run by using a barcoded multiplex approach, which means 
that a unique sequence (adaptor) is incorporated into the primer and barcode amplicons are 
generated. Furthermore, emulsion PRC is carried out for clonal amplification by using capture 
beads complementary to the sequences on the adaptors, thus allowing DNA fragments to attach 
to the beads. The DNA fragments are then separated into single-stranded DNA and copied 
numerous times on each bead, creating millions of identical copies of DNA sequence. Next, 
beads carrying single-stranded DNA, together with other reagents (including DNA polymerase, 
ATP sulfurylase, luciferase, apyrase) are transferred to the wells proceeding with the 
pyrosequencing reaction (Fig. 6). This method relies on light generation detection upon 
nucleotide incorporation into a growing chain of DNA, creating sequence read length of 
approximately 400-500 base pairs, extended to 800 bp with the Titanium chemistry used in the 
current thesis.[321, 322] However, this platform has been phased out by the manufacturer and 
was only used in Chapter I. 
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Fig. 6. 454 pyrosequencing overview. Isolated genomic DNA is fragmented, separated to single strands 
and ligated to adapters. Fragments are then bound to beads (one fragment per bead) and the beads are 
sorted in the droplets of oil emulsion where PCR amplification occurs. The emulsion is then broken, and 
beads carrying single-stranded DNA templates are enriched and deposited into wells for a further 
pyrophosphate sequencing reaction. Complementary four nucleotides are then incorporated into the 
template strand (red) by the annealed primer and the DNA polymerase. Incorporation of the base 
generates inorganic pyrophosphate (PPi), which is converted to ATP by the sulfurylase. Luciferase uses the 





Currently, the Illumina MiSeq platform is dominantly being used for 16S rRNA-mediated 
documentation of diverse bacterial samples. Extracted and purified DNA is immobilized on a 
flow cell surface and prepared for Illumina sequencing by isothermal PCR that amplifies single 
DNA molecules. The DNA sequencing is then performed by repeated cycles of single-base 
extensions using four fluorescent reversible dye terminators (one for each nucleotide, Fig. 
7).[321, 324] 
 
Fluorescence is identified after base incorporation by a four-channel fluorescent scanner. Using 
Illumina, shorter sequence lengths than those from the 454 platforms are generated. This may 
create difficulties in identifying taxonomic affiliation down to genus or species level, and 
therefore, selection of primers targeting specific variable regions of 16S rRNA gene sequence is 
critical here. However, Illumina MiSeq platform supports sequencing of templates from both 
ends of a DNA fragment, known as paired-end sequencing, providing a wider sequence of the 
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Fig. 7. Illumina sequencing overview. Illumina next generation sequencing includes four steps: 1. Library 
preparation - Random fragmentation of a genomic DNA (around 250-300 bases long fragments) is 
followed by 5´ to 3´ ligation of specific custom adapters to both fragment ends. 2. Cluster amplification – 
Sequencing library is loaded into a flowcell with the fragments attaching to the adapters in a random 
pattern. Each fragment is then amplified into a clonal cluster through bridge amplification. 3. Sequencing - 
Fluorescent labeled nucleotides (dNTPs), together with other sequencing reagents, are added to growing 
DNA copy strands. dNTPs are modified containing a terminator which blocks further polymerization. 
Moreover, only a single fluorescent color is used and therefore, each of the four bases must be added in a 
separate cycle of DNA synthesis and imaging. The emission wavelength and intensity from fluorescent 
labeled nucleotides is then used to identify the base incorporated. This process is repeated in order to 





Flow cytometry and fluorescence activated-bacterial sorting 
Flow cytometry is a technology used for detection and identification of physical and chemical 
characteristics of cells or particles in a fluid as it passed through an interrogation point. Sheath 
fluid directs the cell suspension, causing cells to pass through a laser beam one cell at a time. The 
light that the particles absorb from a laser beam, scatters or emits light to all the angles due to its 
intrinsic and extrinsic physical properties. A detector, located in front of the laser beam, measures 
a forward scatter indicating the size of a particle. The light scattered at wide angles, known as side 
scatter (which indicates cellular granularity), is collected and directed to several mirrors and filters 
that enable the reflection of wanted light to a specific pass filter (red, orange, yellow, green light) 
and to finally be detected by a wavelength-specific photomultiplier tube sensor. The signal of the 
photons is then amplified, converted to voltage pulses, which are called events. The side scatter is 
proportional to the particle´s complexity and roughness (granularity).[326] 
 
Fluorescence activated cell sorting (FACS) is a unique tool for separating the subpopulations of 
interest, by detecting their certain, targeted characteristics. Cell sorter functions basically as a 
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detects the cell of interest, for instance bacteria coated with an antibody that have been marked 
with a fluorescent dye, an electric charge is given to the droplet of sheath fluid containing the 
specific cell. As the droplet passes through the electrostatic field, charged droplets are deflected 
appropriately and collected into a tube. Uncharged droplets, containing cells that do not possess 
the feature of interest (for instance bacteria that are not coated with an antibody), are collected 
into a separate tube or discarded into the waste tank (Fig. 8). This technique is extremely useful 
for the separation of subpopulations, for subsequent molecular analyses, including high 
throughput DNA sequencing.[326] The combination of 16S rDNA sequencing and flow 
cytometry-based sorting has enabled the identification of IgA-coated and non-coated fractions of 





Fig. 8. Fluorescence activated cell sorting. A fluorescent-marked antibody specific for a particular cell 
surface protein is added to a mixture of cells prior to passing through a laser beam, where the complex is 
monitored. Droplets, containing single cells (events), are given a positive or a negative charge, depending 
on whether the cell is coated with fluorescently-tagged antibody or not. Droplets are then directed into 
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Original study design and study subjects included in the papers of 
this thesis 
 
The results of all the papers included in this thesis are based on a prospective, randomized, multi-
center trial conducted at the Department of Pediatrics in university hospitals in South Eastern 
Sweden, between 2001 and 2005. 232 families with allergic disease (i.e. one or more family 
members with eczema, asthma, gastrointestinal allergy, allergic urticaria, or allergic 
rhinoconjunctivitis) were recruited to the study, where the potential allergy protective effect of 
the probiotic Lactobacillus reuteri ATCC 55730 was evaluated in infants until 2 and 7 years of 
age.[327, 328] The mothers started taking L. reuteri, or placebo, four weeks before term and 
continued daily until delivery. After birth, within 1-3 days, the infant continued with the same 
study product as the corresponding mother, daily up to 12 months of age. The mothers were 
encouraged to breastfeed. The families were advised to not use any other probiotic available on 
the market, during the study period. The infants were clinically followed by research nurses at 1, 
3, 6, 12 and 24 months of age and telephone interviews with parents at 2, 4, 5, 8, 10 and 18 
months. A final follow up was done by a pediatrician at two and seven years of age (Fig. 9). In 
total 188 infants completed the study until 2 years of age and 184 until 7 years of age.  
 
Non-stimulated saliva samples were collected from the buccal cavity, using a hand pump 
(Nalgene #6131, ThermoFisher, Stockholm, Sweden) connected to a thin plastic tube, and 
immediately frozen and kept at −20°C. In connection with the oral examination and saliva 
sampling, clinical data about symptoms of allergic disease, adverse events, infections, use of 
antibiotics, and possible confounding factors were registered.[329] Among the 188 infants 
completing the original study, longitudinal salivary samples from 90 children were included in 
chapter I. In chapter III, 47 children that developed allergic symptoms and sensitization and 33 
children that stayed healthy were included. 
Stool samples were collected from the infants at age 5-7 days and at one month and 12 months 
of age. The samples were immediately frozen at -20°C following collection and later stored at -
70°C. In the study presented in chapter II of this thesis, 28 healthy children and 20 children that 
developed allergic symptoms were included. 
Breastmilk samples (approximately 10 mL) were collected within the first 3 days after delivery 
and at 1 month, in sterile plastic containers by the mother at home, immediately placed in the 
freezer, and brought to the hospital and stored at −70°C within 3 days.[330] In chapter IV of this 
thesis, we used breastmilk samples collected one-month post partum from 40 mothers whose 
children did or did not develop allergic and asthmatic symptoms during the first 7 years of age. 
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Lactobacillus reuteri preparation 
The strain L. reuteri ATCC 55730, which was employed in the original study, was originally 
isolated from the breastmilk of a Peruvian mother (strain American Type Culture Collection 
55730, BioGaia AB, Stockholm, Sweden). Safety and tolerance have been evaluated in healthy 
individuals (with up to 1011 bacteria/dose) [331] and in clinical trials with children.[332–336] 
Clinical studies have confirmed beneficial effects in acute diarrhea in children [333, 335], 
reduction of infections in a day-care setting [334], improved feeding tolerance in formula fed 
premature neonates [336], and or the management of infantile colic.[337] 
 
The probiotic preparation consisted of freeze-dried L. reuteri, suspended in refined coconut oil 
and refined peanut oil, containing cryo-protective components. The daily intake, five oil droplets, 
corresponded to 108 colony forming units (CFU). The placebo consisted of the same oil without 




Diagnostic criteria of allergic diseases and asthma 
Infants were regarded as sensitized if they had at least one positive skin prick test and/or 
detectable circulating IgE antibodies to allergens.[327, 328] Skin prick tests were performed on 
the volar aspects of the forearm with egg white, fresh skimmed cow milk and standardized cat, 
birch and timothy extracts (Soluprick®, ALK, Hørsholm, Denmark) at 6, 12 and 24 months of 
and 7 years of age (here also mite (Der p)).[328] Histamine hydrochloride (10 mg/ml) was used 
as positive and albumin diluents as negative control. The test was regarded as positive if the mean 
diameter of the wheal was >3mm. Circulating IgE antibodies to egg white and cow’s milk were 
analyzed at 6, 12, and 24 months of age in venous blood (UniCap® Pharmacia CAP SystemTM, 
Pharmacia Diagnostics, Uppsala, Sweden). The cut off level was 0.35 kU/L, according to the 
protocol of the manufacturer. 
 
Children were diagnosed with allergy if they have had symptoms of and/or have been treated for 
the actual allergic disease during the last twelve months. The diagnosis atopic eczema was defined 
upon visible pruritic, chronic or chronically relapsing non-infectious dermatitis symptoms with 
typical features and distribution. Also, it required that the infant was also sensitized.[265] 
Moreover, symptoms related to allergic disease, physical examination, spirometry and 
measurement of fractional exhaled nitric oxid (FENO) were observed. Asthma diagnosis was 
based on at least one of following two criteria: 1. Doctor diagnosis and asthma symptoms and/or 
medication during the last twelve months; 2. Wheeze or nocturnal cough and a positive 
reversibility test and/or pathological FENO value.[266, 327] All asthmatic children were also 
included in the allergic group analyses. For more details, please see [265, 266, 327–330]. 
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Fig. 9. Schematic overview of the original study. SPT: skin prick test; IgE: Measurements of circulating 
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RATIONALE OF THIS THESIS 
 
In conclusion, the advent of new, advanced high-throughput sequencing technologies, together with 
its combination with flow cytometry techniques, now allow the study of the complex interactions 
between human antibodies and microbiota. IgA antibody is the primary mediator of humoral 
mucosal immunity and low secretory IgA levels in saliva and stool samples have been associated 
with increased risk for allergic manifestations during early life. However, little is known about the 
identities of the bacterial taxa targeted by IgA in the infant gut and what role mucosal immune 
responses to the gut microbiota play in childhood allergy development. In the current thesis, we 
have studied the degree of microbial coating with IgA and patterns of IgA targeting of gut 
microbiota in children staying healthy or developing allergic and asthmatic disease. In addition to 
stool samples, we have also studied the much less explored oral microbiota development in the 
same cohort, identifying the patterns of bacterial succession associated with health and allergy, as 
well as the different postnatal factors influencing bacterial development. As an unhealthy oral 
microbiome can have important effects beyond the oral cavity, microbiological studies in 
longitudinal samples through childhood are essential in providing information about colonization 
patterns of oral commensals and their potential benign effect in preventing oral and systemic 
diseases. Breastfeeding, representing a passive immunization from mother to child, is an 
important factor in shaping microbial colonization of the infant. Therefore, IgA-coating towards 
breastmilk microbiota was also examined, with the hope that the integration of data from these 
different studies and sample types would shed light on the role of microbial exposure and initial 
colonization in preventing or promoting allergic disease development during childhood. 
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AIMS OF THE THESIS 
 
The general aim of this thesis was to assess the microbial composition of oral, fecal and 
breastmilk samples, together with its interaction with IgA, in order to study the role of microbial 
development during early childhood in health and allergic disease.  
 
The specific aims of each individual chapters were: 
 
I  To study the temporal evolution and maturation of the oral microbial ecosystem 
during infancy and childhood and its relation to delivery mode, breastfeeding habits, antibiotic 
use and dental caries status, in longitudinally collected oral samples in 90 children followed from 
birth to 7 years of age. 
 
 
II To determine the proportions of IgA coating together with the characterization of 
the dominant bacteria, bound to IgA or not, in infant stool samples in relation to allergy 
development during childhood.  
 
 
III To evaluate the longitudinal development of oral microbiota during infancy and 
childhood in saliva samples from children developing allergies and children staying healthy up to 
7 years of age by using culture-independent next generation sequencing methodologies. 
 
 
IV To characterize the IgA-bound/non-bound breastmilk microbiota from mothers 
whose children develop, or not, allergic symptoms during early childhood.
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Chapter I - ORAL MICROBIOME DEVELOPMENT 
DURING CHILDHOOD: AN ECOLOGICAL 
SUCCESSION INFLUENCED BY POSTNATAL 
FACTORS AND ASSOCIATED WITH TOOTH DECAY  
 
- Majda Dzidic, Maria Carmen Collado, Thomas R. Abrahamsson, Alejandro Artacho, Malin 
Stensson, Maria C. Jenmalm, Alex Mira; Oral microbiome development during childhood: an 
ecological succession influenced by postnatal factors and associated with tooth decay; © The 




Information on how the oral microbiome develops during early childhood and how external 
factors influence this ecological process is scarce. We used high-throughput sequencing to 
characterize bacterial composition in saliva samples collected at 3, 6, 12, 24 months and 7 years 
of age in 90 longitudinally followed children, for whom clinical, dietary and health data were 
collected. Bacterial composition patterns changed through time, starting with “early colonizers”, 
including Streptococcus and Veillonella; other bacterial genera such as Neisseria settled after 1 or 2 
years of age. Dental caries development was associated with diverging microbial composition 
through time. Streptococcus cristatus appeared to be associated with increased risk of developing 
tooth decay and its role as potential biomarker of the disease should be studied with species-
specific probes. Infants born by C-section had initially skewed bacterial content compared with 
vaginally delivered infants, but this was recovered with age. Shorter breastfeeding habits and 
antibiotic treatment during the first 2 years of age were associated with a distinct bacterial 
composition at later age. The findings presented describe oral microbiota development as an 
ecological succession where altered colonization pattern during the first year of life may have 
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Introduction 
 
The development and structure of the neonatal microbiome have been partially elucidated, with a 
main focus on the microbial population inhabiting the lower intestinal tract, while information 
about the oral cavity colonization following delivery is still limited.[48] As yet, no published 
longitudinal studies have characterized oral microbiota development during infancy and 
childhood with culture independent next generation sequencing methodologies, particularly in 
association with tooth decay. It is believed that by production and excretion of metabolic 
products of pioneer colonizers (including facultative anaerobes Streptococcus and Actinomyces), 
acquired at birth and the following hours, the environment can be altered, thus benefiting and 
selecting the growth of other species (including more strictly anaerobic genera like Veillonella and 
Fusobacteria).[48, 49] As the baby grows, microbial communities evolve and increase in microbial 
diversity.[50, 51] During this period the oral microbiota is characterized by high variability and 
current knowledge indicates that it reaches adult-like stability around two years of age.[48]  
 
Most evidence available today shows that the early oral environment is strongly shaped by the 
mother [49, 338, 339] and maternal oral microbiota has been proposed to colonize the placenta 
[33] where it could influence fetal immune tolerance towards the mother´s microbiome.[340] 
Further transition into a more mature and complex microbial ecosystem is mainly influenced by 
the external environment as well as vertical transmission from the parents.[49, 339, 341, 342] An 
essential question is to identify which factors and at what time point they can influence the 
progression of microbial colonization. Previous studies of the lower gastrointestinal tract 
microbiota have reported that the gut microbiota of infants delivered by caesarean section (C-
section) was mainly colonized by skin bacteria, had lower numbers of Bifidobacterium and 
Bacteroides species and were more often colonized with Clostridium difficile in comparison to 
vaginally born infants.[172, 343] However, research regarding the influence of delivery mode on 
the early oral microbiota development, by using next generation sequencing on longitudinal 
samples, has not yet been reported.  
 
Breastmilk has long been considered a superior food for infants, increasing resistance to 
infections, providing nutrition and being a source of bacteria (106 bacterial cells/ml), who serve 
as inoculum for the newborn.[18, 19, 73, 85] The genus Streptococcus is one of the dominant 
bacterial groups found in human milk [19, 73] and various species, including Streptococcus salivarius, 
are frequently found in the infant oral cavity.[344] The metabolic products derived from 
Streptococcus species from the dietary oligosaccharides in breastmilk might pave the way for the 
establishment of other microorganisms in the oral cavity, thus influencing attachment and 
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growth of selected bacteria.[48, 49, 345–348] However, the longitudinal impact of these initial 
colonizers on the oral ecosystem and the influence of breastfeeding habits on children’s oral and 
systemic health are widely unknown and deserve to be investigated.  
 
Knowledge about the effect of other external factors like antibiotic use, especially at an early age, 
on subsequent microbiome development is also scarce. In children, long-term alterations of the 
gut microbiome as a consequence of early antibiotic administration have been described and 
proposed to have negative effects for systemic health, including obesity and allergy.[349, 350] 
However, the long-term effect of antibiotic use for children’s oral microbiota is currently 
unknown.  
 
An important consequence of oral microbiome development for health is the protection against 
tooth decay (dental caries), considered among the most prevalent diseases worldwide.[351] Tooth 
decay is caused by an interaction between acidogenic bacteria, a carbohydrate substrate and host 
susceptibility, leading to bacterial dysbiosis and demineralization of tooth tissue.[51, 352] The 
acid-tolerant bacterial species Streptococcus mutans is recognized to be an important pathogen in 
dental caries, [353, 354] and its early presence in edentulous children (from 3 months of age), is 
suggesting that the soft tissue may play a role as a reservoir for oral pathogenic 
microorganisms.[50, 355] Given that early colonization with cariogenic microorganisms has been 
associated with higher caries incidence [353], microbiological studies in longitudinal samples 
through early childhood may reveal those bacteria increasing caries risk that could be used as 
early diagnostic biomarkers. This could also provide important information for active and passive 
immunization strategies against oral diseases.[356] Moreover, an unhealthy oral microbiome can 
have important effects beyond the oral cavity, including elevated cardiovascular risk.[357, 358] 
For instance, in vitro studies have demonstrated the ability of periodontal bacteria to increase the 
probability of thrombus formation, which could lead to ischemic cardiovascular events.[359, 360] 
Therefore, it is of interest to understand the colonization patterns of oral commensals during 
childhood and the potential benign effect of oral bacteria in preventing oral and systemic 
diseases, including microorganisms which have been associated with health conditions.[361, 362]  
 
A more detailed understanding of oral microbial communities development in health and disease 
fundamental and the use of high-throughput sequencing techniques now allow exploring 
microbial composition and diversity in low volume oral samples to an unprecedented level of 
detail [363], in comparison with culturing or early molecular methodologies. In this study, we 
aimed to address the temporal evolution and maturation of the oral microbial ecosystem during 
infancy and childhood and its relation to delivery mode, breastfeeding habits, antibiotic use and 
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dental caries status, in longitudinally collected oral samples in 90 children followed from birth to 










Sample collection and study design 
The infants included in the study were part of a larger randomized double-blind trial in Sweden 
between 2001 and 2003 evaluating the potential allergy prevention effect of probiotic Lactobacillus 
reuteri ATCC 55730 until 2 and 7 years of age.[327, 328] Among the 188 infants completing the 
original study, longitudinal salivary samples were collected in 90 children. The participants were 
instructed not to eat or drink for two hours preceding the sampling. Non-stimulated saliva 
samples at 3, 6, 12 and 24 months of age were collected from the buccal cavity, using a hand 
pump (Nalgene #6131, ThermoFisher, Stockholm, Sweden) connected to a thin plastic tube and 
immediately frozen and kept at −80°C. At 7 years of age, paraffin-stimulated whole saliva was 
collected (≈3 ml) in a sterile test tube and immediately frozen at −80°C. By 9 years of age, the 
children were examined at public dental clinics at which the children received their regular dental 
care [329], and the caries status was evaluated. The oral examination included radiographs and 
the registration of manifest and initial caries lesions in the primary dentition according to Koch et 
al. and Alm et al.[364, 365] 
 
Possible confounders, such as mode of delivery, breastfeeding habits (exclusive or partial breast 
feeding), infant health and antibiotics use during the first two years of age were obtained from 
medical records and semi-structured questionnaires (see I-Table 1).[329] 91% and 80% of all 
children included were exclusively breast-fed up to 1 and 3 months of age, respectively, while 
97% were partially breastfed at 3 months of age. No infant received antibiotics before 1 month 
of age while 2% took antibiotics during the first 3 months of life. The studies were approved by 
the Regional Ethics Committee for Human Research in Linköping, Sweden (Dnr 99323, M122-
31 and M171-07, respectively). An informed consent was obtained from both parents before 
inclusion in the study. Written informed consent was also given by the parents or guardians 




250 ul of each saliva sample were centrifuged at 15000 g for 30 min and the pellet, together with 
50 ul of the supernatant, was used for further analysis. DNA was isolated by MagNA Pure LC 
2.0 Instrument (1996-2016 Roche Diagnostics, Barcelona, Spain), using MagNA Pure LC DNA 
Isolation Kit III for Bacteria and Fungi (Roche Diagnostics GmbH, Mannheim, Germany) 
following the manufacturer’s instructions with an additional enzymatic lysis step with lysozyme 
(20 mg/ml, 37°C, 60 min; Thermomixer comfort, Eppendorf, Hamburg, Germany), lysostaphin 
(2000 units/mg protein, 37°C, 60 min; Sigma-Aldrich, Madrid, Spain) and mutanolysin (4000 
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units/mg protein, 37°C, 60 min; Sigma-Aldrich). DNA was resuspended in 100 ul of elution 
buffer and frozen at -20°C until further analysis. 
 
 
16S rRNA gene amplification and sequencing 
Prior to sequencing of 16S rRNA gene, extracted DNA was pre-amplified by using universal 
bacterial degenerate primers 8F–AGAGTTTGATCMTGGCTCAG and 926R- 
CCGTCAATTCMTTTRAGT, which encompass the hypervariable regions V1-V5 of the gene. 
This was performed using the high-fidelity AB-Gene DNA polymerase (Thermo Scientific, 
Waltham, Mass., USA) with an annealing temperature of 52°C and 10 cycles, in order to 
minimize amplification biases.[366] The purification of PCR products was completed using 
Nucleofast 96 PCR filter plates (Macherey-Nagel, Düren, Germany). 
 
An Illumina amplicon library was performed following the 16S rRNA gene Metagenomic 
Sequencing Library Preparation Illumina protocol (Part #15044223 Rev. A). The gene-specific 





targeting the 16S rRNA gene V3 and V4 regions, resulting in a single amplicon of approximately 
460 bp. Overhang adapter sequences were used together with the primer pair sequences for 
compatibility with Illumina index and sequencing adapters. After 16S rRNA gene amplification, 
the DNA was sequenced on a MiSeq Sequencer according to manufacturer’s instructions 
(Illumina) using the 2x300 bp paired-end protocol. Sequences supporting the conclusions of this 
article are publicly available at the European Nucleotide Archive (ENA) database with the 
accession number PRJEB66628. 
  
 
Bacterial load and Streptococcus dentisani measurements with quantitative PCR 
Total bacterial load (number of bacterial cells per ml of saliva) and the presence of Streptococcus 
dentisani in saliva samples were measured by quantitative PCR. Amplifications were performed in 
duplicates on a LightCycler 480 Real-Time PCR System (Roche Technologies) by using annealing 
temperatures of 60°C and 65°C for total bacterial load and S. dentisani, respectively. Each reaction 
mixture of 10 mL was composed of SYBR Green PCR Master Mix (Roche), 0.5 mL of the 
specific primer (concentration 10 mmol/L), and 2 mL of DNA template. For S. dentisani the 
forward primer was 5´GTA ACC AAC CGC CCA GAA GG 3´ and the reverse primer 5´CCG 
CTT TCG GAC TCG ATC A 3´ (Integrated DNA Technologies (IDT); San Diego, California, 
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USA) targeting the carbamate kinase gene, and for total bacterial density measurements the 
universal forward and reverse primers were 5´GTG CCA GCM GCC GCG GTA A 3´ and 
5´GCG TGG ACT ACC AGG GTA TCT 3´ (IDT), respectively, targeting the bacterial 16S 
rRNA gene. The obtained Ct values were transformed in bacterial cell numbers by a standard 
curve calibrated by flow cytometry.[19] 
 
 
Bioinformatics and statistics 
Only overlapping paired end reads were used for analysis. A sequence quality assessment was 
carried out using the PRINSEQ program.[368] Sequences of <250 nucleotides in length were not 
considered; sequence end-trimming was performed by cutting out nucleotides with a mean 
quality of <30 in 20-bp windows. Chimeric 16S sequences were filtered out using USEARCH 
program.[369] 
 
Obtained sequences were taxonomically classified by the RDP-classifier [370] where reads were 
assigned a phylum, class, family and genus and phylogenetic ranks were allocated when scores 
exceeded an 0.8 confidence threshold. Operational taxonomic units (OTUs) were generated by 
using CD-HIT OTU picking with 97% of similarity.[371] Human oral microbiome database 
(HOMID) was used as a reference database for OTU assignment.[372] For the Streptococci-
species analyses, sequences were clustered into operational taxonomic units (OTUs) at 100% 
similarity by BLAST analysis [373] and >350 bp alignment length, against the RDP 
database.[374] A few species appeared to be identical in the sequenced region, namely Streptococcus 
infantis, S. mitis and S. dentisani, and could not be distinguished from each other. 
 
α–diversity analyses (presented here as Shannon and Chao1 indices), were utilized to estimate 
samples’ diversity and richness at the 97% OTU level using the R-package Vegan.[375] 
Constrained correspondence analysis (CCA, a.k.a. canonical correspondence analysis) is a statistic 
tool used to emphasize variation, taking advantage of the fact that the factor provided can 
explain part of the total variability, and bring out strong patterns in a dataset. This analysis was 
performed by R software ade4 package [376] using the function CCA, which is based on Chi-
squared distances. Adonis tests were done with the R library 'vegan'.[375] It performs a 
permutational multivariate analysis of variance using distance matrices and fitting linear 
models to them. The test allows modelling the whole compositional variability at once by 
taking into account different sources of variation as well as interactions between them as it is 
defined in a linear model. 
 
Linear discriminant analysis effect size (LEfSe), a method for biomarker discovery on the online 
interface Galaxy (http://huttenhower.sph.harvard.edu) [377], was used to detect the taxa, at 
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both genus and OTU level, characterizing the populations of caries-free and caries active 
children. 
 
Statistical analyses were performed in R version 3.2.2 and GraphPad Prism 6 (GraphPad 
Software, San Diego, CA, USA, Version 6.1f), where p<0.05 was considered significant. Specific 
statistical tests (including Mann-Whitney U-test for nonparametric comparisons) are stated in 
figure legends. When comparing the frequencies of different bacterial taxa between groups (e.g. 
caries-free and caries-experienced children), the balanced proportions of confounding factors, 
including breastfeeding length, mode of delivery and antibiotic intake, were checked by Chi-
square test, and non-significant differences between the groups were found. 
 
 
Table I-1. The characteristics of children included in this study.  
  Children Prevalence (%) 
Sex (% Girls) 43/90 (48 %) 
Delivery mode (% caesarean section) 13/90 (14 %) 
Breastfeeding (% breastfed, not exclusively)  
   3 months 87/90 (97 %) 
   6 months 74/90 (82 %) 
   12 months 23/90 (26 %) 
Antibiotics use (%)  
   First year 27/90 (30 %) 
   Second year 40/90 (44 %) 
Probiotics use (% L.reuteri) 40/90 (44 %) 
Allergic manifestations at 7 yrs (% ) 42/80 (52 %) 
Caries status at 9 yrs (% Caries) 33/79 (42%) 
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After quality filtering, 34,794,056 sequences were obtained, with an average of 93,532 ± 3,480 
(SEM) sequences per sample.  
 
 
Bacterial load, richness and diversity through time 
Bacterial diversity and richness increased through time, reaching nearly 550 OTUs at 7 years of 
age with a Shannon diversity index of approximately 2.4 (Fig. I-1). The delivery mode and partial 
breastfeeding habits until 12 months of age did not have an impact on species richness (Fig. I-
1A-B). However, bacterial diversity appeared to be higher in C-section delivered infants at 12 
months of age (Fig. I-1A) and at two years of age in children not being breastfed through 12 
months of age (Fig. I-1B).  
 
Oral development, including the emergence of teeth, was accompanied by a steady increase in 
diversity and richness of the oral microbiome in this study, especially between 1 and 2 years of 
age. Interestingly, bacterial diversity at 2 years of age (Fig. I-1B), appears to be higher in children 
which abandoned breastfeeding before 12 months of age. Although this has not been studied 
before in oral microbiota, a similar trend was observed in gut microbiota analyses where children 
not being breastfed had higher microbial diversity [77, 163, 378], probably due to earlier 
introduction of solid food. Our results agree with a scenario in which following delivery, the oral 
cavity gets exposed to the environment, triggering the initiation of microbial colonization 
through diet, vertical transmission from parents and horizontal transmission from caregivers and 
siblings, thus increasing the bacterial diversity.[52, 379] 
 
In order to determine the development of bacterial density through infancy, we measured total 
bacterial load (Fig. I-S1) in saliva samples. Although there were no differences regarding delivery 
mode (Fig. I-S1A) and breastfeeding habits (Fig. I-S1B), the density of bacteria increased 
significantly with age, probably reflecting the influence of environmental interactions and the 
emergence of teeth. Interestingly, bacterial density at each time point appeared to fall within two 
groups (low or high), and this bimodal distribution was maintained through time for each 
individual. This pattern could not be attributed to caries status, allergy development, mode of 
delivery, feeding habits, antibiotics intake or probiotic administration (data not shown). In the 
future, it would be interesting to determine whether the physicochemical properties of saliva may 
influence cell density.  
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Fig. I-1. Species richness and diversity of total microbiota in infant saliva samples. (A) shows species 
richness and diversity in infants delivered vaginally (VD) or by caesarean section (C-section) at 3 months 
(NVD=62; NCS=11), 6 months (NVD=72; NCS=11), 12 months (NVD=59; NCS=10), 24 months (NVD=56; 
NCS =10) and 7 years of age (NVD=68; NCS=12). (B) represents species diversity and richness in infants 
breastfed for 12 months (BF) and in infants breastfed for less than 6 months of age (nBF). Analyzed 
samples were collected at 12 months (NnBF=52; NBF=17), 24 months (NnBF=50; NBF=16), and 7 years of 
age (NnBF=59; NBF=21). (C) shows species richness and diversity in children developing caries (CA) and 
children staying caries-free (CF) during the first 9 years of life. Saliva samples were collected at 3 months 
(NCF=40; NCA=26), 6 months (NCF=43; NCA=31), 12 months (NCF=37; NCA=26), 24 months (NCF = 35; 
NCA = 24) and 7 years of age (NCF= 45; NCA=30). Data are presented with means and standard errors. *p 




Bacterial composition during infancy  
When bacterial composition was analyzed for all samples through child development, clear 
changes emerged through time (Fig. I-S2). Streptococci dominated salivary samples at all times. 
They were particularly high in proportion during the first months of age, and their decrease was 
accompanied by a rise in other genera. These general patterns were influenced by several 
perinatal and postnatal factors.  
 
 
The influence of delivery mode and breastfeeding durations 
Bacterial species composition development was influenced by delivery mode and breastfeeding 
habits (Fig. I-2A, B), but not by L. reuteri supplementation during the first year of age (data not 
shown). The impact of delivery mode was reflected in differences in bacterial composition at 3 
and 6 months of age (Fig. I-2A, p=0.001, CCA analysis), followed by convergent microbial 
patterns at later age. Only the genus Haemophilus was found to be significantly more abundant 
(p=0.047) at 7 years of age in children delivered by C-section (Fig. I-S3). Thus, with the 
exception of this genus, no further colonizers were found to be significantly different between 
vaginally delivered and C-section delivered infants (Fig. I-S3). This could be due to infant 
A B C
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delivery mode affecting the direct transmission of initial bacteria from mother to newborn, 
having a short-term effect. This finding is in line with previous studies [55], where the Human 
Oral Microbe Identification Microarray was used, showing that microbial oral colonization in 
three-month-old infants delivered vaginally and those delivered by C-section was different. 
Similar findings of an early impact, but also more long-term effects [343, 380], have been 
reported for the microbiota of the lower gastrointestinal tract.[171, 172] When a multivariate 
analysis was performed including time, breastfeeding length and caries status as confounding 
factors, the effect of delivery mode on microbiota composition was no longer significant. Given 
that a significant breastfeeding length-delivery mode interaction was detected (p=0.026), part of 
the observed differences between children born by vaginal delivery and C-section can be due to 
the effect of breastfeeding.  
 
The influence of partial compared to no breastfeeding until 12 months of age did appear to have 
a long-term effect, as evidenced by a divergent oral bacterial composition at 24 months and 7 
years of age (Fig. I-2B, p=0.002) while bacterial colonization at early age appeared to be similar. 
This could be due to the fact that the majority of the infants in this cohort were breastfed during 
their first months of life (see Table I-1). A multivariate analysis revealed that the significant effect 
of breastfeeding on microbiota composition was maintained even after removing the effect of 
caries status, time and mode of delivery as confounding factors (p=0.036). Further work should 
therefore address the impact of formula feeding on microbiome development as findings 
presented here suggest that variations in the initial oral microbial communities may result in 
differences in the bacterial succession patterns that persist over time, analogous to the impact of 




Fig. I-2. Salivary microbiota patterns through children’s development. (A) Microbial pattern differences in 
saliva from infants delivered vaginally (VD) or by caesarean section (CS), p = 0.0016, at 3 months 
(NVD=62; NCS=11), 6 months (NVD=72; NCS =11), 12 months (NVD =59; NCS=10), 24 months (NVD=56; 
NCS=10) and 7 years of age (NVD =68; NCS=12). (B) Showing microbial composition pattern differences in 
infants who were breastfed for 12 months (BF) and in infants breastfed (nBF) for less than 6 months (p = 
0.0017). The numbers of children were: 12 months (NnBF= 52; NBF = 17), 24 months (NnBF = 50; NBF = 16) 
A B CBreastfeeding habits Caries statusMode of delivery









































































































   55 
and 7 years of age (NnBF =59; NBF=21). (C) Microbial composition patterns in children developing caries 
(CA) and children staying caries-free (CF) during the first 9 years of life (p = 0.0018). Saliva samples were 
collected at 3 months (NCF=40; NCA=26), 6 months (NCF=43; NCA=31), 12 months (NCF=37; NCA=26), 24 
months (NCF=35; NCA=24) and 7 years of age (NCF=45; NCA=30). Numbers accompanying the variables 
(delivery mode, breastfeeding and caries onset) are representing the time points plotted. p-Values for CCA 
plots were determined by Adonis analysis (a nonparametric statistical method, R package Vegan) and 




Microbial colonization patterns 
Dominant bacterial genera (present at >1%) which inhabited the oral cavity during the first 3-6 
months, here called “Early colonizers”, included Streptococcus, Veillonella and Lactobacillus spp. (Fig. 
I-3A). The most frequent bacterium of the oral cavity in the current study was Streptococcus, and 
children being breastfed until 12 months of age appeared to have higher abundance of this genus 
at one year of age (p=0.005). This finding is consistent with other reports [50, 382] and 
Streptococcus has been found to be one of the dominant bacterial groups in human breastmilk.[19, 
85] Aging of the children was associated with lower levels of Streptococcus, although the decrease 
tended to be more notable in children abandoning breastfeeding before 12 months of age. This 
indicated that settlement of this genus is favored by breastmilk, either by direct transmission or 
by an appropriate nutrient supply.[19, 21] Moreover, this pioneer is often found in the oral cavity 
of the neonate because of its ability to adhere to and colonize the mucosal surface lining.[49] The 
metabolic products (such as lactic acid) derived from Streptococcus species from the dietary 
oligosaccharides in breastmilk might pave the way for the establishment of other microorganisms 
in the oral cavity, including bacterial genera like Veillonella.[48, 347] Veillonella, here ranging 
between 2 to 8% of total abundance with significantly higher levels at 7 years in children keeping 
breastfeeding until 12 months of age (p=0.037), is another bacterial genus commonly 
encountered in breastmilk [74, 91]. This genus requires organic acids as carbon source and 
therefore its presence is likely favored by the high levels of lactate derived from lactose 
fermentation, which this genus will transform to propionate and acetate.[383] An important 
lactose fermenter is obviously Lactobacillus, which in the oral cavity might be acquired by the 
neonate during vaginal delivery, as this genus is highly abundant in vaginal microbiota, [384] but 
also through breastfeeding since breastmilk has been proposed to favor the growth of vaginally 
acquired bacteria.[88, 171, 383] In the current study, no differences in Lactobacillus abundance 
were found between children being breastfed up to one year of age or not (Fig. I-3A) and neither 
between vaginally delivered and C-section infants (Fig. I-S3). Among the components of human 
breastmilk, oligosaccharides are thought to directly influence the gut microbial composition and 
to enrich bacterial functions associated to carbohydrate consumption and biosynthesis of amino 
acids and vitamins [163, 385] and a similar process may be taking place in the oral cavity. Early 
commensals of the oral cavity are likely having an ecological advantage over those arriving later 
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and may promote the change of the environment through the production and excretion of 
products of their metabolism, thus benefitting the growth of further oral bacterial communities. 
This process of microbial succession and increasing diversity, promoted by breastfeeding, could 
lead to subsequent formation of complex and steadier microbial communities, as proposed for 
gut microbiota.[40] 
 
Bacterial genera Gemella, Granulicatella, Haemophilus and Rothia, here defined as “constant 
colonizers” (Fig. I-3B), were present already at 3 and 6 months of age with >1% of abundance, 
and their abundance increased with time. Gemella and Granulicatella are considered as common 
dental plaque inhabitants [386] and were found to increase in abundance through age, ranging 
from 5-10% and 2-8%, respectively. It is likely that the initiation of teeth eruption, starting 
around 6-8 months postnatally, creates new ecological niches in the oral cavity, giving rise to new 
adhesion surfaces, thus favoring their further colonization.  
 
A third set of microorganisms were “late colonizers” and included Actinomyces, Porphyromonas, 
Abiotrophia and Neisseria, which became dominant in the oral cavity at a later stage, approximately 
after the first year of life (Fig. I-3C). Thus, the data suggest that the acquisition or dominance of 
each bacteria may occur optimally only at certain ages. Breastfeeding until 12 months of age was 
associated with significantly lower levels of Actinomyces (p=0.044) at 7 years of age and 
Porphyromonas (p=0.049) and Neisseria (p=0.028) at 12 months and 24 months of age, respectively. 
Porphyromonas, more specifically Porphyromonas gingivalis, is a gram-negative oral anaerobe involved 
in the pathogenesis of periodontitis, an inflammatory disease that destroys the tooth tissue and 
may lead to tooth loss.[387] The results are indicating that children being breastfed by 12 months 
of age, as compared with children no longer breastfed, have significantly lower abundance of this 
genus at one year of age. However, species-level taxonomic analysis revealed that 100% of 
Porphyromonas sequences correspond to Porphyromonas catoniae during the first 12 months of age. At 
2 years, P. gingivalis appeared at 9% of the total, whereas P. catoniae accounted for 91% of the 
sequence reads. At 7 years of age, the proportions were 86.5% for P. catoniae and 13.4% P. 
gingivalis. Thus, an association between reduced breastfeeding length and risk of gum disease is 
uncertain. Neisseria, a common bacterial community member of the healthy human mouth [388], 
was found to be more abundant in children not being breastfed until 12 months of age, in line 
with previous research where species belonging to this genus were found more frequently in 
children being formula fed.[54] Thus, breastmilk had a long-term effect on oral microbiota 
composition, but this altered microbiota could not always be linked to healthy or disease-
associated communities, and further work should study the long-term consequences for the 
child’s oral and systemic health. Beside the potential health effect, the results presented here are 
suggesting that the transmission of bacteria from breastmilk and the nutrients supplied by it at 
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this critical time point in infant´s development, could affect the colonization window of specific 
bacterial genera, and depending on delivery mode and breastfeeding duration, this may lead to 




Fig. I-3. Microbiota composition of dominant bacterial genera in children being or not being breastfed 
until 12 months of age. (A) Genera classified as early colonizers. (B) Genera considered to “constantly 
increase” are already present at 3–6 months of age at >1% frequency, and are increasing in relative 
proportion with time. (C) Bacterial genera considered as “Late colonizers”, are defined as those present at 
3–6 months of age below 1% relative abundance, which undergo significant increase after 12 months of 
age. Plots are showing the relative abundance of dominant bacterial genera, as determined by Illumina 
sequencing of 16S rRNA gene, in saliva samples collected at 3 months, 6 months, 12 months (NnBF=52; 
NBF =17), 24 months (NnBF =50; NBF=16) and 7 years (NnBF=59; NBF=21) of age. *p< 0.05 by both Mann–





The effect of antibiotics intake on microbiota development 
The clinical data of this cohort allowed us to assess the influence of antibiotics intake in early life 
(first and second year) on developing microbiota. The antibiotics courses given were mainly due 
to early otitis media (in 89% of cases) and included Amoxicillin (34 % of cases) and 
Phenoxymethylpenicillin (42 % of cases) (Table I-SI). Upon comparing the microbial succession 
in children who did or did not take antibiotics during the first two years of life, significantly 
divergent colonization was observed at 24 months and 7 years of age, whereas bacterial 
composition at earlier time points were overlapping in children treated with antibiotics (Fig. I-
4A). Multivariate analyses were also performed, considering the effect of time and different 
confounding factors on microbiota composition. Antibiotic use had a significant effect on 
microbiota composition once the effects of caries status and time were removed (p=0.05) and a 
significant antibiotic by time interaction was found (p=0.008). There was a lower effect of 
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analysis, suggesting that part of the significance is due to the strong effect of breastfeeding on 
microbiota composition.  
 
By comparing the most dominant genera (>1% of total microbiota) present in these two groups, 
the genus Granulicatella was higher in abundance at 24 months of age (p=0.003) in children not 
taking antibiotics while Prevotella (p=0.020) was more prevalent at 7 years of age in children 
treated with antibiotics in early life. The data suggest that the abundance of commensal genera 
such as Granulicatella [386] may be disturbed by antibiotics use while the presence of other genera, 
like Prevotella, which has been associated with several oral diseases [389], may be favored.  
 
In order to obtain deeper insight of microbiota alterations upon antibiotics intake, the microbial 
composition was assessed at species-level OTUs (Fig. I-4B). The analysis revealed a high number 
of bacteria uniquely present in children that were treated with antibiotics more than once during 
the first two years of life including several Actinomyces species at 2 and 7 years of age. Moreover, 
the presence of species belonging to Fusobacterium, Veillonella and Lactobacillus was also associated 
with antibiotics intake during the first two years of life in our cohort. The fact that Veillonella spp 
use organic acids as their only carbon source strongly suggests that the oral microbiota of those 
children is more acidogenic. On the contrary, Neisseria and Streptococcus mitis/dentisani, were 
present in our samples at significantly higher levels in 7-year old children that did not take 
antibiotics. Thus, although a divergent microbiota does not necessarily imply a negative effect for 
health, most significant changes in microbial composition detected in the current study as a 
consequence of antibiotic administration, have previously been associated with oral diseases [361, 
363, 390–394] and future studies will need to specifically address whether antibiotic use during 
infanthood has an effect on oral health. 
 
It is of course possible that the divergent microbial succession patterns observed at 7 years of age 
might be affected by further antibiotics courses and other influencing factors, occurring during 
the remaining five years. However, given that the first years of age appear to represent a crucial 
period of microbiota development and immune system modulation and that early changes in 
ecological successions are those with the largest impact on community development [381], it is 
important to consider that early antibiotic treatment can have long-term consequences for 
microbiota development. It has to be emphasized that in adults, the original salivary microbial 
composition appears to be restored after antibiotic use [395], suggesting resilience of the oral 
microbiome; in children, long-term alterations of the gut microbiome, as a consequence of early 
antibiotic administration, have been proposed to have negative effects for systemic health, 
including obesity and allergy.[349, 350] Thus, the impact of early intake of antibiotics for human 
health deserves consideration.  
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Fig. I-4. Accumulative antibiotics effect on salivary microbiota development. (A) shows salivary 
microbiota patterns in children treated with antibiotics during the first 2 years of life and children not 
taking any antibiotics during the first 2 years of life; p = 0.017. p values for CCA plots were determined by 
Adonis analysis (a nonparametric statistical method, R package Vegan) and indicate that the factor 
provided can explain part of the total variability. (B) represents the influence of antibiotics intake on 
bacterial species distribution at 24 months and 7 years of age, here represented with a Venn’s diagram. The 
numbers indicate unique species found in children not treated with antibiotics (purple) and children treated 
with antibiotics (grey) and OTUs differentially distributed are stated in the tables. OTUs presented were 
filtered according to sequence length (>300 bp) and identity (>97%nucleotide similarity). Analyzed sample 
sizes were: 3 months (NNO=28; NYES=11), 6 months (NNO=33; NYES=13), 12 months (NNO=29; 
NYES=11), 24 months (NNO=26; NYES=10) and 7 years (NNO =35; NYES=11); NO = no antibiotics intake 




Oral microbiota in health and disease 
Caries development did not appear to be related with bacterial diversity (Fig. I-1C) or bacterial 
load (Fig. I-S1C) during the first 7 years of life. Although there were no differences between 
children staying caries-free and children developing caries at age 9, the density of bacteria was 
increasing significantly with age, probably reflecting the influence of environmental interactions 
and the emergence of teeth. The overall species richness was higher in children that remained 
caries-free by 9 years of age, but the difference was not significant (Fig. I-1C). However, the 
potential association of lower bacterial diversity to caries risk should be further studied, as a 
lower bacterial diversity has been associated to caries in cross sectional studies.[396] A factor 
reducing the possible association of caries status to diversity could be the use of saliva samples, 
which provide a good representation of overall oral microbial diversity but may not fully 
correlate with bacterial composition at the tooth biofilm, where the disease takes place.[397]  
 
Caries development at 9 years of age was preceded by divergent bacterial composition at 24 
months of age, reaching the maximum at 7 years. (Fig. I-2C). At early age, no differences 
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colonization patterns and ecological factors favoring caries development are associated with later 
age. A critical period may include the eruption of primary incisors, primary molars and 
permanent first molars, where cariogenic bacteria like Mutans streptococci can adhere through 
glucan binding proteins.[398] Although these caries-linked species are considered associated to 
hard-tissues, there are studies suggesting that they can be acquired at any time from under 6 
months (prior to first tooth eruption) to over 3 years of age.[399, 400] Taken together, the data 
here suggest that different bacterial colonization patterns were present between caries-free 
children and children that developed caries, however they were significant only after the second 
year of age.  
 
Bacterial composition and caries development 
Since no significant differences were observed between caries-free and caries-active children at 
the genus taxonomic level (Fig. I-S4) and given that the genus Streptococcus was highly abundant in 
the infants’ oral cavity, it was of great interest to investigate if there were any specific 
Streptococci species associated with caries development in the cohort. The genus Streptococcus 
comprises a large number of species that can have positive effects on human health and some of 
them have started to be used as probiotics in oral diseases.[401] The OTUs found corresponded 
to S. mitis/infantis/dentisani (identical in the sequenced 16S rRNA region), S. salivarius, S. sanguinis, 
S. lactarius, S. cristatus and S. mutans (Fig. I-5). S. mitis/infantis/dentisani were the most prevalent 
OTUs (ranging from 75-85%) and no difference was found between the children who did or did 
not develop caries at 9 years of age. S. infantis belongs to the Streptococcus mitis group [402] and has 
been associated with oral health as it significantly decreases during caries progression in the 
young permanent dentition.[403] S. dentisani is a bacterial species associated with good oral health 
and it has been isolated from caries-free individuals.[361] Because of the high sequence similarity 
within the Streptococcus genus PCR-amplified region used for Illumina sequencing, we could not 
distinguish which 16S rRNA reads belonged to S. mitis, S. infantis or S. dentisani. To clarify this, 
qPCR amplification with S. dentisani-specific primers was performed in order to determine the 
acquisition of this species through age. The quantities of S. dentisani were undetectable by qPCR 
during the first year of age, suggesting that the colonization of this species might be dependent of 
teeth eruption. This is in agreement with its normal association with dental plaque.[361] The 
levels of S. dentisani were higher in children remaining caries-free at 9 years of age in comparison 
with caries-experienced children, but the difference was not significant (Fig. I-S5). 
 
Streptococcus salivarius was another commonly found species in children’s saliva (Fig. I-5). Its 
abundance was highest at 3 months of age, ranging between 10-15% of the total streptococcal 
species, and decreasing steadily through time, likely opposing teeth eruption. This pioneer 
colonizer and a prominent member of the oral microbiota of the healthy mouth has been 
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detected hours after birth because of its unique ability to adhere and colonize tongue and cheek 
mucosa.[52] Although S. salivarius has been intended for use as a probiotic targeting the oral 
cavity [404], no differences in abundance levels of this species through age were discovered 
between children who did or did not develop caries at 9 years of age, perhaps due to its absence 
from dental plaque.[361] Streptococcus lactarius was another species encountered in infant´s saliva, 
predominantly at 3 and 6 months of age, to later decrease and even disappear. This species was 
isolated from breastmilk of healthy mothers [405], explaining its high abundance in early age 
when the majority of the children in this cohort were breastfed. Given the long-term impact of 
breastfeeding for microbiota development (Fig. I-2B), it is plausible that early colonization with 
S. lactarius, acquired from mother´s breastmilk, could benefit later colonization by other beneficial 
microbial species. However, the potential role of S. lactarius in health and disease has not been 
evaluated to date. 
 
Colonization of Streptococcus sanguinis started between 6 and 12 months of age and followed a 
similar pattern of development between children who did and did not develop caries. This 
species is believed to play a benign role in the oral cavity and it has been described to colonize in 
association to tooth emergence, at a median age of 9 months.[406] Moreover, S. sanguinis is 
recognized for its antagonistic role in dental caries since it may compete with cariogenic mutans 
streptococci for colonization sites on tooth surfaces.[406] Interestingly, although at very low 
levels, the cariogenic S. mutans was detected in the oral cavity of the infants already at an early 
age, possibly acquired through their mothers as shown before [398], with a trend of significantly 
higher levels at 7 years (p=0.06) in children developing caries. This is in line with previous studies 
where proportions of S. mutans in saliva were higher in children with caries when compared to 
those who stayed caries-free.[51] Thus, although this species is considered mainly an inhabitant 
of hard tissues, our data show that it can be detected before tooth eruption and therefore the oral 
health of mothers and caretakers during infancy may play an important role in the transmission 
of this pathogen. However, S. mutans has also been detected in caries-free populations and not in 
all cases of childhood caries, suggesting that other species may be cariogenic pathogens.[389, 398] 
In this study, children developing caries had significantly higher abundance of Streptococcus cristatus 
already at 3 months (p=0.026) and 24 months of age (p=0.033), compared to the children that 
stayed caries-free until 9 years of age. Given that S. cristatus, among other species, has been 
associated with severe early childhood caries [354], even in the absence of Streptococcus mutans, its 
role as an important cariogenic species and potential caries risk biomarker should be further 
studied. Nevertheless, it must be emphasized that streptococci are extremely similar in their 16S 
rRNA gene sequence, particularly at the V3-V4 region analysed in the current work, and 
therefore the suggested association of S. cristatus with caries development should be confirmed by 
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Fig. I-5. Relative abundance of most prevalent Streptococci species found in saliva samples of children 
staying caries-free and children developing caries during the first 9 years of age. Plots represent average 
relative abundance of Streptococci through time. Taxonomy assignments were performed with RDP classifier 
at 100% nucleotide identity. All data are presented as means with standard errors. *p < 0.05 by both 





If the association between S. cristatus and dental caries is confirmed, it must be born in mind that 
this species has been found to interrupt the formation of P. gingivalis biofilms by repressing the 
production of several virulence factors in this major periodontal pathogen.[408] In our dataset, a 
scatterplot of the relative frequencies of Porphyromonas and S. cristatus shows an L-shape 
(correlation p-value for the hyperbolic regression was p=0.057), suggesting potential antagonistic 
behaviour (Fig. I-S6), a feature that has been demonstrated in subgingival plaque samples from 
adults.[409] Given that most Porphyromonas sequences in our samples corresponded to P. catoniae 
(P. gingivalis accounted only for 13.4% of total Porphyromonas reads by 7 years of age), the potential 
antagonism between S. cristatus and P. gingivalis may not be apparent until a later age.  
 
In addition, LefSe analyses were performed in order to examine potential biomarkers for early 
caries diagnosis. No specific group of species/genera at early age could be associated with caries 
development at 9 years of age (data not shown), suggesting that other ecological determinants 
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risk assessment models.[410, 411] Interestingly, even though the supplementation with L. reuteri 
during the first year of life has been associated with reduced caries prevalence at 9 years of age 
[329], no differences in caries development related to this Lactobacilli could be detected in the 
present study. Given that some of the infants included in the study developed allergies during 
their early childhood (see Table I-I), the groups were balanced according to allergy status and no 
relationship was found between allergies and caries onset. Even though mode of delivery and 
breastfeeding until 12 months of age have been shown to impact oral microbiota development in 
this study, no correlation between delivery mode or breastfeeding duration with dental caries 
could be detected. However, this could be due to low statistical power of the groups compared. 
Although microbiota composition clearly differed at 7 years of age between caries-free and 
caries-experienced children (Fig. I-2C), the absence of robust individual biomarkers of caries risk 
at an earlier age underlines that microbial-based early diagnostic tests should not be based on 
single species, and new potential bacterial risk indicators should be identified [412], including S. 
cristatus as proposed above. Given the enormous inter- and intra-individual variability in bacterial 
composition at caries lesions [413], and the multi-factorial nature of oral diseases where 
microbial, environmental and host-associated variables are involved, a holistic, ecological 
approach to caries risk assessment where information about the host, the habits (including the 
diet and oral hygiene) and the microbes are integrated will likely provide a better estimate of 




Only limited information is available on oral microbiome development in infants, and most 
studies have focused on taxonomic analysis. Thus, functional, metagenomic analyses are pending 
to fully understand the microbial contribution to oral health and disease.[415] Previous studies 
addressing oral microbiota development in early life have been hampered by retrospective 
approaches, small sample sizes, lack of deep sequence coverage, limited period of follow-up and 
analyses at single time points. The current study demonstrates that the infant’s oral cavity gets 
colonized by microorganisms in a timely manner, increasing in complexity with time. In general, 
the data presented in the current manuscript is consistent with a model where microbiota 
development follows an ecological succession.[416] 
 
In this scenario, several early colonizing species pave the way for the settlement of other 
microorganisms, which further expand microbial diversity towards a mature community which is 
more robust and resilient to change, partly because of the developed immune tolerance.[340] The 
presence of several species (particularly S. cristatus) at an early age was associated in this study to a 
higher frequency of dental caries at 9 years of age. Therefore, these findings open the possibility 
to use this species, together with others identified in other studies, as potential biomarkers of 
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caries risk. The oral cavity is a complex and heterogenous ecosystem with many variables 
influencing microbial composition and function. Several external factors appear to strongly 
influence microbiota development, including mode of delivery, which had a short-term effect, 
and others like breastfeeding length or antibiotic treatment, which appeared to have a long-term 
impact. It is interesting to note that, on the contrary, the oral microbiome composition in adults 
appears to be extremely resilient to antibiotic treatment.[395] This highlights that developmental 
milestones that are critical for oral microbiota succession occur in particular during infancy, and 
that an appropriate microbial colonization pattern can be instrumental for future health. Thus, 
microbial exposure, feeding habits and medical interventions during those initial and fragile 
stages may have a lifelong impact on general microbiome composition, and their potential 
consequences for human health should be carefully studied.  
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Fig. I-S1. Bacterial load of the total microbiota in infant saliva samples. Bacterial density using salivary 
samples that were obtained at different time points until 7 years of age, was determined by qPCR using 
universal primers targeting 16s rDNA bacterial gene. Figures are showing bacterial density depending on 
the mode of delivery (A), partial breastfeeding until 12 months of age (B) and dental caries status (C). 
Data are presented with median with interquartile ranges. Delivery mode: 3 months (NVD=62; NCS=11), 6 
months (NVD=72; NCS=11), 12 months (NVD=59; NCS=10), 24 months (NVD=56; NCS=10) and 7 years of 
age (NVD=68; NCS=12); Partial breastfeeding at 12 months: 12 months (NnBF=52; NBF=17), 24 months 
(NnBF=50; NBF=16) and 7 years of age (NnBF=59; NBF=21); Caries status: 3 months (NCF=40; NCA=26), 6 
months (NCF=43; NCA=31), 12 months (NCF=37; NCA=26), 24 months (NCF=35; NCA=24) and 7 years of 




Fig. I-S2. Oral microbiota development through time. Plots show the relative abundance of dominant 
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Fig. I-S3. Microbiota composition of the most dominant bacterial genera in children delivered vaginally or 
through caesarean section. (A) Genera considered as early colonizers. (B) Genera considered to 
“Constantly increase” are already present at 3-6 months of age, at >1%, and they are increasing with time. 
(C) Bacterial genera considered as “Late colonizers”, present at 3-6 months of age but below 1% of 
abundance and significant increase after 12 months of age. Plots are showing the relative abundance of 
dominant bacterial genera, as determined by Illumina sequencing of 16S rDNA gene, in saliva samples 
collected at 3 months (NVD=62; NCS=11), 6 months (NVD=72; NCS=11), 12 months (NVD=59; NCS=10), 







Fig. I-S4. Microbiota composition of the most dominant bacterial genera in children developing dental 
caries and children staying caries-free until 9 years of age. (A) Genera considered as early colonizers. (B) 
Genera that are constantly increasing through the age. Plots are showing the relative abundance of 
dominant bacterial genera, as determined by Illumina sequencing of 16S rDNA gene, in saliva samples 
collected at 3 months (NCF=40; NCA=26), 6 months (NCF=43; NCA=31), 12 months (NCF=37; NCA=26), 
24 months (NCF=35; NCA=24) and 7 years of age (NCF=45; NCA=30). CF: caries free; CA: caries active; 
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Fig. I-S5. Streptococcus dentisani levels in infant saliva samples determined by qPCR quantification. Detection 
limit was established >2*102 cells/ml saliva. Data are presented with median and interquartile ranges. 24 




Fig. I-S6. Correlation between Streptococcus cristatus and Porphyromonas spp. in children’s salivary samples. 
Scatterplot shows the relative proportions of the two bacteria, which approximate a hyperbolic regression 
(p=0.057), suggesting potential antagonism between the two taxa. Samples with 0% proportion were 
removed from the analysis.  
 
 
Table I-S1. Accumulative antibiotics intake during the first two years of life. 
Patient code Antibiotics courses (age in months) 
1 Phenoxymethylpenicillin (9), Phenoxymethylpenicillin (10), Amoxicillin (11), Phenoxymethylpenicillin (22) 
2 Phenoxymethylpenicillin (7), Phenoxymethylpenicillin (18) 
3 Erythromycin (9), Phenoxymethylpenicillin (13), Loracarbef (17) 
4 Phenoxymethylpenicillin (9), Ampicillin (10), Phenoxymethylpenicillin (20), Amoxicillin (21) 
5 
Phenoxymethylpenicillin (3), Amoxicillin (3), Amoxicillin (10), 
Amoxicillin (13), Flucloxacillin (15), Amoxicillin (15), 
Amoxicillin (19), Amoxicillin (24) 
6 Phenoxymethylpenicillin (10), Phenoxymethylpenicillin (12), Phenoxymethylpenicillin (23) 
7 Phenoxymethylpenicillin (21), Benzyl-penicillin and Phenoxymethylpenicillin (23) 
8 Phenoxymethylpenicillin (8), Amoxicillin (9) Phenoxymethylpenicillin (16) 
9 
Phenoxymethylpenicillin (6), Amoxicillin (7), Amoxicillin (10) 
Amoxicillin (11), Phenoxymethylpenicillin (19), 
Amoxicillin (21), Amoxicillin (22) 
10 Bactrim (6), Furadantin (6-11, as prophylaxis), Phenoxymethylpenicillin (20) 
11 Phenoxymethylpenicillin (2), Amoxicillin (3), Phenoxymethylpenicillin (13), Amoxicillin (13) 

























Chapter II – ABERRANT IgA RESPONSES TO THE GUT 
MICROBIOTA DURING INFANCY PRECEDE ASTHMA 
AND ALLERGY DEVELOPMENT 
 
- Majda Dzidic, Thomas R. Abrahamsson, Alejandro Artacho, Bengt Björkstén, Maria Carmen 
Collado, Alex Mira, Maria C. Jenmalm; Aberrant IgA responses to the gut microbiota during 









Although a reduced gut microbiota diversity and low mucosal total IgA levels in infancy have 
been associated with allergy development, IgA responses to the gut microbiota have not yet been 
studied. Here we sought to determine the proportions of IgA coating together with the 
characterization of the dominant bacteria, bound to IgA or not, in infant stool samples in relation 
to allergy development. A combination of flow cytometric cell sorting and deep sequencing of 
the 16S rDNA gene was used to characterize the bacterial recognition patterns by IgA in stool 
samples collected at 1 and 12 months of age from children staying healthy or having allergic 
symptoms up to 7 years of age. The children with allergic manifestations, particularly asthma, 
during childhood had a lower proportion of IgA bound to fecal bacteria at 12months of age 
compared with healthy children. These alterations cannot be attributed to differences in IgA 
levels or bacterial load between the 2 groups. Moreover, the bacterial targets of early IgA 
responses (including coating of the Bacteroides genus), as well as IgA recognition patterns, differed 
between healthy children and children with allergic manifestations. Altered IgA recognition 
patterns in children with allergy were observed already at 1 month of age, when the IgA 
antibodies are predominantly maternally derived in breast-fed children. An aberrant IgA 
responsiveness to the gut microbiota during infancy precedes asthma and allergy development, 










Allergic diseases have become a major public health problem in affluent societies.[417] Reduced 
microbial exposure, both pre- and postnatally, has been proposed to underlie the increase in 
allergy development.[42, 57, 418, 419] The gut microbiota, hosting a complex bacterial 
community, is quantitatively the most important source of microbial stimulation and may provide 
a primary signal for appropriate immune development.[57] The gut microbiota differs in 
composition and diversity during the first months of life in children who later do or do not 
develop allergic disease,[42, 168, 420–422, 265–270, 275, 278], although no specific microbes 
with consistently harmful or allergy protective roles have yet been identified. Also, we observed 
that the differences in the gut microbiota diversity during infancy between healthy children and 
children developing allergies were mainly related to asthma and not allergic rhinoconjunctivitis 
development.[266] Early establishment of a diverse gut microbiota, with repeated exposure to 
new bacterial antigens, may be more important than the distribution of specific microbial species 
in shaping a normal immune mucosal and systemic maturation.[57]  
 
A reduced mucosal barrier function may increase the risk for allergy development[417] and 
immunoglobulin A (IgA) is the primary mediator of humoral mucosal immunity.[423] 
Immunoglobulin A is the most abundantly produced antibody in humans, with the highest 
amount of secretion in the intestinal tract.[423, 424] Secretory IgA (SIgA) has a crucial role in the 
gut through its binding to bacterial antigens, thus preventing their direct interaction with the host 
via immune exclusion and maintaining the mucosal homeostasis.[423, 425] SIgA may also limit 
overgrowth of select species, thus stimulating diversity.[110, 423] Therefore, this antibody 
represents a key host mechanism in regulation of the commensal community, and innate receptor 
signaling in T-cells seems to decide the specificity of IgA to constrain the composition of the 
intestinal bacteria, ensuring a benign symbiotic relationship.[424] However, in contrast to IgG 
and IgM levels, the generation of this anti-inflammatory antibody is limited during early infancy 
and delayed development of mucosal IgA production, for instance in the absence of 
breastfeeding, may lead to infectious disease in young infants.[58, 426] Studies and clinical 
reports suggest that SIgA that origins from the mothers’ breastmilk is important for immune 
regulation and protection against bacterial, viral and parasitic infections in suckling infants.[58, 
427–430]  
 
Whereas total levels of SIgA in saliva and fecal samples have been investigated in children 
developing allergy before, little is known about the identities of the bacterial taxa targeted by IgA 
in the infant gut and what role mucosal immune responses to the gut microbiota plays in 
childhood allergy development. However, earlier studies have shown that low levels of salivary 
and intestinal SIgA are associated with an increased risk for allergic manifestations during early 
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life.[245, 246, 431] Recent advances in flow cytometry [432] and next generation sequencing [413] 
now allow studying the complex interactions between human antibodies and microbiota. In this 
study, we have used flow cytometry-based cell sorting and barcoded 16S rRNA 454-
pyrosequencing to characterize the dominant gut bacteria, coated or non-coated with IgA, and 
determined total secretory IgA levels and bacterial load in stool samples collected during the first 
year of life in infants who either developed allergic manifestations or stayed healthy up to 7 years 








The infants included in this study were part of a larger randomized double-blind trial in South-
Eastern Sweden between 2001 and 2003, evaluating the potential allergy prevention effect of 
probiotic Lactobacillus reuteri ATCC 55730, until 2 [327] and 7 years of age.[328] The recruited 
children had a family history of allergic disease (1 or more family members with eczema, asthma, 
gastrointestinal allergy, allergic urticaria or allergic rhinoconjunctivitis), and more detailed 
inclusion and exclusion criteria are explained in the study of Abrahamsson et al.[327] Among the 
188 infants completing the original study, infant stool samples collected at 1 and 12 months of 
life in 20 children developing allergy (Table II-SI) and 28 children staying healthy up to 7 years of 
age (Table II-SII), were randomly selected for this study (Fig. II-1). Ten of the allergic children 
developed asthma. Other allergic diseases included eczema (n=9 at 7 years of age; n=17 at 2 
years of age; no infants developed eczema before 1 month of age), allergic rhinoconjunctivitis 
(n=10) and allergic urticaria (n=1), with symptoms defined as described in detail previously.[327, 
328] The samples were immediately frozen at -20°C following collection and later stored at -70°C 
until use.  
 
There were no differences regarding potential confounders, such as sex, mode of delivery, birth 
order, maternal atopy, breastfeeding, antibiotics, and probiotic supplementation, between the 
infants who did or did not develop allergic manifestations (Table II-I). All included infants were 
exclusively breast-fed for at least 1 month, and no infant received antibiotics before 1 month of 
age.[265] The Regional Ethics Committee for Human Research at Linköping University 
approved the study. Informed consent was obtained from both parents before inclusion. The 
study is registered at ClinicalTrials.gov (ID NCT01285830). 
 
Sample labeling and flow cytometry protocol 
Stool samples were suspended in sterile saline solution (autoclaved H2O; NaCl Sodium Chloride 
99.5% PA-ACS-ISO, Panreac; Barcelona, Spain; Ref. 131689.1211) with 5% bovine serum 
albumin (Sigma-Aldrich, St Louis, MO, USA; Ref. A7030-100gr) in order to prevent non-specific 
antibody binding. After short sonication, the samples were stained with goat anti-mouse IgA 
labeled with FITC (Invitrogen, Frederick, MD, USA; Ref. M31001) or with goat anti-human IgA 
labeled with FITC (Invitrogen; Ref. H14001), according to the manufacturer instructions. Anti-
mouse IgA was used as an isotype control, determining the fluorescence intensity corresponding 
to unspecific binding (Fig. II-S1). 
The sorting of the cells according to whether they were IgA coated (IgA+) or IgA non-coated 
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(IgA-) was performed by MoFloTM XDP Cell Sorter (Beckman Coulter, Inc; Brea, CA, USA) 
using blue laser (488 nm; 200 mW power) and red diode laser (635 nm; 25 mW power) as a light 
source. The lasers were aligned using Flow-CheckTM (10 µm) and Flow-SetTM (3µm) spheres. Cell 
separation was performed according to their fluorescence and forward scatter, reflecting the IgA 
coating and cell size, respectively, following the protocol by Simon-Soro et al.[413]  
 
Table II-I. Descriptive data of children included in this study.  













46 (13) 40 (8) 0.66 40 (4) 1.00 
Older siblings 
57 (16) 50 (10) 0.62 50 (5) 0.70 
Caesarean delivery 
14 (4) 20 (4) 0.70 20 (2) 0.64 
Furred pets 
4 (1) 15 (3) 0.29 10 (1) 0.46 
Maternal atopy 82 (23) 80 (16) 1.00 80 (8) 1.00 
Breast-feeding  




36 (10) 30 (6) 0.68 50 (5) 0.43 
Day care 
(1-12 mo) 14 (4) 10 (2) 1.00 (0) 0.56 
Probiotic group 
54 (15) 60 (12) 0.66 60 (6) 1.00 
*The x2 test was used to detect potential differences in frequencies between groups, except when the expected 





DNA from sorted fecal bacteria, IgA+ and IgA-, was isolated using the MasterPureTM complete 
DNA and RNA Purification Kit (Epicentre Biotechnologies, Madison, WI, USA), following the 
manufacturer’s instructions with a previous glass bead beating (0.17 mm diameter) and an 
additional enzymatic lysis step with lysozyme (20mg/ml, 37°C, 30 min; Thermomixer comfort, 
Eppendorf, Hamburg, Germany). DNA was finally purified by isopropanol/ethanol extractions 
as previously reported [433] and the concentration and purity were measured by calculating 
A260/280 ratios in Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific, MA, USA). 
 
16S rRNA gene amplification and sequencing  
DNA from 192 samples in total was used for PCR amplification and pyrosequencing in order to 
describe bacterial composition of the sorted populations. A region of approximately 650 bp of 
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the 16S rRNA gene was amplified using universal bacterial degenerate primers 357F-
CCTACGGGAGGCAGCAG and 926R- CCGTCAATTCMTTTRAGT [434], which 
encompass the hypervariable regions V3-V5 of the gene. This was performed using the high-
fidelity AB-Gene DNA polymerase (Thermo Scientific, Waltham, Mass., USA) with an annealing 
temperature of 52°C and 20 cycles, in order to minimize amplification biases.[366] A secondary 
amplification (25 cycles, annealing temperature of 52°C) was performed by using the purified 
PCR product as a template.[435] The primers in this step were modified to contain the 
pyrosequencing adaptors A and B linked to an 8-bp barcode, specific to each sample. Barcodes 
were different in at least 3 nucleotides, from each other, to avoid errors in sample assignments. 
The purification of PCR products was performed using Nucleofast 96 PCR filter plates 
(Macherey-Nagel, Düren, Germany) and the final concentration of the DNA per sample was 
measured by PicoGreen fluorescence (454 Life Science, Roche, Brandford, USA) in a 
QuantiFlour fluorometer from Promega Biosystems (model nr E6090; Sunnyvale, CA, USA). 
The PCR products were mixed in equimolar amounts and pyrosequencing was performed from 
the forward primer end using 454 GS-FLX pyrosequencer with Titanium chemistry (Roche, 
Basel, Switzerland) at the Center for Public Health Research (CSISP) in Valencia, Spain. One 
eighth of a plate was used for each pool of 20-25 samples.  
 
 
Sequence processing and taxonomic classification 
The resulting 16S rRNA read ends were trimmed in 10 bp sliding windows, with average value 
≥20, using the Galaxy tool [436] as quality has been shown to dramatically decrease towards the 
end of the sequences.[437] Only reads longer than 250 bp were considered, as well as those 
without mismatches in the primer region. The sequences were assigned to each sample by the 8 
bp barcode through the Ribosomal Database Project (RDP) pipeline [374] version 11.3, and 
chimeric sequences were filtered out using UCHIME.[438] 
 
Taxonomic assignment was performed by the RDP-classifier [374] where the reads were assigned 
a phylum, class, family and genus and phylogenetic ranks were allocated when scores exceeded 
0.8 confidence threshold. α – diversity analysis (Shannon indices), based on randomly selected 
700 reads per sample, was utilized to estimate the samples’ diversity on gene and phylum level. 
Here, the sequences over 97% identity, with 90% sequence alignment length, were considered to 
correspond to the same operational taxonomic unit (OTUs), thus representing a group of reads 
presumably belonging to the same species.[439] 
 
For analyzing IgA coating patterns, the threshold used for including the genera was ≥ 1% relative 
abundance in either the IgA+ or IgA- fractions. Further, a pseudocount that was equal to 0.001, 
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was added to every genus dedicated in both the IgA+ and IgA- fractions, thus evading the 
fractions with a value of zero. The abundance proportions of a given genera was log-transformed 
before calculating the ratio between IgA+ and IgA- fractions, giving the IgA index.[140] Thus, 
this score was based on proportional representation, for every given genus, within the IgA+ 
(positive IgA index values) and IgA- fractions (negative IgA index values), reflecting the degree 
of mucosal immune responsiveness to the microbiota. LDA Effect Size (LEfSe) [377] was then 
used for high-dimensional biomarker discovery comparing the IgA-indices between healthy 
infants and infants developing allergic manifestations.  
 
Principal Component Analyses (PCA) is a statistic tool used to emphasize variation and bring out 
strong patterns in a dataset. This analysis was performed by R software ade4 package [376] which 
is using a Principal Component Analysis constrained to Euclidean metric for multivariate data 
analysis and graphical display, where samples with similar IgA index values appear closer to each 
other in the two dimensional space.  
 
 
Bacterial load analysis with qPCR 
qPCR amplification and detection were performed in order to measure the bacterial load per 
human cell using primers targeting the single-copy housekeeping gene FusA, that is present in 
bacterial cells.[440] Single-copy cellular sequence β-actin was used as a quality control for isolated 
genomic DNA (Table II-SIII). The amplifications were performed in duplicates, on a LightCycler 
480 Real-Time PCR System (Roche Technologies), using an annealing temperature of 62°C. 
Each reaction mixture of 10 µl was composed of SYBR Green PCR Master Mix (Roche), 0.5 µl 
of the specific primer (concentration 10 µM) and 2 µl of DNA template. The bacterial cell 
numbers, in each sample, was calculated by comparing the Ct values obtained from those in 
standard curves. These were generated using serial tenfold dilutions of DNA extracted from 10 
million bacteria from infant stool samples and from 5 million human umbilical vein endothelial 
cells (HUVEC, Advancell, Barcelona, Spain) [441] quantified and sorted by flow cytometry.  
 
 
Determination of secretory IgA concentrations in stool samples 
A commercially available ELISA kit was used for the determination of total secretory IgA 
concentrations in feces samples (ImmuChrom ELISA kit, ImmuChrom GmbH, Heppenheim, 
Germany). 1 ml of a fecal suspension (100 mg of stool sample in 5 ml wash buffer) was 
centrifuged for 10 min at 10000xg, and the resulting supernatant (diluted 1:250 with wash buffer) 
was used in the assay. Samples were additionally diluted 1:10 and 1:5 for samples collected at 1 
and 12 months of age respectively, due to high antibody concentrations. The manufacturer's 
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guidelines were followed. The plates were read at 450 nm with 620 nm as the reference 
wavelength on Infinite F200 plate reader (Tecan Trading AG, Männedorf, Switzerland). All 




Statistical analyses were performed in R version 3.2.2 and GraphPad Prism 6 (GraphPad 
Software, San Diego, CA, USA, Version 6.1f), where p<0.05 was considered significant. The chi-
squared test was used to detect the potential influence of confounding factors between the 
groups. Fisher’s exact test was performed when expected frequency for any cell was less than 
five. α – diversity analysis were performed using the statistical software R with the vegan 
package.[442] Bar plots are presented as mean values with error bars representing the SEM while 
the scatter plots are demonstrating median with interquartile ranges. Specific statistical tests are 
noted in figure legends. For the PCA-analysis, DMwR package of R was used for removing two 
outliers, sample code 5 (Table II-SI) and 20 (Table II-SII). This was done according to Local 









Fig. II-1. Schematic workflow of performed experiments. The proportion of the gut microbiota bound to 
IgA (IgA+) or not (IgA-), in infants, was analyzed by flow cytometry-based sorting of fecal samples prior 
to 16S rRNA 454-pyrosequencing. In addition, total secretory IgA levels were estimated by ELISA tests, 









































Proportion of fecal bacteria bound to IgA in relation to allergy development 
Infants developing allergic symptoms during the first 7 years of life had significantly lower 
proportions of IgA-coated fecal bacteria at 12 months of age than healthy children (Fig. II-2A), 
while similar proportions were observed at 1 month of age. A low proportion of IgA-coated fecal 
bacteria at 12 months of age also preceded development of asthma (Fig. II-2B), but not allergic 
rhinoconjunctivitis (Fig. II-S2). Moreover, independently of allergy development, an overall 
decreasing proportion of fecal bacteria bound to IgA from 1 to 12 months of age was observed, 
likely reflecting a change from predominantly maternally breastmilk derived to child derived IgA 
antibodies.[426, 444]  
 
The influence of possible confounding factors was also evaluated. However, supplementation of 
the probiotic bacterium L. reuteri, delivery mode, antibiotic treatments and partial breastfeeding at 




Fig. II-2. Proportions of IgA-coated fecal bacteria in early infancy. (A) The proportion of fecal bacteria 
bound to IgA at 1 month and 12 months of age in children staying healthy (N=28) or developing allergic 
symptoms (N=20) during the first 7 years of life. (B) The proportion of fecal bacteria bound to IgA at 1 
month and 12 months of age in children staying healthy (N=28) or developing asthma (N=10) during the 





Bacterial load, but not total SIgA levels, differ in healthy children and children 
developing allergic manifestations 
In order to better understand detected differences in IgA proportions between healthy children 
and children developing allergic manifestations, bacterial load and total SIgA levels in stool 
samples were measured. The bacterial load was higher at 12 months of age in children staying 

































asthma (p=0.11) and ARC (p=0.61). A similar bacterial load was observed at 1 month of age in 
children staying healthy and developing allergy (Fig. II-3A). 
 
Total fecal SIgA levels were similar in healthy children and children developing allergic 
manifestations (Fig. II-3B), asthma (p=0.38 and p=0.71, for 1 and 12 months, respectively) and 
allergic rhinoconjunctivitis (p=0.77 and p=0.78, for 1 and 12 months, respectively). The fecal 




Fig. II-3. Bacterial load and total fecal secretory IgA levels in healthy infants and infants developing 
allergic manifestations. (A) The quantification of bacterial numbers was obtained by qPCR- detection with 
universal primers targeting the gene FusA (present in single-copy in bacterial cells) and normalized by the 
number of human cells, determined by qPCR- detection with primers for the human β-actin gene. 
NHealthy=28; NAllergic=20. (B) Total secretory IgA levels in stool samples were measured using ELISA 
immunoassay. 1 month of age: NHealthy=25; NAllergic=19; 12 months of age: NHealthy=27; NAllergic=19. Means 
with standard errors are indicated. *p<0.05; **p<0.01; ***p<0.001 (Mann Whitney U-test and Wilcoxon 




Bacterial targets of IgA responses in children developing allergic manifestations 
and children staying healthy up to 7 years of age 
Bacterial 16S rRNA gene sequencing of IgA+ and IgA- fractions was performed in order to 
assess early IgA responses in children staying healthy and children developing allergic 
manifestations during the first 7 years of age. After quality filtering and removal of chimeric 
sequences, 190 samples with 633,378 high-quality sequence reads remained, with an average of 
3,316 reads per sample and a mean length of 515 bp.  
 
While the analysis of the relative abundance of dominant bacterial families was generally similar 
between children developing allergy and staying healthy (Fig. II-S4), clear differences were 
observed upon analyzing the bacterial targets of IgA responses, represented as IgA index. IgA 





















































children developing allergic manifestations (Fig. II-4A, B) and asthmatic symptoms, particularly 
at 1 month but also 12 months of age (Fig. II-4C, D). At 1 month of age the genus 
Faecalibacterium was mainly IgA free (IgA-) in children developing allergic manifestations 
(including asthma but not allergic rhinoconjunctivitis, Fig. II-S5A). Moreover, the genera 
Parabacteroides and Anaerococcus were primarily not targeted by IgA in children developing allergic 
manifestations, when compared with healthy children. 
 
At 12 months of age, the IgA responses of children developing allergic manifestations were 
mainly not targeting the Bacteroides genus (Fig. II-4B), with similar findings observed for children 
developing allergic rhinoconjunctivitis (Fig. II-S5B). Regarding children developing asthmatic 
symptoms, Escherichia/Shigella was predominantly IgA free (Fig. II-4D), while Lachnospiraceae 
incertae sedis, a Firmicutes phylum member, was predominantly IgA bound in children developing 
allergic symptoms, when compared with healthy children (Fig. II-4B). Furthermore, the genera 
Roseburia and Erysipelotrichaceae incertae sedis were generally IgA-targeted in healthy children, but not 
in children showing allergic manifestations during the first 7 years of life. In contrast, decreased 
IgA responses to the Veillonella genus was observed in healthy children. 
 
Possible differences in bacterial diversity in children developing allergy and staying healthy were 
also of interest. Thus, Shannon indices for IgA+ and IgA- fractions were calculated. No 
differences, neither at genus (Fig. II-S6) or at phylum level (Fig. II-S7A, B) were found in relation 
to allergy development, however, except that children developing asthma had increased diversity 
at 12 months among IgA coated Bacteroidetes and Proteobacteria (Fig. II-S7C) but not in the IgA-






IgA recognition patterns of gut microbiota differ between healthy and allergic 
children  
A principal component analysis (PCA), based on the calculated IgA indices, was used in order to 
evaluate the differences in IgA responses to the gut microbiota between healthy children and 
children developing allergic manifestations, including asthma. Interestingly, the IgA recognition 
patterns differed already at 1 month of age when comparing healthy children and children 
developing allergic (Fig. II. 5A) and asthmatic symptoms (Fig. II-5C) but not ARC (Fig. II-S8A). 
Clear separation was observed at 12 months of age for healthy children and children developing 
allergic disease (Fig. II-5B), asthma (Fig. II-5D) and ARC (Fig. II-S8B).  
 
No effect of potential confounding factors (probiotic supplementation, the delivery mode, 
antibiotic treatment and partial breastfeeding at 12 months) on IgA recognition was observed 
(Fig. II-S9). 
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Fig. II-4. IgA responses to the gut microbiota, at 1 and 12 months of age. Plots are depicting IgA responses 
(defined by IgA index, reflecting the ratio in IgA+ and IgA-) to dominant genera (>1% of total) of the gut 
microbiota at 1 month (nHealthy=27; nAllergic=19; nAsthma=10) and 12 months (nHealthy=28; nAllergic=20; nAsthma=10) of 
age when comparing healthy children and children developing allergic (A, B) and asthmatic symptoms (C, D). 
For a given genera, the value of the IgA index can range from positive values, reflecting genera found dominantly 
in the IgA+ fraction, to negative values (genera found dominantly in the IgA- fraction), as a measure of the degree 
of mucosal immune responsiveness to the microbiota. LEfSe (Linear discriminant analysis Effect Size) algorithm, 
emphasizing both statistical and biological relevance, was used for biomarker discovery. Threshold for the 





Fig. II-5. IgA recognition patterns of the gut microbiota at 1 (left panels) and 12 months (right panels). 
Principal component analysis (PCA) based on the IgA index (reflecting the differences in IgA status, e.g. 
the ratio of IgA+ and IgA-) of the dominant genera (>1% of total) of the gut microbiota at 1 month 
(NHealthy=27; NAllergic=19; NAsthma=9; A, C) and 12 months (NHealthy=27; NAllergic=19; NAsthma=10; B, D) of 
age when comparing healthy children with children developing allergic manifestations (A, B) or with 




























































































































































































































The data presented in the current study demonstrate that the first year of life represents an early-
life critical period in which aberrant gut microbiota IgA responses are linked to the risk of 
developing asthma and allergic disease. SIgA functions as a first line of defense by interfering 
with the microbiota and thus protect the intestinal tissue from invasion and destruction by 
pathogenic and commensal bacteria.[130, 423] Thus, intact production and function of IgA is a 
key mechanism to preserve intestinal health by directly influencing the properties of the 
microbiota and enhancing mucosal barrier function.[423] Furthermore, SIgA may also limit 
overgrowth of selected species, thus enabling an increased microbiota diversity.[110, 423] This 
can be particularly crucial during early childhood, when the microbiota plays a central role in 
immune modulation and where microbial recognition by maternal and infant antibodies must be 
appropriately orchestrated for an optimal maturation of the immune system.[235, 445, 446] In 
line with this, low mucosal total IgA levels [245, 246, 431] a reduced gut microbiota diversity in 
infancy [265–270, 420–422] and decreased seroreactivity to gut microbiota antigens [447] have 
been associated with allergy development. However, intestinal IgA responses to the infant gut 
microbiota have not previously been studied in relation to allergy development. To investigate 
this, we have used a combination of flow cytometry and high-throughput deep sequencing to 
characterize the patterns of bacterial recognition by IgA in stool samples collected at 1 and 12 
months of age from children staying healthy or developing allergic symptoms up to seven years 
of age. 
 
Interestingly, development of allergic disease, particularly asthma, during childhood was 
associated with a reduced proportion of IgA bound to fecal bacteria at 12 months of age. To 
better understand these differences, we sought to investigate if the bacterial load and total fecal 
IgA levels might be of any influence. The results showed that the lower proportions of IgA 
coated fecal bacteria among children developing allergic manifestations were independent of total 
fecal SIgA levels that were relatively similar to healthy children, especially at 12 months of age. 
Moreover, the decreased proportions of IgA coated bacteria in allergic children are probably not 
due to lower IgA antibodies-to-bacteria ratios because bacterial densities were actually lower in 
children developing allergies. Thus, in addition to the lower bacterial diversity detected by other 
studies, [265–270, 420–422] allergic children seem also to be exposed to lower microbial densities 
in the gut. These two factors could lead to decreased stimulation of the immune system via TLR:s 
[424], affecting the production and microbial recognition patterns of IgA, thus leading to lower 
proportion of IgA coating in allergic than healthy children. It would be interesting to further 
investigate the role of factors influencing IgA production, such as vitamin A-derived retinoic 
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acid, TGF-b, IL-10, BAFF and APRIL [448], in the aberrant IgA responses in children 
developing allergy in future studies. As we previously found that a low gut microbiota diversity in 
infancy was mainly related with asthma, but not allergic rhinoconjunctivitis, development at 
school age [266], we here aimed to determine the importance of IgA responses to the gut 
microbiota particularly for asthma development. Speculatively, the association with asthma could 
be due to the fact that viral lower respiratory tract infections have been linked to asthma 
development among atopic children.[417, 449, 450] Thus, low IgA responses to the microbiota 
may result in a reduced mucosal barrier function. This may cause an increased susceptibility to 
airway viral infections, leading to amplification of Th2 responses and subsequent asthma 
development.[417, 449, 450]  
 
Previous studies in adults have determined that IgA might be more reactive against disease 
driving bacteria [130, 141, 451, 452], in line with the theory that the immune system can 
distinguish between pathogens and commensals through sensing pathogen-associated behaviors, 
including adherence to the intestinal epithelium and tissue invasion.[141, 452] Also, SIgA may 
enable an increased microbiota diversity by limiting overgrowth of selected species.[110, 423] In 
the current study, we observed that the IgA recognition patterns differed between healthy 
children and children developing allergic symptoms, including asthmatic disease and allergic 
rhinoconjunctivitis, with clearly divergent IgA index patterns already at 1 month of age. As the 
IgA antibodies at 1 month of age in exclusively breast fed infants are predominantly maternally 
derived,[426, 444] the divergent responses observed at this time point suggest that the 
immunological interactions between mother and offspring influence allergy development, in line 
with previous studies.[235, 445, 446] For example, breastmilk derived SIgA had a large impact on 
microbial colonization in neonatal mice and was crucial for healthy intestinal epithelial barrier 
function and immune homeostasis in the offspring.[428]  
 
Interestingly, the gut commensals Faecalibacterium and Bacteroides were mainly IgA free at 1 and 12 
months of age in children showing allergic manifestations but were predominantly IgA coated in 
healthy children, especially at 12 months. These two genera are important human gut symbionts, 
involved in production of butyrate, an end product of colonic fermentation that is important in 
maintaining a healthy gut.[453–455] Furthermore, decreased diversity of the Bacteroidetes phylum 
in infant stool samples have been linked to delivery by Cesarean section [57, 174] and allergy 
development.[57, 265] Other commensals that seem to be ignored by the IgA recognition in 
children developing allergic symptoms were Parabacteroides, at 1 month of age, and Roseburia, at 12 
months of age. The Parabacteroides species distasonis have been shown to reduce inflammatory 
responses in murine models with chronic colitis,[456] while Roseburia is another well-known 
butyrate-producer [457], which was reduced in patients suffering from ulcerative colitis.[458] In 
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all, decreased coating of these commensals might reflect a lower stimulation of the mucosal 
immune system in the infants developing allergic diseases. 
 
The Erysipelotrichaceae family is considered to be highly immunogenic and seems important in 
inflammation related disorders of the gastrointestinal tract as they are enriched in colorectal 
cancer.[459, 460] Palm and colleagues found that a member of Erysipelotrichaceae was highly coated 
by IgA in specific pathogen free mice, relative to other members of the gut microbiota, 
proposing its role as a colitogenic bacteria.[452] Furthermore, deregulation of T-cells in mice 
affecting the selection of IgA plasma cells caused gut dysbiosis, including increased abundance of 
Erysipelotrichaceae that are known to induce immune hyperactivation.[461] Escherichia and Shigella 
genera are Proteobacteria proposed to express highly proinflammatory hexa-acylated endotoxin 
production and were enriched in adult asthmatic patients triggering airway inflammation.[462] 
Moreover, high abundance of fecal Escherichia coli was associated with development of IgE-
associated eczema within the first year of life.[463] As allergy and asthma development were 
associated with reduced IgA responses to the Erysipelotrichaceae and Escherichia/Shigella genus 
respectively, at 12 months of age, this may suggest an impaired mucosal immune exclusion of 
this genus in children developing allergic disease, possibly leading to proinflammatory responses 
enhancing disease susceptibility. 
 
In contrast, allergy development was associated with increased IgA responses at 12 months of 
age to Lachnospiraceae, a Gram positive barrier associated microbes that are colonizing the inner 
mucus layer, staying in close contact with host mucosa.[464, 465] Furthermore, excessive growth 
of species belonging to Lachnospiracea in mice with impaired IgA responses reduces Firmicutes 
diversity.[110] The increased IgA coating of these bacteria in children developing allergies might 
thus be an indication of an altered mucosal barrier function.  
 
Factors that might influence the development of the intestinal microbiota and the mucosal 
immune system include the mode of delivery, exposure to antibiotics, partial breastfeeding at 12 
months of age and probiotic supplementation.[58, 163, 343, 422, 466] These confounding factors 
seem not to have influence in our study population, since the discovered differences are driven 
by health status. However, larger studies are required to further investigate and confirm the role 
of these factors. Also, it needs to be determined whether our findings can be replicated in 
cohorts of other geographic origins and with different family history of allergic disease. 
 
CONCLUSIONS 
Our work suggests that studies of IgA responses to gut microbiota during infancy could be used 
to determine the normal development of mucosal immunity and establishment of a healthy 
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symbiosis with gut microbes, and how maternal immunity affects these processes. Early 
characterization of IgA coating patterns may represent a novel way to identify infants with 
increased risk to develop asthma and allergic disease, although this needs to be confirmed in 
larger cohorts. Furthermore, interventions enhancing infant mucosal barrier function may 
represent efficacious preventive strategies required to combat the asthma and allergy epidemic.  
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Table II-SI. Allergic manifestations and sensitization in the 20 children with allergic symptoms. The 
children were followed prospectively during the first 7 years of life.  
Children Allergy symptoms 
at 2 years 
Allergy symptoms 
at 7 years 









1 SPT+, AD SPT+, ARC, AD Yes VD No Probiotics 
2 AD SPT+, AB, ARC, 
AD 
No VD No Probiotics 
3 SPT+, AD, AB SPT+, AB, ARC, 
AD 
Yes VD Yes Placebo 
4 SPT+, AD SPT+, AB, AD No CS Yes Probiotics 
5 SPT+, AD SPT+, AD No CS No Placebo 
6 SPT+, AD ARC No CS No Probiotics 
7 SPT+, AD AD Yes VD No Placebo 
8 SPT+, AD AB, * No VD No Placebo 
9 SPT+, AD SPT+, ARC No VD Yes Probiotics 
10 SPT+ SPT+, AB, ARC No VD Yes Placebo 
11 SPT+, AD SPT+ AB, AD No CS No Probiotics 
12 SPT+, AD SPT+, AB, AD No VD Yes Probiotics 
13 SPT+, AD SPT+, ARC Yes VD No Placebo 
14 SPT+, AD - No VD No Placebo 
15 SPT+, AD - No VD No Probiotics 
16 SPT+, AD SPT+, ARC, AD No VD No Probiotics 
17 SPT+, AB SPT+, AB No VD Yes Placebo 
18 SPT+, AD SPT+, AB, ARC, 
AD 
No VD No Probiotics 
19 SPT+, AD - No VD No Probiotics 
20 SPT+, AB SPT+, AB, ARC, 
U 
No VD Yes Probiotics 
AB, asthma bronchiale; AD, atopic dermatitis; ARC, allergic rhinoconjunctivitis; CS, caesarean delivery; SPT, skin 
prick test; U, allergic urticarial; VD, vaginal delivery. *No information about skin prick test reactivity was available at 7 
years of age in this child.  
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Table II-SII. 28 children without allergic symptoms and sensitization. The children were followed 
prospectively for the first 7 years of life. 
Children Breastfed at 12 
months 





1 No VD Yes Placebo 
2 No VD Yes Probiotics 
3 No VD No Probiotics 
4 No VD No Placebo 
5 No VD Yes Probiotics 
6 No VD Yes Placebo 
7 No VD Yes Placebo 
8 No VD No Placebo 
9 No VD Yes Probiotics 
10 No VD No Probiotics 
11 No VD No Placebo 
12 Yes VD Yes Probiotics 
13 Yes VD Yes Probiotics 
14 No CS Yes Probiotics 
15 Yes VD Yes Placebo 
16 Yes VD No Probiotics 
17 Yes VD Yes Placebo 
18 Yes CS No Probiotics 
19 Yes CS No Placebo 
20 Yes VD No Probiotics 
21 No VD No Placebo 
22 No VD No Placebo 
23 No VD No Placebo 
24 No VD No Probiotics 
25 No VD No Placebo 
26 No VD No Probiotics 
27 No VD No Probiotics 
28 No VD No Probiotics 




Table II-SIII. Primers used for qPCR-amplification. For the analysis of bacterial load in stool samples, 
FusA single copy gene (present in bacterial cells) and β-actin gene (present in human cells) were targeted 
with universal primers presented below. 
  5´ to 3´ direction PCR-product lenght (bp) 
β-actin F TTGTTACAGGAAGTCCCTTGCC 101 R ATGCTATCACCTCCCCTGTGTG 
FusA F TTGTTACAGGAAGTC 155 R ATGCTATCACCTCCC 
Actin: Isogen Life Science, Barcelona, Spain; FusA: Biomedal, Sevilla, Spain. 
 




Fig. II-S1. Scatter plots presenting how the gating strategy was performed. (A) A blank control (unlabelled 
bacterial cells) was used to determine the threshold for autofluorescence. (B) Anti-mouse IgA antibodies 
were used as an isotype control, determining the fluorescence intensity which was corresponding to 
unspecific binding (indicated as area R2 in the plot). Green fluorescence above the isotype control 
threshold was considered as indicative of true IgA-coating (indicated as area R3 in the plot). (C) An 
example of a scatter plot from an anti-human IgA sample that was gated according to the controls above. 
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Fig. II-S2. Proportion of fecal bacteria bound to IgA in children developing allergic rhinoconjunctivitis 




Fig. III-S3. Proportion of fecal bacteria bound to IgA in relation to probiotic supplementation, mode of 
delivery, antibiotic treatment and breastfeeding. (A) The proportion of faecal bacteria bound to IgA at 1 
month and 12 months of age in children treated with L. reuteri (N=27, circles) or placebo (N=21, triangles). 
(B) The proportion of faecal bacteria bound to IgA at 1 month and 12 months of age in children 
delivered vaginally (N=40, circles) or by Caesarean section (N=8, triangles). (C) The proportion of faecal 
bacteria bound to IgA at 12 months of age in children untreated (N=31, circles) and treated (N=17, 
triangles) with antibiotics during their first year of life. D) The proportion of faecal bacteria bound to IgA 
at 12 months of age in children who were not breastfed (N=36, circles) or who were still partially breastfed 



























































Fig. II-S4. Microbiota composition of the most dominant bacterial families as determined by pyrosequencing of 16S rDNA gene. Plots 
are showing the relative abundance (>1% of the total) of dominant bacterial families, coated (A, C) or not (B, D) with IgA, in stool 
samples collected at 1 month (A, B) and 12 months (C, D) of age in 20 infants showing allergic manifestations and 28 infants staying 
healthy up to 7 years of age. A, allergic; H, healthy; IgA+, IgA-coated bacterial fraction; IgA-, IgA free bacterial fraction. *p< 0.05 
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Fig. II-S5. IgA responses to the gut microbiota in healthy children and children developing allergic 
rhinoconjunctivitis during the first 7 years of life. Plots are depicting IgA responses (defined by IgA index, reflecting 
the differences in IgA+ and IgA-) to dominant genera (>1% of total) of the gut microbiota at (A) 1 month 
(NHealthy=27; NARC=9) and (B) 12 months (NHealthy=28; NARC=10) of age when comparing healthy children and 
children developing allergic rhinoconjunctivitis (ARC) during the first 7 years of age. For a given genera, the value of 
the IgA index can range from positive values, reflecting genera found dominantly in the IgA+ fraction, to negative 
values (genera found dominantly in the IgA- fraction). LEfSe (Linear discriminant analysis Effect Size) algorithm was 
used to detect bacteria with statistically different IgA index values, that could represent potential biomarkers for 

























































Fig. II-S6. Diversity of the total microbiota in stool samples. Shannon index, based on randomly selected 700 reads 
per sample (samples with lower amount of reads were excluded), was used to estimate the samples’ diversity of 
fractions coated or non-coated with IgA, obtained at 1 and 12 months of age from infants who did (A) or did not 
(H) develop allergic manifestations during the first 7 years of life. Shannon indices were calculated after clustering of 
sequences in Operational Taxonomic Units – (OTUs) at 97% nucleotide identity. Data are shown as median and 
interquartile ranges. A, allergic; H, healthy; IgA+, IgA-coated bacterial fraction; IgA-, IgA free bacterial fraction. N1 
month: H IgA+ =22; A IgA+ =19; H IgA- =24; A IgA- =14;  
N12 month: H IgA+ =28; A IgA+ =19; H IgA- =27; A IgA- =20. 
 




Fig. II-S7. Bacterial phyla diversity of IgA-coated and non-coated bacteria in stool samples of healthy children and 
children developing allergic/asthmatic symptoms. Shannon index, based on randomly selected 700 reads per sample, 
was used to estimate the samples’ diversity of the most dominant phyla: Actinobacteria, Bacteroidetes, Firmicutes 
and Proteobacteria. Samples with lower amount of reads were excluded from the analysis. (A) and (B) are showing 
the phylum diversity of IgA-coated (IgA+) and IgA-non coated (IgA-) fractions respectively, at different time points, 
from infants who did (A) or did not (H) develop allergic manifestations during the first 7 years of life. (C) and (D) 
are illustrating Shannon diversity index for the most dominant phyla in IgA+ and IgA- fractions respectively, from 
infants who did (As) or did not (H) develop asthmatic manifestations during the first 7 years of life. Data are 
presented as median and interquartile ranges. * p<0.05; ** p<0.01; *** p<0.001 (Mann-Whitney U test). A, allergic; 
As, asthmatic disease; H, healthy; IgA+, IgA-coated bacterial fraction; IgA-, IgA non-coated bacterial fraction. N1 
month: H IgA+ =22; A IgA+ =19; H IgA- =24; A IgA- =14;  




Fig. II-S8. IgA recognition patterns of the gut microbiota in children with/without allergic rhinoconjunctivitis. 
Principal component analysis (PCA) based on the IgA index (reflecting the differences in IgA status, e.g. the ratio of 
IgA+ and IgA-) of the dominant genera (>1% of total) of the gut microbiota at (A) 1 month (NHealthy=27; NARC=9) 
and (B) 12 months (NHealthy=27; NARC=10) of age when comparing healthy children and children developing allergic 
rhinoconjunctivitis during the first 7 years of age.  
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Fig. II-S9. IgA recognition patterns of the gut microbiota in relation to probiotic supplementation, mode of 
delivery, antibiotics treatment and breastfeeding. Plots are showing Principal component analysis (PCA) based on the 
IgA index (reflecting the differences in IgA status, e.g. the ratio of IgA+ and IgA-) of the dominant genera (>1% of 
total) of the gut microbiota. IgA recognition patterns in children treated with L. reuteri or placebo at (A) 1 month of 
age (NL.reuteri=20; Nplacebo=26) and (B) 12 months of age (NL.reuteri=21; Nplacebo=27). IgA recognition patterns in 
children that were vaginally delivered or by Caesarian section (C-section) at (C) 1 month of age (NVaginally=38; NC-
section=8) and (D) 12 months of age (NVaginally=40; NC-section=8). (E) The patterns of IgA recognition for the children, 
at 12 months of age, who were untreated (N=31) and treated (N=17) with antibiotics during their first year of life. 
(F) IgA recognition patterns towards microbiota, in children who were not breastfed (N=36) or who were still 







































































































































































































































































































































































Chapter III – ORAL MICROBIOTA MATURATION DURING 
THE FIRST 7 YEARS OF LIFE IN RELATION TO ALLERGY 
DEVELOPMENT 
 
- Majda Dzidic, Thomas R. Abrahamsson, Alejandro Artacho, Maria Carmen Collado, Alejandro Mira, 
Maria C Jenmalm; Oral microbiota maturation during the first 7 years of life in relation to allergy 







Allergic diseases have become a major public health problem in affluent societies. Microbial colonization 
early in life seems to be critical for instructing regulation on immune system maturation and allergy 
development in children. Even though the oral cavity is the first site of encounter between a majority of 
foreign antigens and the immune system, the influence of oral bacteria on allergy development has not yet 
been reported. In this study, we aimed to determine the bacterial composition in longitudinally collected 
saliva samples during childhood in relation to allergy development. Illumina sequencing of the 16S rDNA 
gene was used to characterize the oral bacterial composition in saliva samples collected at 3, 6, 12, 24 
months, and 7 years of age from children developing allergic symptoms and sensitization (n = 47) and 
children staying healthy (n = 33) up to 7 years of age. Children developing allergic disease, particularly 
asthma, had lower diversity of salivary bacteria together with highly divergent bacterial composition at 7 
years of age, showing a clearly altered oral microbiota in these individuals, likely as a consequence of an 
impaired immune system during infancy. Moreover, the relative amounts of several bacterial species, 
including increased abundance of Gemella haemolysans in children developing allergies and Lactobacillus gasseri 
and L. crispatus in healthy children, were distinctive during early infancy, likely influencing early immune 
maturation. Early changes in oral microbial composition seem to influence immune maturation and allergy 











During the past decades, allergic diseases have become a major public health problem in affluent 
societies.[467] Microbial colonization occurring early in life seems to be critical for instructing regulation 
on the maturation of the immune system and allergy development in children.[263, 264] Approximately 
700 common microbial species have been detected in the oral cavity.[11] Typically, the commensal 
microbiota here have a symbiotic relationship with the host, although, under certain circumstances, some 
microbes can overcome host defenses and become pathogenic.[468] At the birth and following hours, the 
infant’s oral cavity is exposed to a large amount of microorganisms encountered through the birth canal 
and during breastfeeding, in the contact with parents and medical staff and through breathing.[48] 
Moreover, it has been observed that maternal intrapartum antibiotic administration contributed to the 
shaping of the microbial colonization pattern in the neonatal oral cavity.[469] 
 
During the initial period, the microbiota composition of different niches of the neonate’s body highly 
resemble each other.[171] Niche specific establishment of a microbiota of increasing complexity then 
occurs, concurrent with immune system maturation.[39] However, relatively little is known about how the 
microbiome develops at extra-intestinal sites during infancy. As yet, there are no published longitudinal 
studies regarding oral microbiota development during early childhood with culture independent next 
generation sequencing methodology.  
 
Accumulating evidence shows a close relationship between microbial dysbiosis during infancy and allergy 
development during childhood.[263, 264] Factors such as early life antimicrobial exposure[470], caesarean 
delivery[343], formula feeding[471] and maternal consumption of antimicrobials during pregnancy[213] 
have been identified to have capacity to influence microbial composition, thus potentially contributing to 
allergic disease development in childhood. Most of the studies present today are describing the microbial 
colonization in the gut [39, 263], yet there are also indications that microbial colonization of the skin[17, 
472] and respiratory tract might be associated with allergies.[473] While some studies are demonstrating 
the bacterial dysbiosis and lower microbial diversity already before the onset of the allergic disease[168, 
265, 266, 472, 474, 475], other are describing and comparing the differences in microbiota in children 
having allergies and being healthy.[17] Because the oral cavity is the first line of encounter between the 
immune system and the majority of foreign antigens, it is plausible to believe that the oral microbiota 
might have a crucial role in allergy development. While gut, skin and nasopharyngeal microbial dysbiosis 
during infancy has earlier been associated with the aberrant development of immune responses and 
allergy[472, 474, 475], the influence of oral bacteria on allergy development has not yet been studied in 





In this study, we aimed to evaluate the longitudinal development of oral microbiota during infancy and 
childhood in saliva samples from children developing allergies and children staying healthy up to 7 years 










Sample collection and study design  
The infants included in this study were part of a larger randomized double-blind trial in south-eastern 
Sweden, recruiting participants between 2001 and 2003, where the potential allergy prevention effect of 
probiotic Lactobacillus reuteri ATCC 55730 until 2 and 7 years of age was evaluated.[327, 328] Among the 
188 infants completing the original study, longitudinal salivary samples were collected at 3, 6, 12 and 24 
month and 7 years of age in 47 children developing allergic symptoms and 33 children staying healthy up 
to 7 years of age. The selection of saliva samples for this study was based on sample availability. The 
included children were not statistically different from the children included in the main trial with regards 
to the variables presented in Table 1. The participants were instructed not to eat or drink for two hours 
preceding the sampling. Non-stimulated saliva samples were collected from the buccal cavity, using a hand 
pump (Nalgene #6131, ThermoFisher, Stockholm, Sweden) connected to a thin plastic tube, and 
immediately frozen and kept at −20°C. In connection with the oral examination and saliva sampling, 
clinical data about symptoms of allergic disease, adverse events, infections, use of antibiotics, and possible 
confounding factors were registered.[327, 328] Infants were regarded as sensitized if they had at least one 
positive skin prick test and/or detectable circulating allergen specific-IgE antibodies.[327, 328] Skin prick 
tests were performed on the forearm with egg white, fresh skimmed cow milk and standardized cat, dog, 
birch, peanut and timothy extracts at 6, 12, 24 months and 7 years of age (here also mite (Der p)).[328] 
Moreover, symptoms related to allergic disease, physical examination, spirometry and measurement of 
fractional exhaled nitric oxid (FENO) were observed. Children were diagnosed with allergy if they have had 
symptoms of and/or have been treated for the actual allergic disease during the last twelve months. 
Asthma diagnosis was based on at least one of following two criteria: 1. Doctor diagnosis and asthma 
symptoms and/or medication during the last twelve months; 2. Wheeze or nocturnal cough and a positive 
reversibility test and/or pathological FENO value.[266, 327] All asthmatic children were also included in 
the allergic group. For further details, please see the publications from Abrahamsson et al.[266, 327, 328] 
Possible confounders, such as mode of delivery, breastfeeding, probiotics supplementation, maternal 
allergy and antibiotics use during the first two years of age were obtained from medical records and 
questionnaires (see Table I). 90% and 77% of all the children included were exclusively breast-fed up to 1 
and 3 months of age, respectively, and 96% were partially breastfed at 3 months of age. No infant 
received antibiotics before 1 month of age and one at 3 months of age. 
The studies were approved by the Regional Ethics Committee for Human Research in Linköping, Sweden 
(Dnr 99323, M122-31 and M171-07, respectively). An informed consent was obtained from both parents 
before inclusion in the study.  
 





*The x2 test was used to detect potential differences in frequencies between children developing allergic/asthmatic symptoms and 
children staying healthy, except when the expected frequency for any cell was < 5, in which case the Fisher exact test was used. 





250 ul of saliva sample was centrifuged at 15000 g for 30 min and the pellet, together with 50 ul of the 
supernatant, were used for further analysis. DNA was isolated with a MagNA Pure LC 2.0 equipment 
(1996-2016 Roche Diagnostics, Barcelona, Spain), using MagNA Pure LC DNA Isolation Kit III for 
Bacteria & Fungi (Roche Diagnostics GmbH, Mannheim, Germany) following the manufacturer’s 
instructions with an additional enzymatic lysis step with lysozyme (20 mg/ml, 37°C, 60 min; Thermomixer 
comfort, Eppendorf, Hamburg, Germany), lysostaphin (2000 units/mg protein, 37°C, 60 min; Sigma-
Aldrich, Madrid, Spain) and mutanolysin (4000 units/mg protein, 37°C, 60 min; Sigma-Aldrich). DNA 
was resuspended in 100 ul of elution buffer and frozen at -20°C until further analysis. 
 
 
16S rDNA gene amplification and sequencing 
Prior to sequencing of the 16S rDNA gene, extracted DNA was pre-amplified in order to increase total 
nucleic acid yield by using universal bacterial degenerate primers 8F– AGAGTTTGATCMTGGCTCAG 
and 926R-CCGTCAATTCMTTTRAGT, which encompass the hypervariable regions V1-V5 of the gene. 













Girls 57 (19) 51 (24) 0.57 70 (14) 0.40 
Caesarean delivery 15 (5) 13 (6) 0.75 20 (4) 0.72 
Breastfeeding      
1 month exclusive 93 (31) 87 (41) 0.46 90(18) 0.63 
3 months exclusive 76 (25) 79 (37) 0.91 70 (14) 0.53 
3 months partially 100 (33) 94 (44) 0.26 95 (19) 0.38 
12 months partially 21 (7) 21 (10) 0.99 10 (2) 0.46 
Antibiotic treatment       
first year 30 (10) 30 (14) 0.96 40 (8) 0.47 
second year 48 (16) 43 (20) 0.60 65 (13) 0.25 
Day care      
first year 12 (4) 4 (2) 0.22 5 (1) 0.64 
second year 76 (25) 72 (34) 0.73 90 (18) 0.29 





Mass., USA) with an annealing temperature of 52°C and 10 cycles, in order to minimize amplification 
biases.[366] The purification of PCR products was completed using Nucleofast 96 PCR filter plates 
(Macherey-Nagel, Düren, Germany). 
An Illumina amplicon library was performed following the 16S rDNA gene Metagenomic Sequencing 
Library Preparation Illumina protocol (Part #15044223 Rev. A). The gene-specific primer sequences used 
in this protocol were selected from the Klindworth et al. publication and target the 16S rDNA gene V3 
and V4 regions, resulting in a single amplicon of approximately 460 bp. Overhand adapter sequences were 
used together with the primer pair sequences for compatibility with Illumina index and sequencing 
adapters. After 16S rDNA gene amplification, the DNA was sequenced on a MiSeq Sequencer according 
to manufacturer’s instructions (Illumina) using the 2x300 bp paired-end protocol. 
 
Bacterial load and measurements with quantitative PCR 
Total bacterial load (bacterial cells per ml of saliva) in saliva samples was measured by quantitative PCR. 
Amplifications were performed in duplicates on a LightCycler 480 Real-Time PCR System (Roche 
Technologies) by using annealing temperatures of 60°C. Each reaction mixture of 10 mL was composed 
of SYBR Green PCR Master Mix (Roche), 0.5 mL of the bacterial universal primer (concentration 10 
mmol/L), and 2 mL of DNA template. The forward primer was 5´GTG CCA GCM GCC GCG GTA A 
3´ and the reverse primer 5´GCG TGG ACT ACC AGG GTA TCT 3´ (Integrated DNA Technologies 
(IDT); San Diego, California, USA), targeting the 16S rDNA gene.[476] The obtained Ct values were 
transformed to bacterial cell numbers by a standard curve calibrated by flow cytometry.[19] 
 
Bioinformatics and statistics 
Only overlapping paired end reads were used for analysis. A sequence quality assessment was carried out 
using the PRINSEQ program. Sequences of <250 nucleotides in length were not considered; 5′ trimming 
was performed by cutting out nucleotides with a mean quality of <30 in 20-bp windows. Chimeric 16S 
sequences were filtered out using USEARCH.[477]  
 
Obtained sequences were taxonomically classified by the RDP-classifier [374] where the reads were 
assigned a phylum, class, family and genus and phylogenetic ranks were allocated when scores exceeded 
0.8 confidence threshold. Operational taxonomic units (OTUs) were generated by using CD-HIT OTU 
picking with 97% of similarity.[371] Normalized OTU tables were used for downstream analysis. The 
human oral microbiome database (HOMD) was used as a reference database for OTU 
assignment.[372]  
Microbiota diversity metrics were determined from normalised OTU tables. α – diversity analysis 




richness using the R-package Vegan.[442] Constrained correspondence analysis (CCA, a.k.a. canonical 
correspondence analysis) is a statistic tool used to emphasize variation, taking advantage of the fact that 
the factor provided can explain part of the total variability, and bring out strong patterns in a dataset. This 
analysis was performed by R software ade4 package [376], using the function CCA (related to 
correspondence analysis) and based on Chi-squared distances. Furthermore, the Adonis statistic for 
permutational multivariate analysis was used to measure differences in variance between groups. 
 
Linear discriminant analysis effect size (LEfSe), a method for biomarker discovery on the online interface 
Galaxy (http://huttenhower.sph.harvard.edu) [377], was used to determine taxa that best characterize 
the populations of healthy children and children developing allergies. LEfSe scores measure the 
consistency of differences in relative abundance between taxa in the groups analysed, where a higher score 
indicates higher consistency. In this study, LEfSe was used for biomarker discovery at both genus and 
species-level OTUs. The threshold for the logarithmic LDA score was set at 2.0. The influence of 
confounding factors was determined by the CCA statistic tool and Adonis permutational multivariate 
analysis. 
 
Statistical analyses were performed in R version 3.2.2 and GraphPad Prism 6 (GraphPad Software, San 
Diego, CA, USA, Version 6.1f), where p<0.05 was considered significant. Comparison between 
categories was performed by Mann-Whitney U test. Specific statistical tests are stated in figure legends. 
Sequences supporting the conclusions of this article are publicly available at the European Nucleotide 








After quality filtering, 30,870,369 high-quality sequences were obtained, with an average of 92,700 ± 3,652 
(SEM) reads per sample.  
 
 
Bacterial diversity and density in saliva  
An overall increase in microbial diversity and richness was observed through time, reaching over 450 
species at 7 years of age. Children developing allergic diseases had significantly lower bacterial diversity at 
7 years, when compared with children staying healthy (Fig. III-1A, p=0.037). Moreover, a similar trend 
was observed at 7 years of age in children developing asthma (Fig. III-1B, p=0.044). No significant 
differences were observed upon comparing species richness between children staying healthy and children 
developing allergic diseases during the first 7 years of age (Fig. III-1C). However, children developing 
asthma tended to have higher bacterial richness at 12 and 24 months (Fig. III-1D).  
 
In subjects with allergies, the effect of asthma medication on microbiota diversity (using species-level 
OTUs), at 7 years of age was taken into account. When comparing healthy children and children 
developing allergies that were not taking asthma medication, a similar trend was observed (Shannon 
diversity index; MedianHealthy= 2.82, MedianAllergic= 2.26, p=0.066). As only four asthmatic children were 









Fig. III-1. Species richness and diversity of the total microbiota in infant saliva samples of children developing 
allergies and children staying healthy up to 7 years of age. Bacterial richness and diversity (here presented by Chao1 
and Shannon estimate indices at OTU level), obtained at different time points until 7 years of age, were determined 
by 16s rDNA Illumina sequencing. (A) and (C) are describing bacterial diversity and richness, respectively, during 
the first 7 years of life in children staying healthy and children developing allergies. (B) and (D) are presenting 
species diversity and richness in children developing asthma and children staying healthy up to 7 years of age. Data 
are presented with mean and standard error. (*p <0.05; Mann-Whitney U-test). 3 months (NHealthy=28; NAllergic=36; 
NAsthmatic=20), 6 months (NHealthy=31; NAllergic=45; NAsthmatic=20), 12 months (NHealthy=27; NAllergic=35; NAsthmatic=16), 





In order to better understand the progress of bacterial density through the children’s age, the bacterial 
load (bacterial cells/ml saliva) in saliva samples was measured. While there were no significant differences 
between children developing allergies/asthmatic symptoms and children staying healthy (Fig. III-S2), an 
overall growth of bacterial density was observed from 3 months to 7 years, reaching levels of 108 bacterial 
cells/ml saliva. Also, children developing allergic disease tended to have higher levels of bacterial load at 7 
years of age (p=0.054, Fig. III-S2A), when compared to children staying healthy. Individuals with low or 
high bacterial load through time did not correspond to any of the clinical variables measured, such as sex, 
antibiotic use or probiotic supplementation. 
 
Microbial colonization patterns  
Adonis testing supported the clustering of children´s oral microbiota according to time of development, 


















































that, during the first 2 years of life, no clear separation of microbial patterns between children staying 
healthy and children developing allergies was detected (Fig. III-2A). However, differences in microbiota 
patterns appeared at 7 years of age between healthy and allergic children, and a similar trend was observed 





Fig. III-2. Salivary microbiota colonization patterns in children developing allergies and children staying healthy up 
to 7 years of age. Constrained correspondence analyses (CCA), here used to emphasize variations in microbiota 
species-level patterns, show compositional characteristics of total microbiota at different time points. The percentage 
of variation explained by constrained correspondence components is indicated on the axes. (A) Microbial 
composition differences in saliva of infants staying healthy and infants developing allergies during the first 7 years of 
age (p=0.001). (B) Microbial composition patterns of salivary samples in children developing asthmatic symptoms 
and children staying healthy up to 7 years of age (p=0.004). Different colors represent different time points 
(M=Months, Y=Years). p values for CCA plots were determined by Adonis and indicate if the factor provided (in 
this case time) can significantly explain data variability. Sample sizes were: 3 months (NHealthy=28; NAllergic=36; 
NAsthmatic=20), 6 months (NHealthy=31; NAllergic=45; NAsthmatic=20), 12 months (NHealthy=27; NAllergic=35; NAsthmatic=16), 




The LEfSe algorithm was applied for biomarker discovery. Bacterial genera that were increased in 
abundance in healthy children, as compared with children developing allergies during the first 7 years of 
age, were Eubacterium and Neisseria at 3 months (Fig. III-3A), Lactobacillus, Alloprevotella, Corynebacterium, 
Selenomonas and Eubacterium at 6 months (Fig. III-3B) and Lactobacillus, Selenomonas, Veillonella, Megasphera, 
Fusobacterium and Lachnoanaerobaculum at 7 years (Fig. III-3C). Genera that were associated with allergy 
development were Bacteroides at 3 months and Gemella at 7 years (Fig. III-3A, C). 
 
Bacterial genera that were increased in abundance in children developing asthmatic symptoms as 
compared with healthy children were Alloprevotella at 12 months of age (Fig. III-4A) and Staphylococcus at 24 
months of age (Fig. III-4B). Upon checking the staphylococci species present (hits with >97% of identity 
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S. warneri (4%) were the most abundant. Bacterial genera that were increased in abundance in healthy 
children were Lactobacillus and Atopobium at 24 months of age (Fig. III-4B) and Fusobacterium, 
Capnocytophaga, Lactobacillus and Streptococcaceae at 7 years of age (Fig. III-4C).  
 
 
Fig. III-3. Salivary bacterial genera associated with allergy development during the first 7 years of age. The plots 
show statistically significant genera associated with allergy development at (A) 3 months, (B) 6 months and 7 years 
of age (C). The LEfSe algorithm was used for biomarker discovery and the threshold for logarithmic discriminant 
analysis (LDA) score was 2. Sample sizes: 3 months (NHealthy=28; NAllergic=36), 6 months (NHealthy=31; NAllergic=45), 





Fig. III-4. Salivary bacterial genera associated with asthma development during the first 7 years of life. (A) At 12 
months of age only the genus Alloprevotella was increased in abundance in children developing allergies. (B) Genera 
associated with children developing allergies (grey) and children staying healthy (orange) at 24 months of age. (C) At 
7 years of age, all significant differences corresponded to bacteria associated with healthy children. The LEfSe 
algorithm was used for biomarker discovery and the threshold for logarithmic discriminant analysis (LDA) score was 
2. Sample sizes were: 12 months (NHealthy=27; NAsthmatic=16), 24 months (NHealthy=25; NAsthmatic=15) and 7 years of 




Microbial species biomarkers  
The differences in bacterial composition between children staying healthy and children developing 
allergies and/or asthma were further evaluated at species-level OTUs (>97% of nucleotide identity) by 
using LefSe for biomarker discovery. At 3 months of age (Fig. III-5A), bacterial species that were 
significantly increased in abundance in children staying healthy until 7 years were, among others, Prevotella 
sp. and Neisseria mucosa/sicca/flava, while Streptococcus parasanguinis and Gemella haemolysans were more 
prevalent in children developing allergies. At 6 months (Fig. III-5B), Bacteroidales [G-2] sp. and 
Corynebacterium matruchotii were some of the bacteria that were observed in increased abundance in children 
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staying healthy, while Streptococcus salivarius/cristatus/vestibularis and Selenomonas sp. were associated with 
allergy development. At one and two years, Veillonella dispar, Lactobacillus gasseri and Neisseria 
oralis/flava/mucosa were among bacterial species that were increased in abundance in children staying 
healthy (Fig. III-5C, D). At the same time point, OTUs belonging to the genera Gemella (including G. 
sanguinis and G. haemolysans) and Streptococcus (including S. mitis/dentisani, S. lactarius and S. cristatus), as well as 
Alloprevotella sp. were associated with allergy development (Fig. III-5C, D). At 7 years of age (Fig. III-5E), 
Gemella haemolysans, Prevotella sp. and Streptococcus lactarius were associated with allergy development, while 
the larger diversity detected in healthy children at this age was reflected in a larger list of over-represented 
species, including Prevotella salivare, Veillonella rogosae and Lactobacillus gasseri. 
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Fig. III-5. Salivary bacterial OTUs associated with allergy development during the first 7 years of life. Bars represent 
bacterial species at 3 (A), 6 (B), 12 (C) and 24 (D) months, and at 7 years (E) of age increased in abundance in 
children developing allergies (grey) and children staying healthy (orange). The LEfSe algorithm was used for 
biomarker discovery and the threshold for logarithmic discriminant analysis (LDA) score was 2. Sample sizes were: 3 
months (NHealthy=28; NAllergic=36), 6 months (NHealthy=31; NAllergic=45), 12 months (NHealthy=27; NAllergic=35), 24 




It was also of interest to compare microbial biomarkers between children staying healthy and children 
developing asthmatic symptoms (Fig. III-6) showing that Lactobacillus crispatus and L. gasseri were found in 








Fig. III-6. Salivary bacterial OTUs associated with asthma development during the first 7 years of life. Bars show 
bacterial species at 3 (A), 6 (B), 12 (C) and 24 (D) months and 7 years (E) of age increased in abundance in 
children developing asthmatic symptoms (grey) and children staying healthy (orange). The LEfSe algorithm was used 
for biomarker discovery and the threshold for logarithmic discriminant analysis (LDA) score was 2. Sample sizes 
were: 3 months (NHealthy=28; NAsthmatic=20), 6 months (NHealthy=31; NAsthmatic=20), 12 months (NHealthy=27; 





The CCA statistic tool was used to examine the influence of confounding factors on microbial 
colonization patterns. No effect of delivery mode, antibiotic treatments, partial breastfeeding and maternal 
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observed (data not shown). However, probiotic supplementation with L. reuteri ATCC 55730 during the 
first year of age appeared to influence the association of microbial composition with asthma, but not 
allergy development, at 12 months, 24 months and 7 years of age (Fig. S2; p=0.0083, Adonis 









Given that the oral cavity is the first site of encounter between a majority of foreign antigens and the 
immune system, it is plausible that oral microbiome maturation might influence allergy development 
during childhood. In the present study, we use cultivation-independent techniques to characterize the 
development of microbial oral communities during the first 7 years of life in 33 healthy children and 
47 children that developed allergic symptoms.  
 
Development of allergic disease during childhood, and particularly asthma, was associated with a 
significantly lower bacterial diversity at 7 years of age. In comparison to gut microbiota studies where 
children developing allergic disease tend to have lower bacterial diversity than healthy children already 
during the first months of life [168, 265, 266], the association of disease with oral microbiota diversity 
appears to increase with age. Likely, the diverse intestinal microbiota might be of great importance for a 
primary establishment and for maturation of a balanced postnatal innate and adaptive immunity. 
However, this study suggests that infant oral microbiota composition, including the abundance of G. 
haemolysans in children developing allergic symptoms and L. gasseri and L. crispatus in children staying 
healthy, is more important than the oral microbiota diversity for later allergy development. Oral cavity 
development during infancy was accompanied by an overall steady increase in both diversity and richness 
of the oral microbiome, reaching 300 OTUs and bacterial densities of 106 cells/ml saliva already at three 
months of age. Further oral microbiota acquirement is probably facilitated by microbial colonization 
through diet and transmission from parents, caregivers and siblings.[48] Even though children developing 
allergies and asthmatic symptoms tended to have higher species richness and bacterial load, specifically 
after the first year of life, in comparison to children staying healthy, no statistically significant differences 
during the first 7 years of life could be observed. The deficient mucosal immune system of the oral cavity 
may favour an altered species colonization, even for those species appearing at low abundance.  
  
Increased abundances of the genus Bacteroides at 3 months of age and Gemella at 7 years were associated 
with allergy development. The identification of disease-associated bacteria, especially at an early age, could 
provide potential biomarkers of allergy risk. Bacteroides species are among the earliest-colonizing and one 
of the most numerically dominant commensals of the gut microbiota.[11, 264] They provide many 
beneficial effects to the host, including breakdown of complex dietary carbohydrates and modulation of 
mucosal glycosylation, and immune maturation.[478] However, Bacteroides is not a common oral inhabitant 
under healthy circumstances.[11] In addition, as these bacteria are potent stimulators of the immune 
system, the host immune responses can differ between the immunomodulatory molecules from different 
species of Bacteroides[479], possibly leading to aberrant immune development. Gemella is a predominant 
genus of the mucosal epithelium [11, 480] and in this study, it was related to allergy development in saliva 




associated with allergy development not only at 7 years of age, but also at 2 years, 1 year, and as early as 3 
months of age. G. haemolysans has previously been shown to produce human IgA1 protease activity[481], a 
feature that is unique to this species within the genus Gemella, suggesting that its potential use as an early 
diagnostic marker in altered mucosal immunity deserve further investigation.  
 
The primary colonizers of the oral microbiota, including both mucosal and tooth surfaces, are commonly 
streptococci, accounting for approximately 80% of early biofilms.[48] Most oral streptococci are 
commensal, frequently acquired during breastfeeding [19], although some are known to cause infective 
endocarditis when disseminated through the blood stream.[358] We observed that S. parasanguinis, a 
member of viridans streptococci [482], and S. lactarius, belonging to the S. mitis group [389], were here 
associated with allergy development in saliva samples from 3, 12, 24 months and 7 years of age. Both of 
these species have been described as primary colonizers, with S. parasanguinis frequently found in the 
tongue dorsum [480] and S. lactarius isolated from breastmilk of healthy women.[405] Moreover, children 
developing asthmatic manifestations also had higher abundance of several Streptococci, including S. 
sanguinis (at 6 months), S. salivarius/vestibularis and S. cristatus (at 24 months) and S. australis and S. mitis 
at 7 years. Early asymptomatic colonization of the nasopharynx with Streptococcus, during infancy, has been 
proposed as a strong asthma predictor.[475] Because pioneer colonizers may facilitate the environment for 
later colonizers, the initial competition for bacterial colonization might have direct implications for the 
spatial and temporal composition of the developing oral microbiome, and therefore play a crucial role in 
immune modulation. 
 
Neisseria sicca/mucosa/flava were increased in abundance in children staying healthy. The genus Neisseria is 
an abundant member of the oropharyngeal flora [483], tongue, oral mucosa and dental plaque.[480] 
Furthermore, higher abundance of Corynebacterium at 6 months of age and the species C. matruchotii at 7 
years of age were observed in children staying healthy, as compared with children developing allergy. 
Corynebacterium, particularly C. matruchotii, with its highly interactive filamentous structure is considered 
instrumental in oral biofilm architecture.[484] Members of this genus have been shown to utilize 
carbohydrates and metabolize lactate and acetate, likely maintaining pH homeostasis in a healthy oral 
biofilm.[403]  
 
Children staying healthy up to 7 years had higher abundance of Lactobacillus both at genus and species 
level at 3, 6 and 24 months and 7 years when compared to children developing asthmatic symptoms, 
or to children developing allergies (at 24 months and 7 years). Lactobacilli colonize the gastrointestinal 
tract, including the oral cavity [55], and vagina [485], and may promote health by their influence on 
biofilm microbial composition, or by stimulating the host immune responses.[263] L. crispatus and L. 
gasseri were both associated with reduced allergy development. Lactobacillus gasseri is an important 
health-promoting immunomodulator of innate and systemic immune responses with an antimicrobial 




demonstrating that supplementation with L. gasseri may be beneficial because of its effect on nasal 
blockage [487], and decreased nasal clinical symptoms scores in children suffering from allergic 
rhinitis.[488] As L. crispatus and L. gasseri were also observed to suppress allergic responses [489] and 
reduce mite-induced airway inflammation and hyperresponsiveness in mice models [490], these species 
may have a protective role in asthma development and deserve to be further investigated. 
 
The use of antibiotics during the first years of life, birth mode, feeding habits and urban versus farm living 
have all been shown to affect microbiota composition [13], and several studies have found associations 
between these factors and allergy development.[263] To understand how these early-life risk factors may 
be related to allergy development during childhood, it is of great importance to consider how they affect 
the microbiome development in early infancy. Delivery mode, breastfeeding duration, antibiotics intake 
and maternal allergy seem not to have influence on the microbiota in relation to allergy and asthma 
development in our study population because the discovered differences are driven by health status (e.g. if 
children developed allergies or stayed healthy). However, the majority of the infants were exclusively 
breastfed until 3 months of age (Table III-I), upon the first collection of the saliva samples, making it 
difficult to demonstrate the possible differences between breastfed and not breastfed infants due to low 
statistical power. Supplementation with L. reuteri during the first year of life seemed to influence the 
association between oral microbiota composition and asthma development (Fig. III-S2). This was 
reflected in distinctive microbiota clustering at 12 and 24 months and 7 years of age between children 
taking probiotics and not developing asthma and children that did not take probiotics and developed 
asthma. However, the probiotic intervention in this study did not directly reduce asthma development in 
the cohort. Reduced allergen responsiveness have previously been observed in L. reuteri supplemented 
infants, suggesting enhanced capacity for immunoregulation during infancy [317], associated with reduced 
incidence of IgE-associated eczema in infancy.[327] L. reuteri colonizes in a close contact with intestinal mucosa, 
priming dendritic cells to produce increased levels of anti-inflammatory IL-10 and inhibit the proliferation 
of bystander effector T-cells.[491] This species may have a similar mode of action in the oral mucosa, 
beside its symbiotic relationship with the immune system, and may support the co-colonization of other 
oral microbes beneficial for immune system development. However, larger studies, including the 
replication of our findings in other geographic origins, are required to further investigate and confirm the 
role of L. reuteri in allergy development. Beside saliva samples, it would be interesting to address other oral 
habitats, including tongue dorsum and buccal mucosa, in order to obtain the overall picture of oral 
microbiota maturation. Even though the time between 24 months and 7 years of age might be 
important to address in this type of longitudinal studies, the majority of the studies published today are 







By 7 years of age, allergic children appear to have a higher density and lower diversity of salivary bacteria, 
as well as a highly divergent bacterial composition, showing a clearly altered oral microbiota in these 
individuals, likely a consequence of an impaired immune system. Several individual bacterial species during 
infancy were associated with allergy development. The bacterial species detected in the current study as 
clearly associated to allergic conditions even years before the appearance of allergic manifestations, could 
potentially be used as early biomarkers capable to predict the risk of allergy and asthma. In addition, the 
possibility that some of these early changes in microbiota composition could impact immune modulation, 
inflammation and allergy development should be considered. Thus, the potential immunomodulatory 













Figure III-S1. Bacterial load in infant saliva samples. Bacterial density in salivary samples, obtained at different time 
points until 7 years of age, was determined by qPCR using universal primers targeting the 16S bacterial gene. Figures 
show number of bacterial cells/ml in allergic (A) and asthmatic children (B) when compared to children staying 
healthy up to 7 years of age. Children developing allergies tended to have higher levels of bacterial load at 7 years of 
age (p=0.054), when compared to children staying healthy (A). Data are presented with median with interquartile 
ranges. Mann-Whitney U-test was used for statistical comparisons. 3 months (NHealthy=28; NAllergic=36; NAsthmatic=20), 
6 months (NHealthy=31; NAllergic=45; NAsthmatic=20), 12 months (NHealthy=27; NAllergic=35; NAsthmatic=16), 24 months 

















































Figure III-S2. The effect of probiotic supplementation with Lactobacillus reuteri on the oral microbiota composition in relation 
to asthma development. Constrained correspondence analyses (CCA), here used to emphasize variations in microbiota species-
level patterns, show compositional characteristics of total microbiota at different time points. The percentage of variation 
explained by constrained correspondence components is indicated on the axes. The plot is showing the impact of probiotic 
supplementation, during early infancy, on the oral microbiota composition in saliva samples collected at 3, 6, 12, 24 months and 
7 years of age in children staying healthy and children developing asthmatic manifestations (p=0.0083). Different colours 
present different time points (M=Months, Y=Years) and probiotic supplementation in children and asthma development are 
marked with either 0 or 1 describing the absence or presence, respectively. p values for CCA plots were determined by Adonis 
and indicate if the factor provided (in this case time) can significantly explain data variability. Sample sizes were: 3 months 
(NProbiotics=14; NPlacebo=9), 6 months (NProbiotcs=16; NPlacebo=12), 12 months (NProbiotcs=13; NPlacebo=7), 24 months (NProbiotics=10; 
NPlacebo=8); 7 years of age (NProbiotics=15; NPlacebo=10). 
































Chapter IV – RELATIONSHIP BETWEEN BREASTMILK IgA-
COATED MICROBIOTA, PROBIOTIC SUPPLEMENTATION 
AND ALLERGY DEVELOPMENT IN CHILDHOOD  
 
- Majda Dzidic, Alex Mira, Alejandro Artacho, Thomas R. Abrahamsson, Maria C. Jenmalm, Maria 
Carmen Collado; Relationship between breastmilk IgA-coated microbiota, probiotic supplementation and 






Early colonization with a diverse microbiota seems to play a crucial role for appropriate immune 
maturation during childhood, and breastmilk microbiota is one important source of microbes for the 
infant, transferred together with maternal IgA antibodies. We previously observed that allergy 
development during childhood was associated with aberrant IgA responses to the gut microbiota already 
at 1 month of age, when the IgA antibodies are predominantly maternally derived in breastfed infants. 
Here we aimed to determine the microbial composition and IgA-coated bacteria in breastmilk in relation 
to allergy development in children participating in an intervention trial with pre- and postnatal Lactobacillus 
reuteri supplementation. A combination of flow cytometric cell sorting and 16S rRNA gene sequencing 
was used to characterize the bacterial recognition patterns by IgA in breastmilk samples collected one-
month post partum from 40 mothers whose children did or did not develop allergic and asthmatic 
symptoms during the first 7 years of age. The milk fed to children developing allergic manifestations had 
significantly lower bacterial richness, when compared to the milk given to children that remained healthy. 
Probiotic treatment influenced the breastmilk microbiota composition. The proportions of IgA-bound 
bacteria and the total bacterial load were similar in breastmilk between mothers of healthy children and 
those developing allergies, but the pattern of IgA-coated bacteria tended to appear different. 
Consumption of breastmilk with a reduced microbial richness in the first month of life may play an 






The infant’s immune system is immature at birth, with reduced innate and adaptive effector cell functions, 
including limited early production of secretory IgA, an antibody playing a crucial role in maintaining 
mucosal homeostasis.[492] In addition to learn to appropriately eliminate infectious or foreign stimuli, it is 
essential that the neonatal immune system develops the ability to distinguish between harmless and 
potentially dangerous antigens, thus inducing tolerance to prevent development of allergic reactions, 
autoimmunity, and inflammatory bowel disorders.[64] 
 
Human breastmilk, with its evolving and complex composition of nutrients and bioactive compounds, is 
considered to be an optimal nutritional source for the immature immune system of the infant.[200, 493] 
Among the bioactive factors, breastmilk contains various immunological substances, including 
immunoglobulins, cytokines, chemokines and growth factors that can be transferred to the offspring 
through breastfeeding.[193] Breastmilk antibodies are believed to reflect the numerous pathogens which 
the mother has had contact with in the gut and airways, thus providing an important defense against the 
same pathogens likely encountered by her infant.[196, 197] Although all immunoglobulin isotypes can be 
encountered in breastmilk, secretory IgA (SIgA) is the dominating isotype and considered most important 
due to its anti-inflammatory properties and important role in defending the mucous membranes.[198] 
SIgA acts locally on the newborn’s mucosal surfaces, thus regulating the binding and penetration of 
commensals and pathogenic microorganisms.[196] 
 
Breastmilk hosts a diverse array of microbiota and potential probiotic bacteria that are believed to 
orchestrate the infant's developing mucosal immune system.[64] Culture-independent techniques, 
including sequencing and metagenomics analysis, have demonstrated a complex and diverse group of 
bacteria in human milk, including the presence of Staphylococcus, Lactobacillus, Pseudomonas, Streptococcus, 
and Acinetobacter, with large degree of individual-specific profiles.[18, 19, 67, 68] In addition to these 
microbes, prebiotic oligosaccharides are also present.[494] Human breastmilk thus contributes directly to 
the colonization of the infant intestinal microbiome[18, 65, 72, 74], and multiple studies have observed the 
sharing of several microbial strains between breastmilk and infant stool.[78–80] 
 
Allergic diseases have become a major public health problem in affluent societies.[417] The increasing 
prevalence of allergy is hypothesized to be caused by reduced intensity and diversity of microbial 
stimulation.[57, 263, 495] In support of this theory, the gut microbiota differs in composition and 
diversity during the first months of life in children who later do or do not develop allergic disease.[42, 57, 
265, 266, 275] The breastmilk microbiota is one important source of microbes for the infant [18, 65, 496], 
and is transferred together with maternal IgA antibodies.[264] The secreted antibodies in breastmilk likely 
shield the neonate from inadequate stimulation of its own mucosal immune system and may thus shape 
the composition of its acquired microbiota that is important for appropriate immune system 
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maturation.[107, 197] SIgA can also limit overgrowth of selected species, thus stimulating development of 
a diverse microbiota.[110, 423]  
 
We have observed aberrant IgA responses to the gut microbiota during the first year of life in children 
developing allergies and asthma.[474] Allergy development during childhood was associated with 
divergent patterns of IgA recognized bacteria in the gut already at 1 month of age, when the IgA 
antibodies are predominantly maternally derived in breast-fed children.[474] However, the identities of the 
bacterial taxa targeted by IgA in the breastmilk and what role they may play in immune and allergy 
development are unknown. In this study, we aimed to characterize the composition and IgA coating 
pattern of the breastmilk microbiota from mothers whose children developed allergic symptoms during 








The subjects included in this study were part of a larger randomized double-blind trial in South-eastern 
Sweden, recruiting participants between 2001 and 2003, where the potential allergy preventive effect of 
probiotic Lactobacillus reuteri ATCC 55730 in the infants with family history of allergic disease was 
evaluated.[327, 328] The mothers were supplemented with L. reuteri during pregnancy from postmenstrual 
week 36+0 to delivery and the infants from day 1-2 of life until 12 months of age. Among the 184 
mothers, out of 232 recruited, of children that completed the 7-year follow up in the original study, 
breastmilk samples from 24 mothers whose children did not and from 26 mothers whose children did 
develop allergic disease during early childhood, were randomly selected for flow cytometry based-sorting 
of IgA-coated bacteria in the current study. Subsequently, 16S rRNA gene characterization was performed 
on the IgA-coated and IgA-free fractions of breastmilk bacteria from 20 mothers whose children did not 
and from 20 mothers whose children did develop allergic manifestations as well as from total, non-sorted 
breastmilk samples from the same mothers. Selection of the samples used for 16S rRNA sequencing in 
this study, was based on the sample availability and a clear allergy diagnosis (based on proven symptoms 
to allergy provocation) of the child. There were no differences regarding potential confounders, such as 
sex, mode of delivery, birth order, maternal atopy, breastfeeding, antibiotics, and probiotic 
supplementation, between the infants who did or did not have allergic manifestations. Allergic disease 
included eczema, gastrointestinal allergy, asthma, allergic rhinoconjunctitivis and allergic urticaria. The 
criteria of these diagnoses are described in detail in [327, 328]. All children with allergic disease in the 
current study were also sensitized (i.e. they had at least one positive skin prick test (evaluated at 6, 12 and 
24 months and 7 years of age) and/or detectable circulating allergen specific-IgE antibodies (assessed at 6, 
12 and 24 months), while the healthy children were non-sensitized.  
 
Breastmilk samples were collected one-month post partum by the mother at home. They were immediately 
placed in the freezer and brought to the hospital and stored at −70°C within 3 days. All the children 
included in the current study were exclusively breastfed during the first month of life. Total IgA levels 
were measured by ELISA in a study by Böttcher et al.[497] 
 
The studies were approved by the Regional Ethics Committee for Human Research in Linköping, Sweden 
(Dnr 99323, M122-31 and M171-07, respectively). An informed consent was obtained from both parents 



























Sample preparation and flow cytometry-based sorting 
After thawing, the breastmilk fatty layer and whey were removed by centrifugations. The resulting sample 
fraction was further suspended in sterile saline solution (autoclaved H2O; NaCl Sodium Chloride 99.5% 
PA-ACS-ISO; Panreac, Barcelona, Spain; reference 131689.1211) with 5% BSA (Sigma-Aldrich, St Louis, 
Mo; reference A7030-100gr) to prevent nonspecific antibody binding. The samples were stained with goat 
anti-mouse IgA labelled with fluorescein isothiocyanate (FITC), used as an isotype control corresponding 
to unspecific binding (Sigma; reference SLBD9273), or with goat anti-human IgA labelled with FITC (Life 
Technologies; reference A18782), according to the manufacturer’s instructions. The sorting of the 
bacterial cells according to whether they were IgA-coated or IgA-free was performed with the MoFlo 



















Girls 50(10) 60(12) 0.53 60(6) 0.71 
Older siblings 40(8) 35(7) 1.00 30(3) 0.70 
Caesarean delivery 20(4) 20(4) 1.00 20(2) 1.00 
Furred pets 15(3) 10(2) 1.00 10(1) 1.00 
Breastfeeding      
1 month exclusive 90(18) 95(19) 1.00 90(9) 1.00 
 3 months exclusive 85(17) 70(14) 0.45 50(5) 0.08 
 12 months partial 20(4) 25(5) 1.00 0(0) 0.27 
Maternal atopy 85(17) 80(16) 1.00 70(7) 0.37 
Antibiotic treatment 
(1-12 m) 35(7) 30(6) 1.00 50(5) 0.46 
Day care (1-12 m) 10(2) 5(1) 1.00 10(1) 1.00 
Probiotics-L. reuteri 45(9) 55(11) 0.53 60(6) 0.70 
 
Table IV-I. Descriptive data of children compare in this study.  
*The x2 test was used to detect potential differences in frequencies between groups, except when the expected 




DNA from sorted breastmilk bacteria, both IgA+ and IgA-, as well as the total milk sample (2 ml) was 
isolated by using the MasterPure complete DNA and RNA Purification Kit (Epicentre Biotechnologies, 
Madison, Wis), according to the manufacturer’s instructions, with a previous glass bead beating (0.17 mm 
in diameter) and an additional enzymatic lysis step with lysozyme (20 mg/mL, 378C, 30 minutes; Thermo-
mixer comfort, Eppendorf, Hamburg, Germany), lysostaphin (2000 units/mg protein, 37 °C, 60 min; 
Sigma-Aldrich, Madrid, Spain) and mutanolysin (4000 units/mg protein, 37 °C, 60 min; Sigma-Aldrich).  
 
 
16S rDNA gene amplification and sequencing  
DNA from sorted bacterial fractions (in total 80) together with total non-sorted breastmilk samples (in 
total 40) was used for PCR amplification and Illumina sequencing to describe the bacterial composition of 
breastmilk. Universal bacterial degenerate primers 8F—5ʹ-AGAGTTTGATCMTG GCTCAG-3ʹ and 
926R—5ʹ-CCGTCAATTCMTTTRAGT- 3ʹ, which encompass the hypervariable regions V1–V5 of 16S 
ribosomal RNA (rRNA) gene were used for an initial amplification in order to increase the bacterial yield. 
Purification of PCR products was completed using Nucleofast 96 PCR filter plates (Macherey-Nagel, 
Düren, Germany).  
 
An Illumina amplicon library was performed following the 16S rRNA gene Metagenomic Sequencing 
Library Preparation Illumina protocol (Part #15044223 Rev. A). The gene-specific primer sequences used 
in this protocol were selected from Klindworth et al. [367], and target the 16S rRNA gene V3 and V4 
regions, resulting in a single amplicon of approximately 460 bp. After 16S rRNA gene amplification, the 
DNA was sequenced on a MiSeq Sequencer according to manufacturer’s instructions (Illumina) using the 
2 × 300 bp paired-end protocol. Sequences supporting the conclusions of this article are publicly available 
at European Nucleotide Archive database (ENA) with accession number PRJEB30065. 
 
 
Total bacterial load 
Total bacterial load (number of bacterial cells per ml breastmilk) was measured by quantitative PCR. 
Amplifications were performed in duplicates on a LightCycler 480 Real-Time PCR System (Roche 
Technologies) by using annealing temperatures of 60 °C. Each reaction mixture of 10mL was composed 
of SYBR Green PCR Master Mix (Roche), 0.5 mL of the specific primer (concentration 10 mmol/L), and 
2 mL of DNA template. The universal forward and reverse primers were 5ʹ-
CGTGCCAGCAGCCGCGG-3ʹ and 5ʹ- TGGACTACCAGGGTATCTAATCCTG-3ʹ, targeting a 293bp 
long region of the bacterial 16S rRNA gene. The obtained Ct values were transformed in bacterial cell 





The PRINSEQ program was used for a sequence quality assessment.[368] Sequences of <250 nucleotides 
in length were discarded; sequence end-trimming was performed by cutting out nucleotides with a mean 
quality of <30 in 20-bp windows. Chimeric 16S sequences were filtered out using USEARCH 
program.[369] OTUs were built at 97% of identity by using vsearch program and Qiime modules (version 
qiime2-2017.12) were used for taxonomic annotation.[498] In order to assign taxonomy up to species level 
to each OTU’s centroid, we classified them using a naïve bayes classifier model previously fitted against 
the Green Genes database version 13.5. 
 
16S rRNA gene reads from the total milk samples were used in order to perform an accurate filtering of 
the flow cytometry IgA-sorted fractions that, due to low bacterial yield, were more susceptible to 
sequencing contaminations. This was done by eliminating OTUs in IgA sorted fractions that were absent 
in corresponding total non-sorted milk samples. Moreover, OTUs were also removed in cases where 
either IgA positive or IgA negative fractions presented an abundance of less than five reads, compared to 
its corresponding OTU in non-sorted milk sample. In addition, we filtered out low signal OTUs that were 
presented in less than five sequences through the total set of samples.  
 
α-diversity analyses (presented here as Shannon and Chao1 indices), were utilized to estimate the samples’ 
diversity and richness at the 97% OTU level using the R-package Vegan.[375] Constrained 
correspondence analysis (CCA) was used here to emphasize variation and bring out strong patterns in the 
dataset. This analysis was performed by R software ade4 package together with permutational multivariate 
analysis (Adonis) determining the differences in variance between groups.  
 
For analyzing IgA coating patterns, the threshold used for including the genera was 0.5 % or greater in 
relative abundance in either the IgA positive or IgA negative fractions. A pseudocount that was equal to 
0.001 was added to every genus dedicated in both the IgA positive or IgA negative fractions, thus 
avoiding the fractions with a value of zero. The abundance proportions of a given genera were log-
transformed before calculating the ratio between the IgA positive or IgA negative fractions, resulting in 
the IgA index.[140, 474] The IgA index (calculated according the formula log(IgA+/IgA-)) score reflects 
the degree of mucosal immune responsiveness to the microbiota, where the positive values represent the 
genera predominantly found IgA-coated while the negative values the bacterial genera predominantly 
found IgA uncoated. 
 
The MaAslin multivariate statistical framework was used in this study in order to evaluate if the 
confounding factors, including probiotics supplementation during pregnancy and maternal atopy, could 
influence microbial community abundance.[499] Statistical analyses were performed in R version 3.2.2 and 
GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA, Version 6.1f), where p<0.05 was 
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considered significant. Specific statistical tests (including Mann–Whitney U-test/ Wilcoxon rank-sum test 
for nonparametric comparisons together with false discovery rate control giving the adjusted p-value) are 







IgA proportions in breastmilk 
On average, approximately 40% of bacteria in breastmilk appeared to be IgA-coated. Proportions of IgA-
coated bacteria were similar in breastmilk samples of mothers whose children did or did not develop 
allergic (Fig. IV-1A) and asthmatic symptoms (Fig. IV-1B) during the first 7 years of life. Furthermore, 
IgA proportions observed did not seem to be influenced by the total IgA levels in breastmilk samples of 
these mothers (n=29; Spearman correlation test r=0.32, p=0.095).  
 
 
Fig. IV-1. IgA responses towards breastmilk microbiota in samples collected one-month post partum. Proportion of 
breastmilk IgA-bound bacteria (here presented as medians and interquartile ranges) in mothers whose children 
stayed healthy (N=24, circles) or developed allergic symptoms (N=26, A) and/or asthmatic symptoms (N=13, B) 
during the first 7 years of life.  
 
 
Bacterial diversity, richness and density in total non-sorted milk samples and IgA-coated 
fractions 
The overall species richness (as determined by Chao1 index) in total non-sorted breastmilk samples was 
significantly higher (p=0.02, Fig. IV-2A) in mothers with healthy children, although the bacterial load (Fig. 
IV-S1) and species diversity (Shannon index, Fig. IV-2B) were similar in breastmilk samples of mothers 
whose children did/did not develop allergic manifestations. The total species richness also tended to be 
higher in breastmilk from mothers whose children stayed healthy than from mothers whose children 
developed asthmatic symptoms (p=0.066, Fig. IV-2A). However, no significant differences between 
mothers of healthy and allergic subjects were observed upon comparing the richness and diversity of the 
IgA-bound fractions in breastmilk (Table IV-SI). Additionally, no differences in bacterial load, species 
diversity or richness was observed between the total non-sorted breastmilk from the mothers treated with 









































Fig. IV-2. Bacterial richness (A) and diversity (B) at OTU’s species level, as described with Chao1 and Shannon 
indices, respectively, of the total non-sorted breastmilk samples from mothers whose children stayed healthy up to 7 
years of age (N=20), mothers whose children developed allergic manifestations (N=20) and/or asthmatic symptoms 
(N=10). Medians and interquartile ranges are indicated. * p-value <0.05, Mann-Whitney U test. 
 
 
Bacterial composition in allergy development and probiotic supplementation 
Bacterial 16S rRNA gene sequencing, of the total non-sorted milk and IgA-coated/uncoated fractions, 
was performed in order to determine the milk microbial composition and to assess IgA responses towards 
specific bacteria. After quality filtering and removal of chimeric sequences, 40 total non-sorted breastmilk 
samples and 80 IgA separated fractions remained with 2,000,107 and 1,525,770 high quality reads, 
respectively. Sequencing of total non-sorted breastmilk samples resulted in an average of 48,987±2725 
(SEM) reads per sample, while the IgA separated breastmilk fractions had an average of 20,322±1660 
(SEM) sequence reads per sample.  
The relative abundance of genera in total breastmilk, i.e. non-sorted samples, is presented in Fig. IV-3A 
and 3B. Infants developing allergies during the first 7 years of life appeared to have higher, although not 
statistically significant, abundance of the genera Enterococcus (p=0.01; adj. p-value=0.18; Fig. IV-S2A) and 
Pseudomonas (p=0.01; adj. p-value=0.18; Fig. IV-S2B). The genus Enterococcus was found in significantly 
higher abundance (p=0.001; adj. p-value= 0.02) in breastmilk given to children that developed asthmatic 
symptoms, when compared to breastmilk given to the children that remained healthy (Fig. IV-3B, Fig. IV-
S2A). No effect of the confounding factors, such as probiotic supplementation during pregnancy, 
maternal atopy, sex and the delivery mode influenced the microbial abundance between the groups, as 







































Fig. IV-3. Microbiota composition of most dominant bacterial genera in total non-sorted milk samples. (A) The 
relative abundance (>0.5 % of the total) of dominant bacterial genera in 20 mothers whose children stayed healthy 
and in 20 mothers whose children developed allergic manifestation during their first 7 years of life. (B) The relative 
abundance of dominant bacterial genera in breastmilk samples in 20 mothers whose children stayed healthy and 10 




Probiotic supplementation during the last month of pregnancy were associated with reduced proportions 
of IgA-coated bacteria (p=0.04; Fig. IV-4A), and particularly in breastmilk of probiotic supplemented 
mothers whose children stayed healthy (p=0.02; Fig. IV-4B). Moreover, microbiota composition patterns, 
of total non-sorted breastmilk, were significantly different (p=0.04 Adonis testing) between mothers that 
received, or not, probiotic supplementation (Fig. IV-4C) with significantly increased relative abundance 
(p=0.03, Wilcoxon rank-sum test adjusted p-value) of the genus Rothia in mothers treated with placebo. 
However, upon comparing IgA pattern recognitions of bacteria in mothers who were treated, or not, with 
probiotics supplementation during the last month of the pregnancy, no statistically significantly different 
































































































Fig. IV-4. IgA-coating responses in breastmilk of mothers treated, or not, with probiotics. Breastmilk microbiota 
composition and IgA-coating patterns of the dominant genera (>0.5% of total), in probiotic supplementation. (A) 
Proportions of IgA bound bacteria in breastmilk (medians and interquartile ranges) of mothers treated with L. reuteri 
(N=24) or placebo (N=27). (B) Proportions of IgA-bound bacteria in breastmilk of mothers, treated with probiotics 
or not, whose children stayed healthy (p=0.02, NPlacebo=11, NProbiotics=13) or developed allergic diseases 
(nPlacebo=13, nProbiotics=14). *p<0.05. (C) Constrained correspondence analyses (CCA) based on microbiota 
patterns in breastmilk of mothers treated with probiotics L. reuteri or placebo. The percentage of variation explained 
by constrained correspondence components is indicated on the axes. p value for CCA plots were determined by 
Adonis (p=0.04) and indicate if the factor provided (in this case probiotics) can significantly explain data variability. 
(D) Plots represent IgA coating patterns (defined by IgA index, reflecting the ratio in IgA bound and IgA free 
breastmilk microbiota) to dominant genera in breastmilk samples collected at one month post partum from mothers 
whose were treated with probiotic L. reuteri or placebo. For a given genera, the value of the IgA index can range 
from positive values, reflecting genera found dominantly in the IgA bound fraction, to negative values (genera found 
dominantly in the IgA free fraction). NProbiotics=20, NPlacebo=20. 
 
 
IgA responses towards milk microbiota in allergy development 
Although the analysis of the relative abundance of dominant bacterial genera in breastmilk, and the 
composition patterns of sorted IgA fractions (Fig. IV-S3) were generally similar between the IgA-bound 
and IgA-free fractions, upon considering the health status of the children, some differences at genus level 
were observed when analyzing the bacterial targets of IgA responses, represented as the IgA index here. 
The value of the IgA index can range from positive values, reflecting genera found dominantly in the IgA 
positive fraction, to negative values (genera found dominantly in the IgA negative fraction). Breastmilk 
given to children that developed allergic symptoms had higher levels of IgA-coating, although with non-
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significant tendencies, for genera Rothia Acinetobacter, Granulicatella and Veillonella. On the contrary, milk fed 
to children that stayed healthy appeared to have greater IgA coating of Pseudomonas, although the results 
were statistically non-significant (Fig. IV-5A). 
Regarding the breastmilk given to children that developed asthmatic symptoms, the genera Acinetobacter, 
Rothia, Granulicatella and Veillonella tended to be predominantly found as IgA-bound, when compared to 
the milk given to children that remained healthy (Fig. IV-5B). On the contrary, Veillonella and Rothia were 
predominantly IgA-free in breastmilk fed to children that stayed healthy until 7 years of age (Fig. IV-5B).  
 
 
Fig. IV-5. IgA responses towards breastmilk microbiota. Plots represent IgA-coating patterns to dominant genera 
(>0.5 % of total) from mothers whose children stay healthy (N= 20) compared to children that develop allergic (A, 
N=20) or asthmatic (B, N=10) symptoms. For a given genera, the value of the IgA index can range from positive 
values, reflecting genera found dominantly in the IgA-bound fraction, to negative values (genera found dominantly 
in the IgA-free fraction). Means with SEs are indicated.  
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The data presented in the current study demonstrate that total non-sorted breastmilk from mothers whose 
children developed allergic symptoms during early childhood had lower bacterial richness, when compared 
to milk fed to children staying healthy. While no differences in bacterial composition of the total non-
sorted milk samples, nor the IgA proportions between the mothers whose children develop allergies or 
not could be observed, IgA-coating patterns of several bacterial genera, tended to be different. 
Additionally, IgA proportions observed were not influenced by the total IgA levels in breastmilk samples 
of these mothers.[497] 
 
The influence of breastmilk composition on later allergy development appears to be linked to higher 
richness of bacterial species and not to the relative abundance of specific bacteria. For instance, intestinal 
bacteria can stimulate the formation of intestinal blood vessels, B cell development in Peyer’s Patches and 
increase the production of mucosal IgA.[95, 500] Previously, low total diversity of the gut and oral 
microbiota have been associated with atopy and asthma development during early childhood.[265–267, 
421, 501] Moreover, aberrant IgA immune responses towards gut microbiota were observed as early as 1 
month post partum, in exclusively breastfed children who subsequently developed allergies.[474] At this 
time point, the IgA antibodies are predominantly maternally derived in exclusively breastfed children, as 
the levels of endogenously produced IgA in the baby during this period is limited.[58, 426] Therefore, any 
divergent responses observed at this time suggest that immunological interactions between mother and 
infant may play an important role in subsequent immune development. 
 
Streptococcus, Acinetobacter, Staphylococcus and Veillonella were the most commonly found bacterial genera in 
milk samples used in this study. Furthermore, lactic acid bacteria Lactococcus, Lactobacillus and Enterococcus as 
well as oral inhabitant Gemella were also detected, in agreement with previous reports.[19, 21, 73] Various 
studies have demonstrated that there is a mother-to-infant transfer of bacterial genera including 
Lactobacillus, Staphylococcus, Enterococcus and Bifidobacterium through breastfeeding.[78–80, 88, 502–504] The 
constant intake during lactation of breastmilk bacteria leads to the establishment of an intestinal 
microbiota that deeply impacts on the newborn’s immune maturation.[60, 496]. An interesting finding is 
the significantly higher levels of the lactic acid bacteria Enterococcus in breastmilk fed to children developing 
asthma. Work from other authors have shown that Enterococcus is a common inhabitant of breastmilk 
microbiota and one of the first microbes to colonize the infant gut after birth[265, 505], being more 
abundant in the gut of atopic infants, from the same cohort, at 12 months of age.[265] Moreover, 
Enterococcus faecalis has been shown to regulate inflammatory responses in the host.[506] However, whether 
our finding here reflects an overgrowth of Enterococcus due to the absence of competing species, or 
whether Enterococcus is suppressing the growth of allergy protecting bacteria remains to be addressed. 
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Independently of the original source of bacteria, breastmilk, with its hundreds of bacterial genera, 
influences the colonization of infant gastrointestinal tract. It has been proposed that exposure of the 
breastfed infant to a variety of bacterial antigens may favor the infant’s protection against gastrointestinal 
and respiratory infections.[21, 179, 507] Furthermore, breastfed newborns have been shown to possess a 
more stable intestinal bacterial population and controlled mucosal immune response as compared to 
formula fed neonates.[188, 508]  
 
An important function of SIgA is immune exclusion, a mechanism where this antibody binds to 
commensals, through its recognition of multiple antigenic epitopes on the surface, encountered in gut 
lumen and prevents their attachment to mucosal barrier.[197] IgA coating patterns appeared to be 
different, although mainly not statistically significant, between mothers having allergic and healthy 
children in this study. Typical oral inhabitants, including Streptococcus, Veillonella, Rothia and Granulicatella 
[386], appeared to be more IgA-bound in the allergic or asthmatic samples compared to the healthy group. 
This contrasted with the higher levels of IgA-free Lactococcus and Lactobacilli in the healthy group (Figure 
4). However, these differences were not statistically significant and larger studies are needed in order to 
evaluate possible distinctive IgA-coating patterns. Also, the full function of IgA coating is still not 
completely understood. An interesting hypothesis is that the IgA binding does not necessarily only cover 
neutralizing function and exclusion of bacteria but also that this antibody can promote bacterial adhesion 
to the mucosa, as shown in vitro and in vivo [108, 144, 145], thus enriching for the growth of particular 
microbial strains.[430] In this study, we were not able to observe significant differences in the patterns of 
IgA-binding in breastmilk fed to children staying healthy and children developing allergies but the 
possibility that the true differences are at the lower bacterial resolution (for instance species and even 
different strains), should not be excluded. The fact that the majority of the mothers included in this study, 
and also in the original study of this cohort, suffered from allergic disease, should be considered as it also 
may affect both the IgA-coating patterns and the microbiota transferred to the child. 
 
IgA-coating proportions of breastmilk bacteria were higher in mothers treated with placebo, compared to 
those treated with probiotic L. reuteri. As the mothers were treated with probiotics until delivery, likely the 
changes in the microbial composition were more significant in colostrum than in breastmilk samples 
extracted at one month post partum, as in the present study. We have previously shown that Lactobacilli 
colonization was significantly increased in colostrum of the mothers treated with L. reuteri, but not in 
samples obtained one month post partum.[330] This could in turn suggest that part of the mother´s IgA 
responses, while treated with probiotics, were directed towards L. reuteri, but that the ending of probiotic 
supplementation was reflected in diminished targeting of this bacterial species and decreased proportions 
of IgA-bound microbiota. However, this requires to be address further in larger studies. Additionally, 
microbiota patterns of total non-sorted milk were also significantly different between mothers treated with 
probiotics and those with placebo, with the genus Rothia significantly increased in the placebo group. This 
further confirms that the probiotic supplementation during pregnancy has an effect on mother´ breastmilk 
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microbiota that in turn may aid transfer of probiotic bacteria at delivery and during infancy, along with 
immunomodulatory antibodies [264], to the infant. However, results obtained here needs to be further 
confirmed in larger cohorts and the role of Rothia, needs to be further evaluated. Rothia, a common oral 
inhabitant associated with good oral health, is an important nitrate reducer that in combination with other 
nitrate reducing microbes has been shown to give rise to nitric oxide, which is involved in vasodilation in 
cardiovascular system and inflammation in different tissues.[509, 510]  
 
Together with the maternal intestinal and vaginal microorganisms that are ingested by the neonate during 
the passage through the birth canal, breastmilk microbiota appears to contribute to the initial microbial 
colonization in infants, thus having a pivotal role in modulating and influencing the newborns’ immune 
system. The bacterial species that initially colonize the mucosal surfaces likely define the ecosystem 
conditions which in turn will affect the establishment of further co-colonization patterns. Also, milk 
microbes are transferred together with maternal IgA antibodies, that may enable maintenance of a 
mutually beneficial relationship with a diverse set of commensals, while protecting against pathogens. Our 
findings support the hypothesis that perinatal transmission of microbes and immunomodulatory factors 




Consumption of breastmilk with a reduced microbial richness in the first month of life correlates with the 
risk for allergy development during childhood. In addition, our data show that probiotic supplementation 
during pregnancy alters the breastmilk microbiota composition and the proportion of IgA coated bacteria. 
This opens the possibility of modulating breastmilk microbiota and its interaction with antibodies as a 
strategy to promote a healthy microbial colonization with the purpose of reducing allergy risk. 
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Table IV-SI. Chao1 and Shannon indices describing the species richness and diversity, respectively, in total milk 








Chao1 SEM Chao1 SEM Chao1 SEM H vs Allergic / H vs Asthmatic 
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Shannon SEM Shannon SEM Shannon SEM H vs Allergic / H vs Asthmatic 








Shannon SEM Shannon SEM Shannon SEM H vs Allergic / H vs Asthmatic 
2.45  0.10 2.38 0.11 2.42 0.18 0.490/0.893 
HEALTHY IgA-free 
(n=40) 





Shannon SEM Shannon SEM Shannon SEM H vs Allergic / H vs Asthmatic 
2.40 0.09 2.32 0.15 2.18 0.28 0.875/0.859 
* Mann-Whitney U test. 
 
 
Fig. IV-S1. Bacterial load in breastmilk collected at one month post partum. Quantification of bacterial numbers was 
obtained by using qPCR detection with universal primers targeting the 16S rRNA bacterial gene. NHealthy=19; and 
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Fig. IV-S2. Selected bacterial genera found in milk of mothers whose children stay healthy or develop allergic 






Fig. IV-S3. Breastmilk microbiota composition patterns of sorted IgA fractions, IgA-coated and IgA-free, in allergy 
development. Constrained correspondence analyses (CCA) based on breastmilk microbiota patterns of the dominant 
bacterial genera (>0.5% of total) coated with IgA (A) or not coated with IgA (B), from mothers whose children did 
































































































































































































In this thesis, we have used longitudinally collected infant stool and oral samples in order to investigate 
the importance of microbiota maturation in relation to health and allergy development. We described that 
colonization of the oral cavity during early childhood is transitional, increasing in complexity with time, 
and several external factors appear to greatly influence oral microbiota maturation, having either a short or 
a long-term impact. We have also shown that early changes in oral microbial composition influence 
immune maturation and allergy development in childhood, and that the presence of specific bacterial 
species may be important for this progress. Furthermore, altered IgA responses towards the gut 
microbiota during infancy were detected to preceded asthma and allergy manifestations during the first 7 
years of age, and we observed that consumption of breastmilk with a reduced microbial richness in the 
first month of life may play an important role in allergy development during childhood. However, there 
are some methodological aspects to consider in more detail that could introduce biases and errors in the 




The Power (and Limitations) of High-throughput Sequencing 
 
During the last decade, high-throughput next generation sequencing (NGS) technologies have contributed 
to a step change in the sequencing of human and bacterial genomes, among other organisms.[511] This 
has been received by the scientific community as a way to improve the limited classical culture techniques 
for describing complex microbial environments. A pioneer second-generation technique, 454 
pyrosequencing, delivers longer read lengths, in comparison to Illumina technique, but lower coverage, as 
well as errors in homopolymeric tracts (i.e. difficulties to detect the actual number of bases in repetitive 
regions, for example AAAAA).[322, 512, 513] On the other side, MiSeq generates shorter reads but higher 
throughput coverage per run and lower error rate of the instrument (Table I). Also, when performing 
amplicon sequencing of the 16S rRNA gene, an overlap between the forward and reverse sequences can 
be obtained if a paired-ends strategy is used (as with Illumina in the current thesis), allowing for more 
stringent quality control.[513]  
 
Vertical transmission of bacteria from the mother´s body and breastmilk to her offspring has gained 
attention as a significant source of early microbial colonization.[91, 171, 514] Therefore, it is of interest to 
study possible transmission of shared bacterial species between mother and the offspring. Moreover, 
assessment of bacterial composition between different niches, at comparable time-points, allows to obtain 
a global overview of colonization patterns and timing of bacterial settlement during childhood. In this 
GENERAL DISCUSSION 
133 
dissertation, both 454 pyrosequencing and Illumina MiSeq technologies were used in separated 
manuscripts, in order to describe composition of gut, oral and breastmilk microbiota in the same cohort 
of children. However, by sequencing two different regions of the 16S rRNA gene (V3-V4 and V3-V5 for 
Illumina and 454 pyrosequencing, respectively) of stool and breastmilk microbial communities, together 
with distinctive pre-sequencing amplification protocols (and PCR primers), we found it inaccurate to 
compare the findings between the studies. Nevertheless, upon characterization of the same microbial 
community samples, using an identical sequencing region and the same set of primers, both Illumina 
MiSeq and 454 pyrosequencing were shown to be reliable for quantitatively assessing genetic diversity, by 
revealing similar microbial operational taxonomic units.[512] Production of kits for 454 pyrosequencing 
was stopped by the manufacturing company during the course of this thesis, not allowing the use of the 
same sequencing platform for the different chapters. For future studies, in order to more accurately 
compare data between studies, it is required that the same region of 16S rRNA gene is targeted by 
preferably using the same sequencing platform and PCR primers, which would minimize differences in 
bacterial composition estimates due to methodological biases. Additional limitation was that the collection 
of breastmilk samples and first saliva samples in infants was performed at two different time-points (one 
month post partum and at three months of age, respectively). As it has been shown that human milk 
microbiota changes over lactation [91], we did not consider to search for potential shared bacteria.  
 
 




16S ribosomal RNA NGS is a common sequencing method used to identify and compare microbial 
populations present within a given sample. 16S rRNA, encoded by a ∼1,500 base pair gene [515, 516], is a 
widely used housekeeping genetic marker gene that is present in almost all bacteria with a function that 
has not changed over time, implying that random sequence alterations in the gene are an accurate measure 
of evolution.[517] The gene has several conserved segments, which are therefore used as targets where 
PCR and DNA sequencing primers anneal, and a highly variable region that serve as a species-specific 
mark for taxonomic purposes.[515] Thus, variations within the 16S rRNA sequences facilitate 
identification of bacteria at the genus [518] (and in many cases at the species [519]) level and, therefore, 
Sequencing method Characteristics
454 pyrosequencing
• Read lenght: 400 - 800bp
• Coverage: > 1 million reads/run)
• Errors in homopolymeric tracts 
• Obsolet
Illumina MiSeq
• Read length: 250 - 300bp (400bp in paired-ends 
libraries)
• Throughput coverage: > 25 million reads/run
• Moderate cost per base sequences
• Paired-ends strategy sequencing -> Stricter quality 
control
• Quality diminishes with sequence length
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the sequencing of this gene is an ideal tool for bacterial taxonomic studies.[520] Nevertheless, different 
organisms contain different 16S gene copy numbers, which might lead to biased read count 
estimates.[521] 
 
Partial (approximately 500 base pair) 16S rRNA gene sequencing is a commonly used approach today to 
fast and accurately identify a wide variety of aerobic and anaerobic bacterial communities.[522–524] 
However, while a non-full length sequencing of 16S rRNA gene allows for rapid identification, it also 
limits the taxonomic resolution of the gene, as specific hypervariable regions dictate taxonomic 
coverage.[367] Commonly, 16S rRNA gene sequencing provides genus identification in >90% of the cases 
but an important limitation is its inability to discriminate among all bacterial species.[517] In the majority 
of cases this is due to recognition of taxa under-represented in databases, or to high similarity of 16S 
rRNA sequences between neighbouring species, such as the species within the Streptococcus genus that we 
discuss in chapter I.[517] 
 
There is a general consensus for the definition of species boundaries via 16S rRNA gene sequencing and 
commonly the interval of within-species match includes 97-99% similarity (1-3% divergence).[439] 
However, some authors consider that this is not a standardized approach between studies within this field, 
as mentioned by Janda and colleagues [517], and these threshold values may not be sufficient in all 
instances to assure an accurate species identification, particularly in cases when only 30% of the total gene 
is targeted. In chapter I and III, where we described the oral microbiota at the species level (including the 
species within Streptococcus and Lactobacillus genera) we intended to avoid this problem by using 100% of 
similarity for species identification. However, we could observe that there were differences in only one 
base pair between closely related species, making it difficult to accurately distinguish between them. The 
length of the sequenced 16S rRNA reads in this case was approximately 400 bp and likely longer 
fragments, ideally >1,000 bp, would be more convenient for accurate species identification. This will be 
possible in the near future by the use of single-molecule, third generation sequencing such as PacBio 
(Pacific Biosciences) or Nanopore technologies (Oxford Nanopore technologies), which have longer sequencing 
reads spanning the full length of the 16S rRNA gene.[525] 
 
Other concerns in 16S rRNA sequencing technologies involve DNA extraction methods, PCR 
amplification and possible chimeric molecule formation. All of these difficulties, to some extent, affect 
final bacterial identifications.[517] For all the studies presented in this thesis, an additional PCR 
amplification of extracted bacterial DNA was performed, in order to increase the bacterial yield prior to 
the sequencing. PCR amplification is not flawless since it may introduce both biases and new hybrid, or 
incorrect sequences, into the pool of amplified DNA molecules.[526] Commonly used PCR primers are 
designed to amplify many different 16S rRNA gene sequences, from as wide a range of organisms as 
possible. However, the use of different primers changes the inferred bacterial composition, due to the 
selective amplification of some bacterial groups.[527] In addition, careful selection of primers is needed in 
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order to, for instance, amplify bacteria with high CG-content (such as bifidobacteria) that generally might 
be underrepresented in 16S rRNA surveys of diversity due to poor primer matching.[434] Also, for 
adequate discrimination of bifidobacterial, V3-V5 sequencing region of 16S rRNA gene appears to be 
optimal.[434] Due to their beneficial role in shaping the gut microbiome of breastfed infants, 
bifidobacterial prevalence in infant’s gut has been studies frequently. For instance, they appear to reduce 
inflammation, enhance gut mucosal barrier integrity and direct the immune system towards tolerance 
during weaning period, thus potentially influencing the development of allergic diseases.[528] Therefore, 
we used modified, bifidobacteria-universal primers in order to ensure effective detection of this taxa 
too.[434] Furthermore, PCR might also have a large impact on sequence representation after PCR 
amplification basically due to stochastic events. This means that in the cases when the sequences are 
present at very low copy numbers, stochastic amplification may have a significant impact on sequence 
representation.[529] However, we aimed to limit the abovementioned mentioned errors by keeping the 
cycles of the amplification process as low as possible and by maintaining a low annealing temperature in 
order to reduce amplification bias.[366] We also tried to improve the confidence of the data by advanced 
bioinformatics tools and quality filtering criteria in order to limit the errors, presence of chimeras or 
misassignment. 
 
An important general limitation of this thesis is that we focused exclusively on explaining the bacterial 
taxonomic abundance of the samples, without exploring the potential function of the bacteria present. 
Indeed, mapping the microbial composition of the different habitats during the early childhood, before 
and after the development of different disease (in this case allergy), is crucial for reaching an overview of 
the target environment and establishing a foundation for further studies within this field. For establishing 
the repertoire of functions encoded by complex microbial communities, an alternative to 16S rRNA 
studies is direct shotgun metagenomic sequencing.[530] This type of pipeline would also be able to 
accurately track mother-to-infant vertical transmission of microbes, and its influence on post-infancy 
microbiome development, as shown by Ascnicar et al.[531] Also, characterization of gene expression 
profiles by transcriptomics methods may enhance our understanding of the core activities involved in 
disease conditions.[532] Inference of biological functions and potential pathways, based on the 16S 
composition, has also been suggested [533], but its accuracy may be limited by the enormous intra-specific 
genomic variability of the bacterial pan-genome.[534] Therefore, we consider the work presented here an 
important first step for future studies that will be able to answer more functional or mechanistic questions 
about the microbiota in health and allergy. The significance of the 16S rRNA data presented here for 
understanding potential interactions with the immune system is stronger when combined with flow 





Combining Fluorescence Activated Cell Sorting and 16S rRNA Sequencing  
 
In chapters II and IV of this dissertation, fluorescence activated cell sorting was used in combination with 
16S rRNA sequencing as a purpose to characterize the IgA responses towards the gut and milk microbiota 
in relation to allergy development. This type of approach has been used in several other reports up to date 
[451, 452, 535–537], and it will likely become increasingly common in future studies of the microbiota and 
its interactions with the host. 
 
Our data clearly illustrate the utility of this methodology as a way to functionally categorize 
intestinal/breastmilk bacteria based on their interactions with and recognition by the host immune system. 
However, it is important to mention that the fluorescence activated cell sorting may introduce 
contaminants in the system (including the contamination with environmental bacteria and other 
contaminants present in the instrument) which could bias the results. This was mainly problematic in 
breastmilk samples, which had lower bacterial load in comparison to stool samples, and several typical 
environmental contaminants in both IgA coated and non-coated fractions were detected here.[538, 539] 
This problem was limited by sequencing the whole breastmilk sample (beside the IgA+/- fractions), and 
by using powerful bioinformatic tools in order to eliminate the contaminants. Cell sorting appeared to 
reduce bacterial diversity and richness (see chapter IV), when compared to unsorted breastmilk samples, 
which is logical since only the extreme IgA-coated/non-coated populations (mainly IgA coated or mainly 
not IgA coated, as detected with the fluorescence) were collected upon sorting. The bacterial populations 
sorted have, most likely, the expected IgA-status; however, there is a risk that a fraction of targeted cells 
(mainly those coated with IgA) are not collected due to restrictive gating strategies. Nevertheless, the same 
procedure is done between all the samples, thus making the data obtained comparable.  
 
An alternative method to fluorescent activated cell sorting is the magnetic bead-based separation of 
immunoglobulin - recognized bacteria.[540] In this approach, anti-human immunoglobulin-coated beads 
are incubated with biological samples in order to separate immunoglobulin-coated bacterial cells from 
non-coated ones, which resemble the method described above. Compared to FACS, and beside the fact 
that this approach needs less preparation in form of proper calibration and a dedicated machine operator, 
this methodology may reduce the risk of contamination that can be obtained upon separation with the 
FACS instrument, although appropriate protocols still need to be developed. While the samples are 
commonly fixed with paraformaldehyde prior to FACS, thus avoiding the contamination in the system, 
the magnetic bead-based separation (or Magnetic Activated Cell Sorting) would allow to maintain the cells 
viable and use them for further analyses, including bacterial isolation and other in vitro and in vivo model 
experiments. However, the bead-based separation method is not a quantitative method (e.g. not giving any 
information about the proportions of coated/non-coated bacteria) and it does not provide a real-time 
image of the sorted fractions. Moreover, it is difficult to predict the appropriate cellular load/density of 




In conclusion, fluorescence activated cell sorting is a powerful and reliable method for separating 
(bacterial) cells according to a specific immunological status (like IgA coating in this thesis) in samples 
with medium and high microbial load. However, this approach may cause contamination, causing biases 
(with subsequent PCR and sequencing methodology), particularly in the case of samples with low bacterial 
density, although this might be avoided by the use of appropriate controls. In addition to the information 
about the proportions of IgA coating immune responses towards microbiota, bacterial load quantification, 
as described in the following section, can explain if the IgA-coated proportions detected partly depend on 
the bacterial density of the samples investigated.  
 
 
Bacterial Load Measurements  
 
In general, most of the studies published nowadays are focusing on bacterial composition while bacterial 
load (the density of microorganisms in a sample) in different habitats, its levels under health-disease 
conditions or how external factors influence it, are still understudied. The information of total bacterial 
numbers could be useful in understanding bacterial behavior at the interface of host immunity, but also 
for establishing the standard levels in healthy conditions and compare them with alterations that may 
occur during infectious and inflammatory disorders. For instance, increased bacterial load in bovine and 
human milk has been positively associated with clinical signs of mastitis [541–543], an inflammation of the 
breast tissue that commonly occurs during the time of breastfeeding. Moreover, increased bacterial density 
has also been associated in airway inflammation in human patients with chronic bronchitis [544, 545] and 
similarly with the severity of ileal Crohn's disease.[546] In order to better understand the progress of 
bacterial density through the children’s age, the bacterial load (defined as bacterial cells/ml saliva) in 
the oral cavity has been measured in two different studies within this thesis. Oral development, 
presented in the chapters I and III, was accompanied by a steady increase in oral bacterial load from 3 
months to 7 years of age, probably reflecting the influence of environmental interactions and the 
emergence of teeth. While there were no statistically significant differences between children developing 
allergies/asthmatic symptoms and children staying healthy, children developing allergic disease tended to 
have higher levels of bacterial load at 7 years of age (p=0.054). The patterns observed could not be 
attributed to the confounding factors studied (including sex, probiotics and antibiotics intake, 
breastfeeding habits etc.) and future studies should focus on whether the physicochemical properties of 
saliva and other potentially influencing factors, including treatment with asthma medication and oral 
hygiene habits, may influence cell density. 
 
We detected that gut bacterial load decreased with age, with significantly higher levels at 1 month than 
at 12 months of age. Furthermore, children developing allergic diseases had significantly lower 
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bacterial density at 12 months of age, when compared to healthy children. However, the bacterial load 
at 1 month of age showed the opposite, although not significant, pattern with higher density in 
children developing allergic symptoms. Likely, the differences observed at this age were influenced by 
breastmilk as all the children included in this study were exclusively breastfed until 1 month of age. 
Moreover, while the bacterial load in healthy children appeared stable from 1 to 12 months of age, 
children developing allergic manifestations had significantly higher bacterial load at 1 month of age 
when compared to 12 months of age. We further observed the bacterial levels in the breastmilk of 
corresponding mothers, at one month post pregnancy (chapter IV). Although no statistically 
significant differences could be observed, bacterial levels appeared to be higher in breastmilk of 
mothers whose children developed allergic, and asthmatic, symptoms during childhood. This might 
explain the higher levels of gut bacterial density, at 1 month of age, in children developing allergic 
diseases (chapter II). Perhaps, bacterial transmission through breastfeeding might be important for the 
differences observed, and larger studies are necessary to evaluate this further. 
 
Traditional culture-dependent methods (measurements of the colony forming units (CFU)/ml samples) 
for determining bacterial density are known to underestimate the bacterial diversity simply because all 
bacteria are not culturable with current methods and growth media.[547] During the last decades, real time 
quantitative PCR (qPCR), in combination with 16S rRNA primers with broad interspecies specificity, have 
been frequently used as a reliable molecular technique to describe bacterial numbers in complex 
communities.[19, 548–552] However, an important limitation is the varying number of 16S rRNA operons 
in any given bacterial species that may bias the total bacteria numbers.[553] The use of a single-copy 
protein coding gene, such as fusA [554], would tackle this problem, making it a more accurate target for 
bacterial load estimations compared to the 16S rRNA gene.[19] However, these genes are not as widely 
used and tested as the 16S rRNA gene and they might underestimate the load of some bacterial taxa.[553] 
Another solution that we applied in our studies was the use of specific standard curves for each particular 
type of biological sample where bacterial load was quantified. The standard curves consisted of a 
combination of the most common bacteria encountered in a pool of representative samples (for instance 
breastmilk or saliva samples). Shortly, bacterial isolates obtained by traditional microbiological methods 
were sorted and quantified by a MoFlo XDP cytometer. Standard curves were then generated by using 
serial 10-fold dilutions of DNA extracted from a known number of sorted bacteria.[19, 413] 
 
No statistically significant differences of bacterial density in the oral cavity, considering the allergy status, 
could be detected in the current thesis, indicating that this feature does not have an early predictive value. 
It should be born in mind that we are investigating the microbial composition and density before the 
allergic symptoms appeared. If changes in bacterial load are produced later in life or at the time of 




In conclusion, quantification of bacterial load in biological samples is a useful method to estimate the 
bacterial density both under normal as well as infectious conditions, thus providing an overall image of the 
alterations that might occur in different inflammatory diseases. Moreover, determination of bacterial levels 
by qPCR is a great complement to 16S rRNA composition analysis, as it provides the information about 
bacterial cells/ml samples, and this approach has been extensively used in the studies presented in this 
thesis. We assume that the bacterial load measurements should be performed at the time of an 
inflammation, and not as part of a predictive analysis, where this approach could be used as a screening 
tool to detect problems rapidly, for instance in situations of nursing mothers suffering from mastitis. 
However, the methodology has various caveats (for instance the viability of bacteria is not taken into 
account) that should be controlled with traditional microbiological procedures and other molecular 





Microbiota Beyond the Gut 
 
 
Sample selection for representing different habitats 
Over the past decade, microbiota studies have been an attractive topic in the biomedical field. The 
findings describing bacterial composition have been carried out in both healthy subjects and patients 
affected with different disorders, exploring various microbial habitats. However, accurate analysis of 
microbial composition requires appropriate selection of representative samples, where a worthy example is 
provided by gut microbiota studies. The gut microbiota is probably the most complex bacterial 
community in the human body [555], playing an important contributing role in nutrients uptake and 
development of the immune system, among many other functions.[556, 557] The majority of gut 
microbiota studies, including the study presented in the chapter II of this thesis, are based on the 
examination of stool samples, simply because they are easily collected in a non-invasive manner. However, 
the microbial composition of stool samples reflect mainly luminal colonic microbiota, and not necessarily 
bacterial communities located in the small intestine, where a major part of the gut immune system is 
located.[9, 558, 559] Even though our observations were limited to stool samples, we were able to detect 
differences in IgA responses towards gut microbiota between children staying healthy and children 
developing allergic manifestations. Nevertheless, we are not excluding the possibility that a more severe 
dysbiosis might be occurring in the small intestine and this deserves to be evaluated further.  
 
Similarly, it is important to consider that the bacterial communities can vary between different collection 
sites in the oral cavity [560] and both culture and molecular based approaches have shown that the tongue, 
teeth, mucosa, palate, and gingiva harbor a distinctive composition.[386] In the chapters I and III of this 
thesis, saliva samples were used to address the maturation of microbial communities in the oral cavity of 
GENERAL DISCUSSION 
140 
children through age. Several studies have reported that saliva serves as the optimal oral compartment to 
detect microbial differences in various human diseases, as it reveals the closest true representative 
microbiota in the oral cavity.[561–563] However, in chapter III, where we evaluate the importance of oral 
microbiota maturation for allergy and asthma development during childhood, additional analyses of buccal 
mucosa would be of a great interest as they would likely reflect the microbial communities located in the 
near proximity to the host immune system.  
 
Overall, it may be said that the oral and gastrointestinal tract microbiome represent the major part of the 
overall human microbial load, thus providing unique perspectives for advancing human health prognosis, 
diagnosis, and therapy development. Most of the studies published today are focusing on the importance 
of the gut microbiota for allergy and asthma development but since the oral cavity is the first site of 
encounter between the bacteria and the host immune system, it is plausible to believe that oral microbiota 
plays a significant role in early establishment of microbial communities and subsequent allergic disease 
development. Another strength of the studies presented here, particularly in the case of the oral 
microbiota, included the blinded, controlled design with a long-term, closely monitored follow-up of a 
birth cohort, longitudinal sample collection and well-documented clinical records, which is still 
uncommon in many pediatric studies. However, in the future, it would be ideal to expand the study size to 
children without an allergy family history and confirm if our observations in Swedish children can be 
translated to children in other regions of the world. Moreover, the role of other parts of microbiota, 




Other important microbiota niches  
We have exclusively focused on describing the bacterial compartments of oral, gut and breastmilk 
microbiota but the human microbiota consists also of other organisms as archaea, viruses, and fungi that 
build a highly complex network of interactions between each other and the host.[564] However, the 
members of these microbial community have rarely been assessed up to date. Filamentous fungi and 
yeasts are common members of the gut microbiota [565] and their role in the development of allergic 
airway disease has been reported in murine models. Manipulation of the mycobiota (i.e. fungal 
microbiota), resulted in increased severity of murine lung inflammation and specific fungal species 
overgrowth in the gut.[566] When it comes to human studies, the importance of fungal gut dysbiosis for 
the development of atopic wheeze in babies, has been reported in few studies.[277, 567] For instance, 
high relative abundance of Candida and Rhodotorula, together with decreased abundance of Bifidobacterium, 
Akkermansia and Faecalibacterium have been associated with neonates with the highest risk to develop atopy 
and asthma.[277] It is also known that during the first 3 months of life, fungi are present at a significantly 
higher diversity than later in life [277], which is likely due to elevated transmission or growth promotion 
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through breastmilk.[568] However, now that the bacterial composition has been widely mapped, the 
importance of fungi (as well as viruses and archaea) for the early establishment of the infant microbiota 
and immune system development needs to be further evaluated. Taxonomic composition of archaea and 




Microbiota and Immune Maturation During Childhood 
 
Microbial colonization of the gut and oral cavity 
Early microbial colonization of the neonate exerts a major effect on host future health status. The 
selective growth and timing of early colonizing pioneers, is determined by various factor, including 
breastfeeding.[571] Microbial colonization observed in the gut and oral cavity in the studies presented 
here, was likely influenced by breastfeeding as the majority of the children were exclusively breastfed 
during the first month of age. Therefore, the colonization pattern might reflect the bacteria encountered 
in the breastmilk of the mothers and be influenced by the presence of HMOs, which may act as prebiotics 
favouring the growth of specific microorganisms.[572] Deeper sequencing technologies, with higher 
resolution, are required for establishing the bacterial species transmission and stimulation through 
breastmilk.[531]  
 
Generally, the Streptococcus genus was the primary, and the most abundant, commensal to colonize both the 
oral cavity at 3 months of age and the infant gut at 1 month of age. This genus, together with Staphylococcus 
and Pseudomonas, was also a main constituent of the breastmilk microbiota collected at 1 month of age, 
which has also been reported before.[19, 571, 573] Streptococcus is a facultative anaerobe that commonly 
colonizing the infant already during the vaginal delivery where, together with Escherichia coli 
and Staphylococcus species, they produce an environment that favor the thriving of strict anaerobes, 
including Bacteroides and Bifidobacterium spp. [574] Although we were not able to catch this transmission, as 
the stool samples were collected at 1 month of age, the families Staphylococcaceae and Bacteroidaceae were 
observed as dominant members of gut microbiota by this age. Moreover, Veillonella, a common oral 
commensal associated to acidic pH (it metabolizes organic acids such as lactate), was found to colonize 
both the gut microbiota at 1 month of age and the oral cavity at 3 months of age, probably due to 
transmission by breastmilk in these children. Similarly, a colonization of Lactobacillus in the oral cavity at 3 
months of age was likely due to breastfeeding, as species belonging to this genus have been frequently 




In chapter II, we used stool samples, obtained at 1 and 12 months of age, to describe the microbial gut 
maturation during the first year of life. We observed that beside increased bacterial diversity and richness 
during this period, Streptococcaceae, that dominated during the first month of life, was later accompanied by 
the bacterial families Lahnospiraceae and Ruminococcaceceae. The Lachnospiraceae family, which includes the 
Roseburia, Blautia and Lachnospiraceae incertae sedis genera, is known to participate in the breakdown of 
carbohydrates into SCFAs [575] and increased abundance of this bacterial family has been associated with 
transition from milk-based feeding to solid foods-diet.[75] Moreover, these colonization events during the 
first years of age were also in agreement with an European study including infants from five different 
countries, demonstrating that consistent compositional changes characterized by an increase 
in Ruminococcaceae and Lachnospiraceae species (and decreased Bifidobacteriaceae, Enterobacteriaceae 
and Clostridiaceae) occurred with the introduction of solid foods [189], including dietary fibers and protein 
from cheese and meat.[576]  
 
Oral development (chapter I), from 3 months to 7 years of age, was accompanied by a steady increase in 
diversity and richness of the oral microbiome in this study, especially between the first and second year of 
life. The abundance of bacterial genera varied through age, starting with early pioneers that were replaced 
by steady levels of constant colonizing bacteria (including Gemella and Granulicatella), associated with 
emergence of the teeth and dental plaque formation. We also observed that there were several bacterial 
genera, here referred to as “late colonizers”, that became dominant in the oral cavity at a later stage, 
approximately after the first year of life. 
 
Early infant colonization sets the stage for the complex and more stable adult microbiome.[577] 
Generally, early commensals of both the oral cavity and the gut are likely having an ecological 
advantage over the bacteria arriving later [40], and their presence can contribute to environmental 
changes that benefit, but also limit, the growth of arriving bacterial communities. Moreover, these 
pioneers educate and stimulate the developing immune system, thus protecting the colonizing microbes 
against systemic immune responses [578], as discussed in the next section. The early process of microbial 
succession and increased diversity is likely influenced by several perinatal factors during the important 
window of opportunities.[61] As lactation ends and dentition begins, bacterial communities will adapt to 
handle solid foods which in turn will result in selection of bacterial populations with relevant metabolic 
activities, as we could observe in the oral microbiota. However, the real key features of colonizing 
microbiota, and inter-species interactions, deserve to be further evaluated, as the majority of the studies 
available focus on the descriptive composition of body sites. Do individuals respond to the same 
microorganism in the same way? Moreover, longitudinal sampling and prospective studies are crucial to 
describe important phenomena of the infant colonization process. These efforts will in turn help us to 
understand the alterations occurring from health to disease conditions and directs us towards discovering 





The effect of perinatal factors on oral microbiota 
Delivery mode, breastfeeding and antibiotics use, among other factors, have been shown to influence the 
initial development and maturation of the neonatal microbiota [571], thus playing an important role in 
development of allergic diseases.[571, 579] We found that the overall bacterial composition development 
in the oral cavity was influenced by delivery mode, breastfeeding habits and antibiotics intake during the 
first years of age (chapter I). The impact of delivery mode was reflected in differences in oral bacteria 
composition at 3 and 6 months of age, while the effect disappeared at later time points. Hence, we assume 
that the delivery mode might have a short-term effect that is due to the direct transmission of initial 
bacteria from mother to newborn, favoring the establishment of specific pioneers. This would in turn 
regulate further settlement of specific bacterial species but, likely, the clear effect that we observe at early 
age will fade later due to the influence of other external factors and immunological events. It is also well 
known that early events occurring during critical window of initial microbial colonization and immune 
development, may have long-standing consequences on immune-related diseases, as allergies, during 
childhood.[235] The early differences detected here is in line with previous studies showing that microbial 
oral colonization in 3-month-old infants delivered vaginally and those delivered by C-section was 
different.[55] Similar findings of an early impact, but also more long-term effects [343, 380], have been 
reported for the microbiota of the lower gastrointestinal tract [171, 172], and increased incidence of 
allergic disease due to disruption of early bacterial colonization caused by C-section.[580–584] However, 
we did not observe any effect of the mode of delivery on microbial composition, in relation to allergy 
development, in any of the allergy-related studies presented in the thesis. The possibility that the 
differences were masked by low statistical power in C-section group of this cohort, should not be 
excluded. It has also been proposed that the human milk microbiota is shaped by mode of delivery [91], 
but this has been debated [20] and we were not able to detect any effect either. 
 
The clinical data of the cohort used in this thesis allowed us to access the influence of partial 
breastfeeding, compared to no breastfeeding until 12 months of age, and antibiotics intake in early life 
(first and second year) on the developing oral microbiota. We identified that partial breastfeeding, as well 
as antibiotics intake, had a long-term effect on overall composition of oral microbiota at 2 and 7 years of 
age. We assume that the effect of breastfeeding observed at later age, and not in bacterial colonization at 
early age (3, 6 and 12 months) that appeared to be similar which, is due to the fact that the majority of the 
infants in this cohort were breastfed during their first months of life. Interestingly, partial breastfeeding 
was also associated with lower bacterial diversity through age, and particularly at 2 years of age, when 
compared to children which abandoned breastfeeding before 12 months of age. Similar finding have been 
reported in gut, where children not being breastfed had higher bacterial diversity [77, 163, 378], likely due 
to introduction of solid foods. As findings presented here suggest that variation in the initial oral 
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microbial communities may result in differences in the bacterial succession patterns that persist over time, 
further work should therefore address the impact of formula feeding on the microbiome.  
 
We also detected that the repeated use of antibiotics (at least one treatment per year, during the first 2 
years) during infancy was associated with significant increase in abundance of several bacterial species at 7 
years of age, and many of them (including Fusobacterium and Actinomyces) has previously been associated 
with oral diseases (chapter I). It is important to mention that we lack the clinical follow-ups (additional 
antibiotics courses that have not been registered) and salivary samples between year 2 and 7 of age might 
affect the results observed here. However, given that the first year of age represents the crucial “window of 
opportunity” for microbial development and immune system regulation, we hypothesize that the changes 
observed here can have long-term consequences for microbiota development. 
 
In conclusion, colonization and development of the oral microbiota in this longitudinal study is dynamic 
and follows an ecological succession influenced by delivery mode, breastfeeding duration and antibiotics 
courses, factors that together shape the microbial composition and have a crucial role in long-term health 
of the child. Our data suggest that this succession pattern may be critical for appropriate immune 




IgA-coating of Gut and Breastmilk Microbiota in Relation to Allergy 
Development 
 
SIgA antibodies at the mucosal surfaces target and regulate pathogenic bacteria invasion, but they also 
target common resident commensal microbes that inhabit the epithelial mucosa or live free in 
suspension (such as in the gut lumen).[107] Although it has been suggested that this immunoglobulin 
influences microbiota composition during homeostasis, the exact importance of this immunoselection 
remains controversial and poorly understood. However, lack of IgA against specific bacterial epitopes 
has been shown to result in innate immune system activation in the intestine [141], confirming the 
importance of IgA for protection from mucosal inflammation. 
 
Breastmilk counteracts early deficiency of IgA production in neonatal gut, as this antibody is the principal 
Ig (>90%) in human milk.[64] Endogenous IgA production is induced during the first month of life and 
increases during infancy, while the IgA concentration in breastmilk decreases with time.[585, 586] At one 
month of age, approximately 50% of stool microbiota was IgA-coated, while the proportions decreased 
significantly to 20% at 12 months of age. The proportions observed during the first month of age are 
likely reflecting both the endogenous production of IgA as well as IgA transmitted through breastmilk, 
compared to 12 months of age where the proportions are dependent on the infant’s own production. 
These findings were further confirmed upon measuring SIgA levels in stool samples, by ELISA immune 
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assay, as the levels were three-fold higher at 1 month of age than at 12 months of age. Interestingly, the 
overall proportions of IgA-coated bacteria in breastmilk, collected one-month post partum, were 
comparable to the percentages of coated gut bacteria (»40% vs 50%), indicating that breastmilk may be 
responsible for initial bacterial targeting with IgA. The slightly increased proportions observed in stool 
samples are likely reflecting the endogenous IgA production by infants. In the future, this could be further 
confirmed by studying IgA coating levels and IgA bound bacterial patterns in formula fed children, as 
those would not have any maternal contribution of IgA. As a pilot test, we tested IgA coating levels in a 
sample of a formula-fed 1-month old baby and observed that proportions of bacterial coating were 
extremely low (approximately 4%, Fig. 10). This confirms the importance of vertical transmission, from 
mother to offspring, of immunomodulatory components that may aid and direct early mucosal immunity 




Fig. 10. Proportion of the stool bacteria bound to IgA or not at 1 month of age in a formula-fed infant. (A) The 
histogram shows the green fluorescence intensity on the horizontal axis and the number of events is shown on the 
vertical axis. (B) Scatter plot showing the proportion of IgA bound fecal bacteria where the Y-axis corresponds to 
the green fluorescence, which is related to the number of bacteria bound to IgA (here 3.98%), and the X-axis is 




Proportions of IgA-coating differed between healthy children and children that developed allergic 
manifestations later in life. Children that remained healthy during the first 7 years of age had significantly 
higher proportions of IgA-coated bacteria at 12 months age, compared to children developing allergic and 
asthmatic symptoms. However, no statistically significant differences could be observed at 1 month of 
age, which is consistent with the findings in IgA-coated breastmilk microbiota of corresponding mothers. 
Possibly, the initial transmission of IgA via breastmilk mainly provides a protective coating of the mucosal 
barrier, independently of allergy status, while the infant is developing its own nascent immune system, 
which plays a role in subsequent allergy development. This in turn implicates that additional factors, 
influencing during the first year of life, are important for an appropriate immune system development. 
Moreover, it is important to mention that the majority of mothers included in the study (80%) had been 
diagnosed with allergic disease, which could bias the results. Cohorts following children without a clinical 
history of allergic disease in the family would be important in this aspect, as well as additional stool 
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samples collected at earlier (for instance at 6 months of age) and later (around 2 or 3 years of age) time 
points, when IgA production resembles adult-like levels.[587] 
 
An important question to address is the selectivity of the bacterial taxa targeted by IgA. Is IgA useful as a 
marker of potentially immunomodulatory taxa on mucosal surfaces? In a study by Palm and colleagues, 35 
different bacterial species were selectively IgA-coated in patients with inflammatory bowel diseases and 
upon colonization of germ-free mice with this bacterial population, these animals were more prone to 
display signs of colitis, when compared to mice colonize with IgA-free taxa.[452] The selectivity can also 
depend on immune-location of IgA induction and secretion. Mouse experiments have shown that IgA 
responses are selectively focused on microorganisms located in the small intestine, as this antibody is 
dominantly produced there.[140] In contrast, bacteria found primarily in the colon are not major targets of 
IgA. In this way, IgA can protect the thin layer of small intestinal mucus from proinflammatory 
exposures, in contrast to thicker mucosal barrier of the colon that is less vulnerable.[100]  
 
In the studies presented in this thesis, we observed that IgA recognition patterns of gut microbiota 
differed between healthy children and children with allergic symptoms, with divergent coating patterns 
already found at 1 month of age. For instance, two important human gut symbionts [453], Faecalibacterium 
and Bacteroides, were mainly IgA-free at 1 and 12 months of age in children with allergic manifestations but 
were predominantly IgA-coated in healthy children, which could reflect lower stimulation of the mucosal 
immune system in infants with allergic diseases. In contrast, allergy development was associated with 
increased IgA responses at 12 months of age to Lachnospiraceae, gram positive barrier associated microbes 
that colonize the inner mucus layer, staying in close contact with host mucosa. This might imply that 
increased IgA coating of these bacteria in children with allergies might be an indication of an altered 
mucosal barrier function.[464, 465] Even though we speculate that different IgA coating patterns of 
bacteria may play a distinctive role in mucosal barrier function, it is inevitable to doubt the actual function 
of IgA-targeting in health and allergy development. An interesting hypothesis is that the IgA-coating is not 
necessarily solely involved in neutralization of microorganisms and their exclusion but it can also endorse 
bacterial adhesion to the mucosa, as shown in vitro and in vivo.[108, 144, 145] As a consequence, IgA and 
gut microbes co-colonize the epithelial outer mucus, thus enriching for the growth of particular microbial 
strains.[145, 430] Therefore, the function of IgA bacterial coating would support colonization by or 
growth of symbiotic species, while limiting expansion by pathogens and growth of other commensal 
bacteria.[588]  
 
An interesting question here is how a single antibody can mediate that many functions? Since IgA is 
passed from mother to child in breastmilk, possibly symbionts that are targeted by the mother´s IgA can 
be vertically transmitted to the infant, thus favoring colonization by specific bacterial species. As proposed 
by Schofield et al.[588], this event may protect against colonization in the infant by environmental strains 
of the same species, distinguishing between commensals and symbionts, and permitting co-development 
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of host–microbe symbiosis. In line with this, we could observe that IgA antibody responses at 1 month of 
age, in exclusively breastfed infants, were already divergent between children developing allergies and 
children that remained healthy until 7 years of age. To investigate if immunological interaction during 
breastfeeding influence allergy development later in life, we explored the IgA responses towards 
breastmilk bacteria in the corresponding mothers. However, no similarity in IgA-coating patterns could be 
detected between stool and breastmilk samples but, as discussed above, this could mainly be due to use of 
two different sequencing methods to address this problem. Except the methodological issue, it is 
important to consider that only a fraction of the milk SIgA is absorbed by the infant´s intestine after birth. 
Much of the immunoglobulins transferred through breastmilk are moderately resistant to digestion as they 
pass throughout the intestinal tract. This is especially relevant concerning IgG, which is less resistant 
towards digestion than IgA.[197] Also, to which extent can SIgA survive enzymatic digestion needs to be 
further investigated, as most of the studies have been performed on the IgG in animal models. 
 
The approach for studying IgA responses towards bacteria, in different body sites, is relatively novel and it 
provides information that is important for understanding the basis of mucosal immune system responses. 
We cannot exclude the possibility that the differences observed in IgA-coating patterns between healthy 
and allergic children could be due to specific bacterial strains, and this should be explored further. For 
instance, specific isolates from breastmilk and gut microbiota should be addressed in order to see if they 
vary in their immune-inflammatory responses. Moreover, it is also required to complement this kind of 
data with methodologies that identify the specific antigen targets of secretory IgA at high-resolution. 
Beside SIgA, IgM might also play a role in immune responses towards commensals, as it has been 
observed that SIgM co-target with SIgA mucus-embedded commensals thus increasing diversity and 
richness in the gut.[151] Therefore, the understanding of this immunoglobulin in influencing the growth 
of common commensals should be broadened, and the fluorescent activated cell-sorting and sequencing 
approach has also been set up for IgG- and IgM-coated bacteria.[413] 
 
 
The Influence of Environmental Factors on Microbiota Development in 
Health and Allergy 
 
Neither delivery mode, nor breastfeeding or antibiotics intake during early period of life appeared to have 
an impact on microbial composition, in relation to allergy development, in any of the allergy-related 
studies presented in the thesis. However, it is logical to believe that all these environmental factors may 
influence early microbial development and immune system maturation, as reported in other studies.[60] 
For instance, delivery by C-section imposes on microbial establishment, diversity and immune system 
maturation simply due to the lack of exposure to the vaginal and stool microbes of the mother.[571] 
GENERAL DISCUSSION 
148 
Although we were not able to detect any effect of C-section delivery on allergy development, likely due to 
limited statistical power, we do detect the importance of this process for the oral microbiota maturation in 
longitudinally collected saliva samples throughout childhood. Therefore, large intervention studies where 
neonates delivered by C-section are exposed to bacterial populations found in the mother’s vagina and 
stool would be really important for understanding the consequences that delivery mode may cause. 
 
When it comes to the protective role of breastfeeding in asthma and allergic disease in children, the topic 
is still controversial since it is not possible to make a definitive conclusion regarding this relationship.[186] 
Like discussed in a recent systematic review [186], the interaction between breastmilk, the infant intestinal 
ecosystem and the developing immunity is highly complex to study and comprehend. Besides the genetic 
factors, mother’s diet and health status, the heterogeneity in study design complicates the interpretation of 
the data. Likely, some factors in breastmilk may protect the infant from developing allergic disease while 
others have the opposite effect. For instance, breastmilk of atopic mothers have higher concentration of 
cytokines IL-4, IL-5, and IL-13 that are closely related to IgE production and eosinophil induction.[589] 
Therefore, it is important to direct future research on interactions between microbiota and the immune 
system and not only to study these areas separately.[590]  
 
Similarly, the association between early antibiotic use and increased risk of allergic disease and asthma 
has been controversial.[216, 590, 591] The negative impact of antibiotics on the gut microbiota is 
often referred to as potential induction of bacterial dysbiosis, benefiting the growth of opportunistic 
pathogens, that subsequently leads to development of allergic disease. Retrospective studies have 
mainly showed the relation between infant antibiotic use and allergy development while the results 
from prospective studies have varied.[169, 592, 593] The age of initial exposure might be crucial since 
maternal use of antibiotics during pregnancy has been shown to increases the risk of allergy 
development in children.[594] However, the information about prenatal antibiotics intake was not 
available in the cohort studied here. Other studies have revealed that the risk of asthma development 
increases with the number of antibiotic courses administered during the first year of life [595–597] and 
that an association with asthma is stronger upon broad-spectrum antibiotic use.[596, 597] The lacking 
effect of antibiotic use on gut microbiota development in allergy in the study presented here might 
likely be influenced by the small sample size, but also the fact that we observe IgA-coated microbiota 
and not the total, unsorted microbial composition. It is also unclear to what extent antibiotic use can 
alter oral microbiota in relation to allergy and asthma development and this needs to be studied in 
more detail. Another important problem to address in this type of studies is occurrence of reverse 
causation – is the treatment administered for a condition that in fact may be an early symptom for the 
outcome (for instance eczema) measured?  
 
In conclusion, we assume that the discovered microbiota differences between children staying healthy and 
developing allergies are mainly driven by health status. However, larger studies, preferably with 
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longitudinally collected samples and clinical follow-up until school age, are required to further investigate 
and confirm the role of the environmental factors discussed here, in allergic disease development. 
Nevertheless, microbiota studies endure high inter-individual variation and, even by using large study 
groups, we cannot exclude the possibility that the differences will be apparent only upon observation at 
the individual level. Also, because of the multivariate nature of the human microbiota data, and difficulties 
to create robust study design, potential effects on microbial composition and allergy outcome by any of 
these factors might get masked by different variables confounding each other. For instance, by performing 
multivariate analyses we could observe that breastfeeding duration was the main factor driving oral 
microbiota differences through age and that the other factors were partly influenced by it. In addition, it 
needs to be determined whether our findings can be replicated in cohorts of other geographic origins and 
with a different family history of allergic disease. A next step would of course be to investigate if probiotic 




Modifying the Microbiota to Promote Immune-related Health 
 
 
Probiotics and allergy – Can we control the microbial colonization during early life? 
An altered microbial exposure, C-section delivery, short breastfeeding habits and antibiotics use are some 
of the factors that may be partly responsible for microbial dysbiosis in children and subsequent allergy 
development.[271] Probiotic supplementation both during pregnancy and early life has been suggested as 
a potential strategy for both modulating the initial microbiota colonization but also for restoring microbial 
changes that can lead to development of allergic diseases.[308]  
 
Children and mothers included in the publications of this thesis were part of a larger prospective study 
where 232 families with allergic disease were recruited (see Method section and [327, 328] for more details). 
The aim of the original study was to evaluate the potential allergy preventing effect of the probiotic 
Lactobacillus reuteri during early childhood. The mothers started taking L. reuteri ATCC 55730, or placebo, 
four weeks before term and continued until delivery, while infants continued with the same treatment as 
the mother (probiotic or placebo), daily up to 12 months of age. L. reuteri is a gram-positive rod that has 
been isolated from gastrointestinal tract in several mammals, including humans [598–600], and this species 
has been reported to influence immune responses, possessing an anti-inflammatory effect, in both in vitro 
and animal studies.[601, 602] Briefly, the original studies reported that the L. reuteri treated infants had 
higher prevalence of this bacteria in stool samples (as determined by bacterial culturing) during the first 
year of life, when compared to placebo group.[330] Moreover, the L. reuteri group had a lower incidence 
of IgE- associated allergic disease, with lower prevalence of IgE-related eczema and decreased allergen 
responsiveness during the first two years of life.[317, 327] Colostrum of L. reuteri treated mothers had 
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reduced levels of TGF-β2 [497], which has been associated with less allergic sensitization. However, the 
probiotic treatment was not effective in preventing respiratory allergies.[328]  
 
The original studies were analyzed from a more immunological perspective with conventional cultivation 
methods, while 16S rRNA gene sequencing was not performed. Surprisingly, in the studies considering 
gut and breastmilk bacterial composition presented in this thesis, we were not able to identify this 
particular Lactobacillus species in our sequencing data, and this could be due to amplification bias, as our 
primers do amplify this genus when present. Likely, since the breastmilk samples were obtained at one-
month post partum, and the mothers were treated only until delivery, this species may no longer be able to 
colonize milk. When we studied gut microbiota composition (chapter II), the genus Lactobacillus had a very 
low abundance and we were not able to detect L. reuteri. As mentioned before, we were only checking cell-
sorted fractions of bacteria, which could have influenced the detection of this strain. It is also important 
to consider that certain strains of probiotics are less efficient colonizers than others, even after direct 
administration to the infant. A possibility to explore in the future is whether the probiotics administered 
favor co-colonization of other beneficial bacteria for immune system development, even though the 
probiotics themselves are not able to significantly colonize and expand.  
 
Supplementation with L. reuteri during the first year of life seemed to influence the association between 
oral microbiota composition and asthma development (chapter III). This was reflected in distinctive 
microbiota clustering at 12 and 24 months and 7 years of age between children taking probiotics and not 
developing asthma and children that did not take probiotics and developed asthma. In the original study, 
the probiotic intervention was associated with lower prevalence of IgE-related eczema during the first 2 
years of age, while L. reuteri did not directly reduce asthma development in the cohort.[328] A benefit of 
probiotics for primary prevention of eczema, but not significant effect on any other allergic 
manifestations, was further confirmed by two meta-analyses published in 2015.[603, 604] Cuello-
Garcia et al. concluded that there was a benefit of probiotics for eczema reduction (until 2 years of age) 
when administered in the last trimester of pregnancy, when supplemented to mothers 
during breastfeeding or when administered to infants and/or mothers. Also, no significant effect on 
eczema was observed when probiotics were administered exclusively to the infant.[604] The long-term 
preventative effect on eczema using four different strains of specific probiotics has also been reported 
recently.[605] In this study by Peldan et al, they observed that the early use of probiotics was associated 
with a reduction in the incidence of eczema at 10 years of age. However, the results of their long-term 
follow-up data was based on solely on questionnaires, and not clinical examinations, which could be a 
limitation of the study.[605] Intriguingly, in the same study they observed that allergic rhinoconjunctivitis 
was more prevalent in children, between 5-10 years of age, who had previously been treated with 
probiotics, when compared to placebo. A similar finding was reported by another study [304], but as 
authors explain, it can be difficult to distinguish between allergic and viral rhinitis, particularly when the 
outcome has been based on parent-reported data. Generally, there is very little evidence for a role of 
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probiotics in prevention of respiratory allergies, including asthma, rhinitis and wheeze but the possibility 
should not be completely excluded, and further evidence are needed. 
 
Therefore, larger studies including the replication of our findings and the exact role of L. reuteri in the oral 
cavity are required to further investigate and confirm the role of this Lactobacillus in allergy development. 
Interestingly, increased abundance of two other Lactobacilli species (L. gasseri and L. crispatus) in the oral 
microbiota were observed in children staying healthy until 7 years of age, when compared to children 
developing allergies (chapter III). As discussed in the corresponding paper, both of these bacteria have 
been observed to have health-promoting immunomodulating properties with ability to suppress allergic 
responses and reduce mite-induced airway inflammation and hyperresponsiveness in mice models.[489, 
490] Thus, we propose the isolation of these species from the oral cavity of healthy children to be tested 
for possible beneficial effects. Potential probiotic strains, such as the lactic acid bacteria Lactobacillus and 
Enterococcus, are generally isolated from safe sources like fermented dairy products [606], while the use of 
bacteria identified and isolated in the oral cavity is uncommon. In addition, most of the studies present 
today are describing the association between early microbial dysbiosis in the gut [39, 263] and the risk of 
allergic and asthmatic disease. Yet, as the oral cavity is the first line of encounter between the immune 
system and the majority of foreign antigens, the potential role of oral microbiota in allergy developments 
needs to be thoroughly evaluated. In has to be born in mind that some bacterial species observed in paper 
III were clearly associated with allergic conditions even before the appearance of symptoms and therefore 
their potential immunomodulatory effects deserve further attention and future investigation in 




Wider perspective of probiotics in treatment in allergy prevention 
World Allergy Organization (WAO) guidelines suggest administration of probiotics in mothers during 
gestational and lactating period, and later on in infants, when there is a high risk of allergy development 
during childhood.[607] Probiotics may have a potential role in the prevention of atopic eczema but studies 
to date have not been completely conclusive and recommendations today are based on little 
evidence.[608] The heterogeneity in study design, sample size, intervention age and age at sample 
collection, methods of analysis of gut microbiome, and geographic location are factors that make the 
comparisons between studies difficult.[609] Moreover, the hypothesized mechanisms by which the 
commensal microbiota influences the outcome of the allergic response are manifold [610] but necessary to 
understand in order to perform an optimal probiotic selection. As mentioned above, a combination of 
bacterial strains may be important to prevent development of childhood allergic diseases, both due to 
characteristics of strains that will influence the immune system in different manner but also due to 
variation on the initial composition of the host’s (gut) microbiota. However, it has also been reported that 
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solely one probiotic strain has been able to induce allergy preventive effect, across the spectrum of allergic 
disease (although not asthmatic disease), during childhood.[611] The majority of probiotic intervention 
studies in allergy are focused on the most well-known species (Lactobacillus, Enterococcus, Bifidobacterium) but 
they represent only a small fraction of the total composition. Therefore, wider understanding of yet 
unknown species, and their role in colonization and immune system modulation, is needed for improving 
future probiotic therapy. We should also take advantage of longitudinal studies where changes in microbial 
composition between health and disease condition (including allergy) have been reported, in order to 
identify particular biomarkers that might aid in predication of allergy development, as discussed in the 
next section. As we gain broader perspective about these alterations, microbiota-immune system 
interactions and the species present, we may be able to develop more effective intervention strategies and 




Can Microbiota Composition Predict Allergies and Asthma? 
 
As we gain wider understanding of the relation between the human microbiota composition and a variety 
of diseases, the thought of using these findings to predict and diagnose disease conditions is truly 
attractive. Many studies have identified different gut microbiota biomarkers that might predict a variety of 
disease conditions, including intestinal bowel disease, obesity, diabetes and colorectal cancer.[612–615] 
Therefore, modification of gut microbiota may be a potential therapeutic strategy to prevent or reverse 
diseases, as it has been shown in obesity-related studies where transferring healthy microbiota to a second 
host can reverse and prevent metabolic syndrome.[616] The ability to predict allergic disease at an early 
age would have many advantages in Western countries where the prevalence of allergies has increased 
dramatically during the last decades.[617] Due to great advances in gene sequencing technologies, research 
assessing complete gut microbial communities during early period of life, has augmented our ability to 
identify important biomarkers that might predict future allergy development. For instance, reduced 
diversity in gut microbiota, together with decreased abundance of Bacteroides genus at 1 month of age, have 
been associated with the risk of developing atopic eczema at second year of life.[265, 269] Other cohort 
studies have reported that colonization with Clostridium difficile (an opportunistic pathogen), during the first 
month of life, was associated with atopic sensitization at age 2 [278], and with asthma at 6 to 7 years of 
age.[618] Moreover, besides reduced bacterial diversity during the first month in children developing 
asthma [266], low abundance of the bacterial genera Lachnospira, Veillonella, Faecalibacterium, and Rothia has 
also been associated with risk of asthma in children at school age.[168]  
 
With the study II, we aimed to find potential gut microbiota biomarkers related to allergy development 
during childhood, by going one step further than in other studies focused exclusively on describing the 
composition: addressing the interaction between mucosal immunity, represented by IgA, and bacterial 
composition. Our work here suggested early characterization of IgA-coating proportions and patterns may 
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represent a novel strategy to identify children with increased risk of allergy and asthma development. The 
fact that these alterations can be detected already during the first year of life, paves the way for possible 
clinical interventions that might modulate or delay the dysbiosis, thus preventing children from 
developing asthma and allergic diseases. Indeed, these findings need to be followed further and confirmed 
in larger cohorts, as discussed earlier. We speculate that already the transmission of maternal immunity can 
be used as an even earlier predictive event in allergy development, since breastmilk fed to children 
developing allergies had significantly lower bacterial richness, when compared to breastmilk fed to 
children staying healthy. Additionally, the relative amounts of several bacterial species in oral cavity, 
including increased abundance of Gemella haemolysans in children developing allergies and L. gasseri and L. 
crispatus in healthy children, were distinctive during early infancy, likely influencing early immune 
maturation. In conclusion, we have encountered alteration in microbial composition and immune 
responses towards bacteria, at several bacterial habitats, that influence and precede allergy development 
during childhood. We reported that the presence of the bacterial species G. haemolysans in the oral cavity 
was associated with the risk of developing allergic diseases while L. gasseri and L. crispatus were detected as 
potential probiotics associated with children staying healthy until 7 years of age. The possibility that these 
early findings could be applied to clinical research and used as potential early biomarkers capable to 
predict the risk of allergy and asthma should be considered. 
 
In order to translate our findings however, as well as other studies focused on microbiota related 
biomarkers in health and disease, we must address numerous challenges. Taxonomic changes reported in 
different studies that focus on a particular disease condition, like allergy in this case, are inconsistent. 
Distinctive and unstandardized methodological approaches and sample population (size and ethnicity, 
geographical location and lifestyle), as well as external confounding factors such as diet (for instance 
breastfeeding duration) may account for relative lack of consistency among different biomarkers. 
Moreover, the microbiota is highly variable, and it is difficult to define a range of “healthy” composition 
(healthy core) and diversity of the human microbial ecosystem (gut microbiota for instance). Additionally, 
many dysbiotic changes, particularly bacterial diversity and richness, are not disease-specific and can be 
associated with several inflammatory conditions. Another curious thought to study here is – Do the 
observed microbiota changes reflect cause or consequence of allergy development? This is particularly 
interesting in case of respiratory allergies where medication administered, for instance asthma inhalators, 
might affect local microbiota composition. However, in chapter III where we compared bacterial diversity 
of the oral cavity, at 7 years of age, between children developing allergies (and asthma) and healthy 
children, we took into account the effect of asthma medication. While a similar trend was observed even 
after excluding children that were using asthma medication, we were not able to fully evaluate this 
statistically due to a low subject number. Also, there are good reasons to expect that many other potential 
influences, including the oral hygiene habits and diet during childhood, should whenever possible be 




When it comes to methodological aspects, it is worth to mention that 16S rRNA gene sequencing is not 
an optimal approach for identifying microbial communities at species or strain levels, which could provide 
for example different surface antigens within the same species. This is highly limiting as species- or strain-
level differences between individuals can be large and therefore, whole genome sequencing approaches 
would provide better information about human gut microbes and their functions. Another important 
challenge is given by the feasibility of developing an easy-to-use test that can be used in the clinical setting 
or even at home and that is inexpensive. For that, the complex sequence-based approach developed in the 
current thesis must be considered as an open-ended approach to identify potential biomarkers, but future 
development must be directed towards selecting the minimum number of biomarkers with high sensitivity 
and specificity levels which can be translated into simple PCR tests or diagnostic strips that can be 
manufactured with commercial purposes.  
 
On the other hand, microbiota biomarkers are not expected to be a standalone diagnostic assay and 
should be used as a complement with routine clinical laboratory testing (like skin prick test and allergen-
specific IgE blood levels) and clinical (family) history. Moreover, if the approaches targeting IgA-coating 
patterns and proportions of bound bacteria are validated to have early diagnostic power, different 
intervention strategies could be developed in order to prevent allergic disease onset during childhood. 
Conclusively, our findings need to be replicated in other countries and additional controlled studies, 
including experiments directed towards understanding the underlying cellular and molecular mechanisms, 
are required for further understanding of the host-microbiota interactions that seem to play a crucial role 





The “Perfect Storm” 
 
 
Asthma and allergic diseases are complex conditions caused by a combination of susceptibility genes and 
epigenetics, numerous variable environmental factors and host-microbiota interactions. Therefore, any 
attempt to study the causes of allergic diseases by focusing on only one of those factors will be 
incomplete.  
 
Allergy development during childhood consists of a chain of events that are still only partly understood. 
The intra-uterine environment, influenced by maternal factors, acts as a starting point for early 
development of the immune system in the fetus. As shown in the present thesis for oral microbiota 
development, variables like caesarean section and breastfeeding duration are important in directing initial 
extra-uterine colonization of pioneer bacteria, creating a base for further microbial succession. For these 
aspects of early microbiota and immune development, there are relatively fixed windows of susceptibility 
and events occurring here will have a critical role for lifelong host-microbial and immune homeostasis, 
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possibly predisposing us to conditions, such as atopy. Following this “window of opportunity”, antibiotic 
intake, oral hygiene, allergen exposure or number of older siblings are all environmental factors that will 
direct microbial habitats across the body of the toddler, resulting in an adult-like microbiota complexity by 
late childhood or even by preadolescence.[13, 45, 46] Apparently, there are several key events in the 
immune system development and microbial colonization that follow each other, and it is of great interest 
to understand how they might change the microbial/disease outcome more exactly in order to develop 
strategies to neutralize the effects. There might come a time when the host is exposed to different 
microorganisms at different time-points in order to support specific developmental (immune) processes.  
 
Despite accumulating studies in the human microbiota field, we still lack the knowledge to define an 
optimal early life microbiome and how it can be promoted and maintained. Therefore, significant efforts 
have been devoted to identify universally shared core microbiota, in contrast to transient colonizers that 
depend on diet and other external factors.[92] Here we would need to document which specific bacteria, 
and their metabolites, are critical in early programming of immune system. Once classified and 
characterized, this core microbiota representing a selected group of health-associated microorganisms, 
would facilitate relevant strategies to promote or inhibit the microbes which are significant for human 
health with potential diagnostic and therapeutic features. However, there are various difficulties that need 
to be overcome, including technical variations between the studies, the cost and practical feasibility of 
microbiome analyses or the selection of universal biomarkers, if they exist.  
 
We have also observed that early mucosal IgA responses towards gut microbiota might play a role in 
subsequent allergy and asthma development in childhood, as children developing allergies had lower 
proportions of bacteria coated with IgA with distinctive coating patterns of several bacterial genera. These 
findings possibly reflect altered mucosal barrier functions in allergic children and we speculate that early 
characterization of IgA coating patterns might represent a novel way to identify infants with increased risk 
of asthma and allergic disease, although this needs to be confirmed in larger cohorts. Moreover, the exact 
function of IgA requires to be further emphasized, especially in the case of vertical transmission of IgA-
coated bacteria from mother to breastfeeding child.  
 
In parallel to microbial colonization and maturation that are important for development of an appropriate 
and tolerant immune system, there are numerous genes, and epigenetic alterations, involved in allergy 
predisposition. The significance of epigenetic processes in allergic disease is under active research, as these 
mechanisms are identified to be at the interface among gene regulation, environmental stimuli and 
immune-developmental processes, all of which are essential for the pathogenesis for asthma and 
allergy.[619] In parallel, that early-life microbial colonization influences epigenetic modification of host 
DNA in a manner that produces life-long effects on the host immune response.[620] Speculatively, in a 
complex disease, like atopy and asthma, where various factors are involved, microorganisms will have 
different functions and effects depending on the changing environment and host susceptibility. It is 
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therefore plausible that a certain microbiota exposure, under specific external or environmental factors, 
and within genetically susceptible individuals, will cause a “perfect storm”, triggering disease development 
(Fig. 11). From those pillars of disease factors, the genetic predisposition, although a large proportion 
remains still unexplained [621], will give the clinician important information, while both the environmental 
and microbial aspects are susceptible to be modified. Therefore, taking into account and integrating these 
general components of the perfect storm, several therapeutic and preventive interventions could 






Fig. 11. Influence of different factors on immune responses and allergy development during early life.
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While substantial gaps in our understanding on the microbial interactions and parallel immune system 
development in allergy still exist, exploratory studies like those reported in this thesis are crucial for laying 
the foundations for further scientific investigation and knowledge building. I propose that further research 
should go beyond characterization of bacterial community composition and investigate the functional 
mechanisms between early colonizing microorganisms and allergy and asthma development during 
childhood. Given the difficulties to distinguish between cause and consequence in microbiome studies 
[622], we should instead move the focus towards providing explanations of causality. With new techniques 
for microbiota function prediction (with widely agreed standards and protocols), advanced cellular and 
animal models and novel analytical approaches for studying bacterial interactions, future research should 
aid to map and clarify the detailed mechanisms between microbiota and infant development, opening up 
for possible strategies to specifically manipulate different microbial niches, particularly in the earliest 
stages of life when the immune response is maturing and the microbiome settlement appears most plastic. 
Hence, by addressing the importance of infant microbiota in health, and allergy and asthma development, 
at a more profound level, I anticipate that the findings will have a crucial role in clinical research of 










The studies presented in the current thesis suggest that: 
 
1. Colonization of infant’s oral cavity by microorganisms follows a timely manner, increasing in 
complexity with time. 
2. Bacterial density, richness and diversity in the oral cavity increase from 3 months to 7 years of 
age. 
3. Oral microbiome development during childhood is an ecological succession impacted by delivery 
mode, breastfeeding duration and antibiotics treatment.  
4. Low proportions of IgA-coating of gut microbiota during the first year of life are associated with 
asthma and allergy development during childhood. 
5. Early aberrant IgA responses towards bacterial genera in the gut preceded asthma and allergy 
development and could therefore have diagnostic value of disease risk. 
6. Lower bacterial diversity in breastmilk collected at one month post partum, appears to be associated 
with allergy development in children. 
7. Probiotic supplementation with L. reuteri during pregnancy altered the proportions of IgA-coating 
of breastmilk bacteria, at one month post pregnancy.  
8. Development of allergic disease during childhood, and particularly asthma, was associated with 
significantly lower oral bacterial diversity and divergent bacterial composition at 7 years of age. 
9. Increased abundance of Gemella haemolysans in oral microbiota was observed in children 
developing allergies during the first 7 years of age. 
10. Infant oral microbiota composition, including the increased abundance of Lactobacillus gasseri and 
L. crispatus in children staying healthy, compared to children developing allergies during the first 7 
years of age, is likely influencing early immune maturation and I propose the isolation of these 
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Abstract
Information on how the oral microbiome develops during early childhood and how external factors influence this ecological
process is scarce. We used high-throughput sequencing to characterize bacterial composition in saliva samples collected at 3,
6, 12, 24 months and 7 years of age in 90 longitudinally followed children, for whom clinical, dietary and health data were
collected. Bacterial composition patterns changed through time, starting with “early colonizers”, including Streptococcus
and Veillonella; other bacterial genera such as Neisseria settled after 1 or 2 years of age. Dental caries development was
associated with diverging microbial composition through time. Streptococcus cristatus appeared to be associated with
increased risk of developing tooth decay and its role as potential biomarker of the disease should be studied with species-
specific probes. Infants born by C-section had initially skewed bacterial content compared with vaginally delivered infants,
but this was recovered with age. Shorter breastfeeding habits and antibiotic treatment during the first 2 years of age were
associated with a distinct bacterial composition at later age. The findings presented describe oral microbiota development as
an ecological succession where altered colonization pattern during the first year of life may have long-term consequences for
child´s oral and systemic health.
Introduction
The development and structure of the neonatal microbiome
have been partially elucidated, with a main focus on the
microbial population inhabiting the lower intestinal tract,
while information about the oral cavity colonization fol-
lowing delivery is still limited [1]. As yet, no published
longitudinal studies have characterized oral microbiota
development during infancy and childhood with culture
independent next-generation sequencing methodologies,
particularly in association with tooth decay.
It is believed that by production and excretion of meta-
bolic products of pioneer colonizers (including facultative
anaerobes Streptococcus and Actinomyces), acquired at birth
and the following hours, the environment can be altered,
thus benefiting and selecting the growth of other species
(including more strictly anaerobic genera like Veillonella
and Fusobacteria) [1, 2]. As the baby grows, microbial
communities evolve and increase in microbial diversity [3, 4].
During this period, the oral microbiota is characterized by
high variability and current knowledge indicates that it
reaches adult-like stability around 2 years of age [1].
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Aberrant IgA responses to the gut microbiota
during infancy precede asthma and allergy
development
Majda Dzidic, MSc,a,c,e Thomas R. Abrahamsson, MD, PhD,b Alejandro Artacho, BSc,c Bengt Bj€orkst"en, MD, PhD,d
Maria Carmen Collado, PhD,e Alex Mira, PhD,c* and Maria C. Jenmalm, PhDa* Link€oping and Stockholm, Sweden, and
Valencia, Spain
Background: Although a reduced gut microbiota diversity and
low mucosal total IgA levels in infancy have been associated
with allergy development, IgA responses to the gut microbiota
have not yet been studied.
Objective: We sought to determine the proportions of IgA
coating together with the characterization of the dominant
bacteria, bound to IgA or not, in infant stool samples in relation
to allergy development.
Methods: A combination of flow cytometric cell sorting and
deep sequencing of the 16S rDNA gene was used to characterize
the bacterial recognition patterns by IgA in stool samples
collected at 1 and 12 months of age from children staying
healthy or having allergic symptoms up to 7 years of age.
Results: The children with allergic manifestations, particularly
asthma, during childhood had a lower proportion of IgA bound to
fecal bacteria at 12months of age comparedwith healthy children.
These alterations cannot be attributed to differences in IgA levels
or bacterial load between the 2 groups. Moreover, the bacterial
targets of early IgA responses (including coating of theBacteroides
genus), as well as IgA recognition patterns, differed between
healthy children and childrenwith allergicmanifestations. Altered
IgA recognition patterns in children with allergy were observed
already at 1 month of age, when the IgA antibodies are
predominantly maternally derived in breast-fed children.
Conclusion: An aberrant IgA responsiveness to the gutmicrobiota
during infancy precedes asthma and allergy development, possibly
indicating an impaired mucosal barrier function in allergic
children. (J Allergy Clin Immunol 2017;139:1017-25.)
Key words: Allergic disease, asthma, secretory IgA, IgA index, IgA
recognition patterns, microbiome composition, gut microbiota,
childhood
Allergic diseases have become a major public health problem
in affluent societies.1 Reduced microbial exposure, both prena-
tally and postnatally, has been proposed to underlie the increase
in allergy development.2-5 The gut microbiota, which hosts a
complex bacterial community, is quantitatively the most impor-
tant source of microbial stimulation and might provide a primary
signal for appropriate immune development.4 The gut microbiota
differs in composition and diversity during the first months of life
in children who later do or do not have allergic disease,2,6-17
although no specific microbes with consistently harmful or
allergy-protective roles have yet been identified. Also, we
observed that differences in the gut microbiota diversity during
infancy between healthy children and children with allergies
were mainly related to asthma and not allergic rhinoconjunctivitis
(ARC) development.16 Early establishment of a diverse gut mi-
crobiota, with repeated exposure to new bacterial antigens, might
be more important than the distribution of specific microbial spe-
cies in shaping a normal immune mucosal and systemic
maturation.4
A reduced mucosal barrier function might increase the risk for
allergy development,1 and IgA is the primary mediator of humoral
mucosal immunity.18 IgA is the most abundantly produced anti-
body in human subjects, with the highest amount of secretion in
the intestinal tract.18,19 Secretory IgA (SIgA) has a crucial role in
the gut through its binding to bacterial antigens, thus preventing
their direct interaction with the host through immune exclusion
and maintaining mucosal homeostasis.18,20 SIgA can also limit
overgrowth of select species, thus stimulating diversity.18,21 There-
fore this antibody represents a key host mechanism in regulation of
the commensal community, and innate receptor signaling in T cells
seems to decide the specificity of IgA to constrain the composition
of the intestinal bacteria, ensuring a benign symbiotic relation-
ship.19 However, in contrast to IgG and IgM levels, generation of
this anti-inflammatory antibody is limited during early infancy,
and delayed development of mucosal IgA production, for instance
in the absence of breast-feeding, might lead to infectious disease in
young infants.22,23 Studies and clinical reports suggest that SIgA
that originates from the mother’s breast milk is important for
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Abstract
Background: Allergic diseases have become a major public health problem in afflu-
ent societies. Microbial colonization early in life seems to be critical for instructing
regulation on immune system maturation and allergy development in children. Even
though the oral cavity is the first site of encounter between a majority of foreign
antigens and the immune system, the influence of oral bacteria on allergy develop-
ment has not yet been reported.
Objective: We sought to determine the bacterial composition in longitudinally col-
lected saliva samples during childhood in relation to allergy development.
Methods: Illumina sequencing of the 16S rDNA gene was used to characterize the
oral bacterial composition in saliva samples collected at 3, 6, 12, 24 months, and
7 years of age from children developing allergic symptoms and sensitization (n = 47)
and children staying healthy (n = 33) up to 7 years of age.
Results: Children developing allergic disease, particularly asthma, had lower diversity
of salivary bacteria together with highly divergent bacterial composition at 7 years
of age, showing a clearly altered oral microbiota in these individuals, likely as a con-
sequence of an impaired immune system during infancy. Moreover, the relative
amounts of several bacterial species, including increased abundance of Gemella hae-
molysans in children developing allergies and Lactobacillus gasseri and L. crispatus in
healthy children, were distinctive during early infancy, likely influencing early
immune maturation.
Conclusion: Early changes in oral microbial composition seem to influence immune
maturation and allergy development. Future experiments should test the probiotic
potential of L. gasseri and L. crispatus isolates.
K E YWORD S
allergy development, Gemella haemolysans, infancy, Lactobacillus, oral microbiota
1 | INTRODUCTION
During the past decades, allergic diseases have become a major pub-
lic health problem in affluent societies.1 Microbial colonization occur-
ring early in life seems to be critical for instructing regulation on the
maturation of the immune system and allergy development in
children.2,3 Approximately 700 common microbial species have been
detected in the oral cavity.4 Typically, the commensal microbiota
here has a symbiotic relationship with the host, although, under cer-
tain circumstances, some microbes can overcome host defenses and
become pathogenic.5 At the birth and following hours, the infant’s
oral cavity is exposed to a large amount of microorganisms
Accepted: 20 March 2018
DOI: 10.1111/all.13449
2000 | © 2018 EAACI and John Wiley and Sons A/S.
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Abstract: Gut microbiota colonization is a complex, dynamic, and step-wise process that is in
constant development during the first years of life. This microbial settlement occurs in parallel with
the maturation of the immune system, and alterations during this period, due to environmental and
host factors, are considered to be potential determinants of health-outcomes later in life. Given that
host–microbe interactions are mediated by the immune system response, it is important to understand
the close relationship between immunity and the microbiota during birth, lactation, and early infancy.
This work summarizes the evidence to date on early gut microbiota colonization, and how it influences
the maturation of the infant immune system and health during the first 1000 days of life. This review
will also address the influence of perinatal antibiotic intake and the importance of delivery mode and
breastfeeding for an appropriate development of gut immunity.
Keywords: gut microbiota; postnatal immune development; gut immunity; breastfeeding;
probiotics; antibiotics
1. Introduction
Epidemiological studies highlight the relevance of the period from conception to early life in
the physiological and structural patterns of infant development, affecting their potential “health
programming”. The fetus adapts to the intrauterine environment, being able to alter its metabolism in
response to external stimuli. The physiological and metabolic adaptations that the fetus undergoes in
response to those stimuli could produce permanent changes in the host, which may lead to a higher
risk of developing diseases and/or disorders, such as obesity, allergies, diabetes, or cardiovascular
diseases, in adult life [1].
The first 1000 days after conception (including the pregnancy period and the first two years of
life), which are considered a “window of opportunity”, are crucial for the development and health of
the future adult, as well as key to the establishment of the intestinal microbiota and immune system
maturation. The physiological and immune development of the infant and the establishment of their
microbiota occur in parallel throughout this short space of time. This microbiota plays a central role in
health, intervening in key host metabolic and immunological functions.
DEFINITIONS
Microbiota: the microbial community in a specific niche/environment.
Microbiome: the total genomic repertoire of a microbial community (microbiota).
Med. Sci. 2018, 6, 56; doi:10.3390/medsci6030056 www.mdpi.com/journal/medsci
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a b s t r a c t
Large-scale biodiversity loss and complex changes in social behaviors are altering human microbial
ecology. This is increasingly implicated in the global rise in inflammatory diseases, most notably the
“allergy epidemic” in very early life. Colonization of human ecological niches, particularly the gastro-
intestinal tract, is critical for normal local and systemic immune development and regulation. Distur-
bances in composition, diversity and timing of microbial colonization have been associated with
increased allergy risk, indicating the importance of strategies to restore a dysbiotic gut microbiota in the
primary prevention of allergic diseases, including the administration of probiotics, prebiotics and syn-
biotics. Here, we summarize and discuss findings of randomized clinical trials that have examined the
effects of these microbiome-related strategies on short and long-term allergy preventative effects e
including new guidelines from the World Allergy Organization which now recommend probiotics and
prebiotics for allergy prevention under certain conditions. The relatively low quality evidence, limited
comparative studies and large heterogeneity between studies, have collectively hampered recommen-
dations on specific probiotic strains, specific timing and specific conditions for the most effective pre-
ventive management. At the same time the risk of using available products is low. While further research
is needed before specific practice guidelines on supplement probiotics and prebiotics, it is equally
important that the underlying dietary and lifestyle factors of dysbiosis are addressed at both the indi-
vidual and societal levels.
Copyright © 2017, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The epidemic rise in allergic diseases and asthma is inexorably
linked to complex environmental and modern lifestyle changes.
Urbanization and global decline of environmental biodiversity are
directly implicated in changes in human commensal microbiota,
which are critical for both normal immune maturation and sub-
sequent immune function. While these global effects are likely to
vary widely across both macro-scale geographic environments and
micro-scale human microbial habitats, there is growing evidence
that ‘dysbiosis’ is a major factor in the global increase in inflam-
matory non-communicable diseases including allergic disease.1e3
The ecological pressures on microbial diversity are multifaceted
and reflect changes in individual exposures such as nutritional
patterns (increased processed foods, less fresh and fermented
foods), sedentary indoor living (vitamin D insufficiency, reduced
nature relatedness and exposure to environmental biodiversity) as
well as the wider social and economic drivers of ‘dysbiotic
drift’.4e6
Thus while it is important to develop strategies for individuals
to restore personal biodiversity for disease prevention, as is the
subject of this review, it is equally important to address the
fundamental drivers of dysbiosis and nutritional supplements must
be viewed in this broader ecological context.7
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